<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/264291-template-fixed-peptidomimetics-with-antimicrobial-activity by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 00:39:38 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 264291:TEMPLATE-FIXED PEPTIDOMIMETICS WITH ANTIMICROBIAL ACTIVITY</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">TEMPLATE-FIXED PEPTIDOMIMETICS WITH ANTIMICROBIAL ACTIVITY</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>Template-fixed &amp;#946;-hairpin peptidomimetics of the general formula (I) wherein Z is a template-fixed chain of 12 &amp;#945;-amino acid residues which, depending on their positions in the chain (counted starting from the N-terminal amino acid) are Gly, or Pro, or of certain types which, as the remaining Symbols in the above formula, are defined in the description and the claims, and salts thereof, have the property to selectively inhibit the growth of or to kill microorganisms such as Pseudomonas aeruginosa. They can be used as disinfectants for foodstuffs, cosmetics, medicaments or other nutrient-containing materials, or as medicaments to treat or prevent infections. These &amp;#946;-hair-pin peptidomimetics can be manufactured by processes which are based on a mixed solid- and Solution phase synthetic strategy.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>Template - fixed peptidomimetics<br>
The present invention provides template-fixed β-hairpin peptidomimetics incorporating a<br>
template-fixed chain of 12 α-amino acid residues which, depending on their positions in the<br>
chain, are Gly or Pro, or of certain types, as defined herein below. These template-fixed β-<br>
hairpin mimetics have a selective antimicrobial activity. In addition, the present invention<br>
provides efficient synthetic processes by which these compounds can, if desired, be made in<br>
parallel library-format. These β-hairpin peptidomimetics show improved efficacy,<br>
bioavailability, half-life and most importantly a significantly enhanced ratio between<br>
antibacterial activity on the one hand, and hemolysis of red blood cells on the other.<br>
The growing problem of microbial resistance to established antibiotics has stimulated intense<br>
interest in developing novel antimicrobial agents with new modes of action (H. Breithaupt,<br>
Nat. Biotechnol 1999,17, 1165-1169). One emerging class of antibiotics is based on<br>
naturally occurring cationic peptides (T. Ganz, R. I. Lehrer, Mol. Medicine Today 1999, 5,<br>
292-297; R. M. Epand, H. J. Vogel, Biochim. Biophys. Acta 1999, 1462, 11-28). These<br>
include disulfide-bridged β-hairpin and β-sheet peptides (such as the protegrins [V. N.. M.;<br>
O. V. Shamova, H. A. Korneva, R. I. Lehrer, FEBSLett. 1993, 327, 231-236], tachyplesins<br>
[T. Nakamura, II. Furunaka, T. Miyata, F. Tokunaga, T. Muta. S. Iwanaga, M. Niwa, T.<br>
Takao, Y. Shimonishi, Y. J. Biol. Chem. 1988, 263, 16709-16713], and the defensins [R. I.<br>
Lehrer, A. K. Lichtenstein, T. Ganz, Annu. Rev. Immunol. 1993, 11, 105-128], amphipathic<br>
α-helical peptides (e.g. cecropins, dermaseptins, magainins, and mellitins [A. Tossi, L.<br>
Sandri, A. Giangaspero, Biopolymers 2000, 55, 4-30]), as well as other linear and loop-<br>
structured peptides. Although the mechanisms of action of antimicrobial cationic peptides are<br>
not yet fully understood, their primary site of interaction is the microbial cell membrane (H.<br>
W. Huang, Biochemistry 2000, 39, 8347-8352). Upon exposure to these agents, the cell<br>
membrane undergoes permeabilization, which is followed by rapid cell death. However,<br>
more complex mechanisms of action, for example, involving receptor-mediated signaling,<br>
cannot presently be ruled out (M. Wu, E. Maier, R. Benz, R. E. Hancock, Biochemistry 1999,<br>
38, 7235-7242).<br><br>
The antimicrobial activities of many of these cationic peptides usually correlate with their<br>
preferred secondary structures, observed either in aqueous solution or in membrane-like<br>
environments (N. Sitaram, R. Nagaraj, Biochim. Biophys. Acta 1999, 1462, 29-54). Structural<br>
studies by nuclear magnetic resonance (NMR) spectroscopy have shown that cationic<br>
peptides such as protegrin 1 (A. Aumelas, M. Mangoni, C. Roumestand, L. Chiche, E.<br>
Despaux, G. Grassy, B. Calas, A. Chavanieu, A. Eur. J. Biochem. 1996, 237, 575-583; R. L.<br>
Fahrner, T. Dicckmann, S. S. L. Harwig, R. I. Lehrer, D. Eisenberg, J. Feigon, J. Client. Biol.<br>
1996, 3, 543-550) and tachyplesin I (K. Kawano, T. Yoneya, T. Miyata, K. Yoshikawa.. F.<br>
Tokunaga, Y. Terada, S. J. Iwanaga, S. J. Biol. Chem. 1990, 265, 15365-15367) adopt well<br>
defined β-hairpin conformations, due to the constraining effect of two disulfide bridges. In<br>
protegrin analogues lacking one or both of these disulfide bonds, the stability of the ß-hairpin<br>
conformation is diminished, and the antimicrobial activity is reduced (J. Chen, T. J. Falla, H.<br>
J. Liu, M. A. Hurst, C. A. Fujii, D. A. Mosca, J. R. Embree D. J. Loury, P. A. Radel, C. C.<br>
Chang, L. Gu, J. C. Fiddes, Biopolymers 2000, 55, 88-98; S. L. Harwig, A. Waring, H. J.<br>
Yang, Y. Cho, L. Tan, R. I. Lehrer, R. J. Eur. J. Biochem. 1996, 240, 352-357; M. E.<br>
Mangoni, A. Aumelas, P. Charnet, C. Roumestand, L. Chiche, E. Despaux, G. Grassy, B.<br>
Calas, A. Chavanieu, FEBS Lett. 1996, 383, 93-98; H. Tamamura, T. Murakami, S. Noriuchi,<br>
K. Sugihara, A. Otaka, W. Takada, T. Ibuka, M. Waki, N. Tamamoto, N. Fujii, Chem.<br>
Pharm. Bull. 1995, 43, 853-858). Similar observations have been made in analogues of<br>
tachyplesin I (H. Tamamura, R. Ikoma, M. Niwa, S. Funakoshi, T. Murakami, N. Fujii,<br>
Chem. Pharm. Bull. 1993, 41, 978-980) and in hairpin-loop mimetics of rabbit defensin NP-2<br>
(S. Thennarasu, R. Nagaraj, Biochem. Biophys. Res. Comm. 1999. 254, 281-283). These<br>
results show that the β-hairpin structure plays an important role in the antimicrobial activity<br>
and stability of these protegrin-like peptides. In the case of the cationic peptides preferring a-<br>
helical structures, the amphililic structure of the helix appears to play a key role in<br>
determining antimicrobial activity (A. Tossi, L. Sandri, A. Giangaspero, A. Biopolymers<br>
2000, 55,4-30). Gramicidin S is a backbone-cyclic peptide with a well defined β-hairpin<br>
structure (S. E. Hull, R. Karlsson, P. Main, M. M. Woolfson, E. J. Dodson, Nature 1978, 275,<br>
206-275) that displays potent antimicrobial activity against gram-positive and gram-negative<br>
bacteria (L, H. Kondejewski, S. W. Fanner, D. S. Wishart, R. E. Hancock, R. S. Hodges, Int.<br>
J. Peptide Prot. Res. 1996, 47, 460-466). The high hemolytic activity of gramicidin S has,<br>
however, hindered its widespread use as an antibiotic. Recent structural studies by NMR have<br><br>
indicated that the high hemolytic activity apparently correlates with the highly amphipathic<br>
nature of this cyclic β-hairpin-like molecule, but that it is possible to dissociate antimicrobial<br>
and hemolytic activities by modulating the conformation and amphiphilicity (L. H.<br>
Kondejewski, M. Jelokhani-Niaraki, S. W. Farmer, B. Lix, M. Kay, B. D. Sykes, R. E.<br>
Hancock, R. S. Hodges, J. Biol. Chem. 1999, 274, 13181-13192; C. MclnnesL. H.<br>
Kondejewski, R. S. Hodges, B. D. Sykes, J. Biol. Chem. 2000, 275, 14287-14294).<br>
A new cyclic antimicrobial peptide RTD-1 was reported recently from primate leukocytes<br>
(Y.-Q. Tang, J. Yuan, G. Ösapay, K. Ösapay, D. Tran, C. J. Miller, A. J. Oellette, M. E.<br>
Selsted, Science 1999, 286, 498-502. This peptide contains three disulfide bridges, which act<br>
to constrain the cyclic peptide backbone into a hairpin geometry. Cleavage of the three<br>
disulfide bonds leads to a significant loss of antimicrobial activity. Analogues of protegrins<br>
(J. P. Tarn, C. Wu, J.-L. Yang, Eur. J. Biochem. 2000, 267, 3289-3300) and tachyplesins (J.-<br>
P. Tam, Y.-A. Lu, J.-L. Yang, Biochemistry 2000, 39, 7159-7169; N. Sitaram, R. Nagaraij,<br>
Biochem. Biophys. Res. Comm. 2000, 267, 783-790) containing a cyclic peptide backbone, as<br>
well as multiple disulfide bridges to enforce a amphiphilic hairpin structure, have also been<br>
reported. In these cases, removal of all the cystine constraints does not always lead to a large<br>
loss of antimicrobial activity, but does modulate the membranolytic selectivity (J. P. Tarn, C.<br>
Wu, J.-L. Yang, Eur. J. Biochem. 2000, 267, 3289-3300).<br>
A key issue in the design of new selective cationic antimicrobial peptides are bioavailability,<br>
stability and reduced haemolytic activity. The naturally occurring protegrins and tachyplesins<br>
exert a significant hemolytic activity agairst human red blood cells. This is also the case for<br>
protegrin analogues such as IB367 (J. Chen, T. J. Falla, H. J. Liu, M. A. Hurst, C. A. Fujii, D.<br>
A. Mosca, J. R. Embree, D. J. Loury, P. A. Radel, C. C. Chang, L. Gu, J. C. Fiddes,<br>
Biopolymers 2000, 55, 88-98; C. Chang, L. Gu, J. Chen, US-Pat: 5,916,872,1999). This high<br>
hemolytic activity essentially obviates its use in vivo, and represents a serious disadvantage<br>
in clinical applications. Also, the antibiotic activity of analogues often decreases significantly<br>
with increasing salt concentration, such that under in vivo conditions (ca. 100-150 mM NaC1)<br>
the antimicrobial activity may be severely reduced.<br><br>
Protegrin 1 exhibits potent and similar activity against gram-positive and gram-negative<br>
bacteria as well as fungi in both low- and high-salt assays. This broad antimicrobial activity<br>
combined with a rapid mode of action, and their ability to kill bacteria resistant to other<br>
classes of antibiotics, make them attractive targets for development of clinically useful<br>
antibiotics. The activity against gram-positive bacteria is typically higher than against gram-<br>
negative bacteria. However, protegrin 1 also exhibits a high hemolytic activity against human<br>
red blood cells, and hence a low selectivity towards microbial cells. Oriented CD experiments<br>
(W. T. Heller, A. J. Waring, R. I. Lehrer, H. W. Huang, Biochemistry 1998, 37, 17331-<br>
17338) indicate that protegrin 1 may exist in two different states as it interacts with<br>
membranes, and these states are strongly influenced by lipid composition. Studies of cyclic<br>
protegrin analogues (J.-P. Tam, C. Wu, J.-L. Yang, Eur. J. Biochem. 2000, 267, 3289-3300)<br>
have revealed, that an increase in the conformational rigidity, resulting from backbone<br>
cyclization and multiple disulfide bridges, may confer membranolytic selectivity that<br>
dissociates antimicrobial activity from hemolytic activity, at least in the series of compounds<br>
studied.<br>
Protegrin 1 is an 18 residues linear peptide, with an amidated carboxyl terminus and two<br>
disulfide bridges. Tachyplesin I contains 17 residues, also has an amidated carboxyl terminus<br>
and contains two disulfide bridges. Recently described backbone-cyclic protegrin and<br>
tachyplesin analogues typically contain 18 residues and up to three disulfide bridges (J. P.<br>
Tarn, C. Wu, J.-L. Yang, Eur. J. Biochem. 2000,267, 3289-3300; J. P. Tarn, Y.-A. Lu, J.-L.<br>
Yang, Biochemistry 2000, 39, 7159-7169; N. Sitaram, R. Nagaraij, Biochem. Biophys. Res.<br>
Comm. 2000, 267., 783-790).<br>
Cathelicidin , a 37-residue linear helical-type cationic peptide, and analogues are currently<br>
under investigation as inhaled therapeutic agents for cystic fibrosis(CF) lung disease (L.<br>
Saiman, S. Tabibi, T. D. Starner, P. San Gabriel, P. L. Winokur, H. P. Jia, P. B. McGray, Jr.,<br>
B. F. Tack, Antimicrob. Agents and Chemother. 2001, 45, 2838-2844; R. E. W. Hancock, R.<br>
Lehrer, Trends Biotechnol. 1998,16, 82-88). Over 80% of CF patients become chronically<br>
infected with pseudomonas aeruginosa (C. A. Demko, P. J. Biard, P. B. Davies, J. Clin.<br>
Epidemiol. 1995, 48, 1041-1049; E. M. Kerem, R. Gold, H. Levinson, J. Pediatr. 1990, 116,<br>
714-719). Other antimicrobial peptides against Pseudomonads (Y.H. Yau, B. Ho, N.S. Tan,<br>
M.L. Ng, J.L. Ding, Antimicrob. Agents and Chemother. 2001, 45, 2820-2825 and herein<br><br>
cited references), like FALL-39, SMAP-29, and lepidopteran cecropin display a few of the<br>
desired attributes like potent antimicrobial activity over a wide range of pH, rapid killing rate,<br>
and low hemolytic activity.<br>
In the compounds described below, a new strategy is introduced to stabilize P-hairpin<br>
conformations in backbone-cyclic cationic peptide mimetics exhibiting selective<br>
antimicrobial activity. This involves transplanting the cationic and hydrophobic hairpin<br>
sequence onto a template, whose function is to restrain the peptide loop backbone into a<br>
hairpin geometry.<br>
Template-bound hairpin mimetic peptidcs have been described in the literature (D, Obrecht,<br>
M. Altorfer, J. A. Robinson, Adv. Med. Chem. 1999, 4, 1-68; J. A. Robinson, Syn. Lett. 2000,<br>
4, 429-441) and the ability to generate β-hairpin peptidomimetics using combinatorial and<br>
parallel synthesis methods has now been established (L. Jiang, K. Moehle, B. Dhanapal, D.<br>
Obrecht, J. A. Robinson, Helv. Chim. Acta. 2000, 83, 3097-3112). Antibacterial template -<br>
fixed peptidomimetics and methods for their synthesis have been described in International<br>
Patent applications W002/070547 Al and W02004/018503 Al but these molecules do not<br>
exhibit high plasma stability selectivity and particularly high potency.<br>
The methods described herein allow the synthesis and screening of large hairpin mimetic<br>
libraries, which in turn considerably facilitates structure-activity studies, and hence the<br>
discovery of new molecules with potent selective antimicrobial and very low hemolytic<br>
activity to human red blood cells. The present strategy allows to synthesize P-hairpin<br>
peptidomimetics with novel selectivities towards various multi-drug resistant pseudomonas-<br>
strains.<br>
The β-hairpin peptidomimetics of the present invention are compounds of the general<br>
formula<br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br>
R1 is	H; lower alkyl; or aryl-lower alkyl;<br>
R2 is H; alkyl; alkenyl; -(CH2)m(CHR6l)sOR5S; -(CH2),n(CHR61)sSR56;<br>
-(CH2)m(CHR61)sNR33R34;-(CH2)m(CHR61)sOCONR33R75;<br>
-(CH2)m(CHR61)sNR20CONR33R82;-(CH2)o(CHR61)sCOOR57;<br>
-(CH2)0(CHR61)sCONR58R59;-(CH2)a(CHR61)sPO(OR60)2;<br>
-(CH2)O(CHR61)S SO2R62; or -(CH2)O(CHR61)SC6H4R8;<br>
R3 is H; alkyl; alkenyl; -(CH2)m(CHR61)sOR55; -(CH2)m(CHR61)sSR56;<br>
-(CH2)m(CHR61)sNR33R34;-(CH2)m(CHR61)sOCONR33R75;<br>
-(CH2)m(CHR61)sNR20CONR33R82; -(CH2)O(CHR61)SCOOR57;<br>
-(CH2)0(CHR61)SCONR58R59; -(CH2)o(CHR61)sPO(OR60)2;<br>
-(CH2)O(CHR61)S SO2R62; or -(CH2)O(CHR61)SC5H4R8;<br>
R4 is H; alkyl; alkenyl; -(CH2)m(CHR61)sOR55; -(CH2)m(CHR6l)sSR56;<br>
-(CH2)m(CHR61),NR33R34;<br>
-(CH2)m(CHR61)sOCONR33R75;-(CH2)m(CHR61)sNR20CONR33R82;<br>
-(CH2)p(CHR61)sCOOR57;-(CH2)p(CHR61)sCONR58R59;-(CH2)p(CHR61)sPO(OR60)2;<br>
-(CH2)p(CHR61)s SO2R62; or -(CH2)o(CHR61)sC6H4R8;<br>
R5 is alkyl; alkenyl; -(CH2)o(CHR61)sOR55; -(CH2)o(CHR61)sSR56;<br>
-(CH2)o(CHR61)sNR33R34;<br>
-(CH2)0(CHR61)SCONR33R75; -(CH2)o(CHR61)sNR20CONR33R82<br>
-(CH2)O(CHR61)S COOR57;-(CH2)O(CHR61)SCONR58R59;-(CH2)O(CHR61)SPO(OR60)2;<br>
-(CH2)O(CHR61)S SO2R62; OR -(CH2)o(CHR61)SC6H4R8;<br>
R6 is H; alky!; alkenyl; -(CH2)O(CHR61)SOR55; -(CH2)0(CHR61)sSR56;<br>
-(CH2)O(CHR61)SNR33R34;<br>
-(CH2)o(CHR61)sOCONR33R75;-(CH2)o(CHR61)sNR20CONR35R82;<br>
-(CH2)o(CHR61)sCOOR57;-(CH2)o(CHR61)sCONR58R59;-(CH2)o(CHR61)sPO(OR60)2;<br><br>
-(CH2)O(CHR61)S SO2R62; or-(CH2)o(CHR61)sC6H4R8;<br>
R7 is alkyl; alkenyl; -(CH2)q(CHR61)OR55; -(CH2)q(CHR61)sNR33R34;<br>
-(CH2)q(CHR61)SOCONR33R75;-(CH2)q(CHR61)SNR20CONR33R82;<br>
-(CH2)r(CHR61)sCOOR57;-(CH2)r(CHR61)sCONR58R59;-(CH2)r(CHR61)sPO(OR60)2;<br>
-(CH2)r(CHR61)SSO2R62; or -(CH2)r(CHR61)s C6H4R8;<br>
R8 is H; Cl: F; CF3; NO2; lower alkyl; lower alkenyl; aryl; aryl-lower alkyl;<br>
-(CH2)o(CHR61)SOR55; -(CH2)0(CHR61)sSR56; -(CH2)O(CHR61)NR33R34;<br>
-(CH2)O(CHR61)SOCONR33R75; -(CH2)o(CHR61)sNR20CONR33R82;<br>
-(CH2)o(CHR61)sCOOR57;-(CH2)o(CHR61)sCONR58R59;-(CH2)o(CHR61)sPO(OR60)2;<br>
-(CHV)o(CHR61)sSO2R62; or -(CH2)0(CHR61)SCOR64;<br>
R9 is alkyl; alkenyl; -(CH2)o(CHR6l)sOR55; -(CH2)O(CHR61)SSR56;<br>
-(CH2)o(CHR61)sNR33R34;<br>
-(CH2)o(CHR61)sOCONR33R75;-(CH2)o(CHR61)sNR20CONR33R82;<br>
-(CH2)o(CHR61)sCOOR57;-(CH2)o(CHR61)sCONR58R59;-(CH2)o(CHR61)sPO(OR60)2;<br>
-(CH2)o(CHR61)s SO2R62; or-(CH2)o(CHR61)sC6H4R8;<br>
R9 is alkyl; alkenyl; -(CH2)o(CHR6l)sOR55; -(CH2)O(CHR61)SSR56;<br>
-(CH2)o(CHR61)sNR33R34;<br>
-(CH2)o(CHR61)sOCONR33R75;-(CH2)o(CHR61)sNR20CONR33R82;<br>
-(CH2)o(CHR61)sCOOR57;-(CH2)o(CHR61)sCONR58R59;-(CH2)o(CHR61)sPO(OR60)2;<br>
-(CH2)o(CHR61)s SO2R62; or-(CH2)o(CHR61)sC6H4R8;<br>
R11 is H; alkyl: alkenyl; -(CH2)m(CHR61)5OR55; -(CH2)m(CHR61)sNR33R34;<br>
-(CH2)m(CHR61)sOCONR33R75; -(CH2)m(CHR61)sNR20CONR33R82;<br>
-(CH2)o(CHR61)sCOOR57;-(CH2)o(CHR61)SCONR58R59;-(CH2)o(CHR61)sPO(OR60)2;<br>
-(CH2)o(CHR61)sSO2R62; or -(CH2)o(CHR61)s C6H4R8;<br>
R12 is H; alkyl; alkenyl; -(CH2)m(CHR61),OR55; -(CH2)m(CHR61)sSR56;<br>
-(CH2)m(CHR61)sNR33R34;-(CH2)m(CHR61)sOCONR33R75;<br>
-(CH2)m(CHR61)sNR20CONR33R82;-(CH2)r(CHR61)sCOOR57;<br>
-(CH2)r(CHR61)5CONR58R59; -(CH2)r(CHR61)sPO(OR60)2; -(CH2)r(CHR61)s SO2R62; or<br>
-(CH2)r(CHR61)sC6H4R8;<br>
R13 is alkyl; alkenyl; -(CH2)q(CHR61)sOR55; -(CH2)q(CHR61)sSR56;<br>
-(CH2)q(CHR61)sNR33R34;<br>
-(CH2)q(CHR61)3OCONR33R75; -(CH2)q(CHR61)sNR20CONR33R82;<br>
-(CH2)q(CHR61)sCOOR57;-(CH2)q(CHR61)sCONR58R59;-(CH2)q(CHR61)sPO(OR60)2;<br><br>
-(CH2)q(CHR61)s SO2R62; or -(CH2)(CHR61)sC6H4R8;<br>
R14 is H; alkyl; alkenyl; -(CH2)m(CHR61)sOR55; -(CH2)m(CHR61)sNR33R34;<br>
-(CH2)m(CHR61)sOCONR33R75;-(CH2)m(CHR61)sNR20CONR33R82;<br>
-(CH2)q(CHR6l)sCOOR57;-(CH2)q(CHR61)sCONR58R59;(CH2)q(CHR61)sPO(OR60)2:.<br>
-(CH2)q(CHR61)sSOR62; or -(CH2)q(CHR61)s C6H4R8;<br>
R15 is alkyl; alkenyl; -(CH2)O(CHR61)SOR55; -(CH2)o(CHR61)sSR56;<br>
-(CH2)O(CHR61)sNR33R34;<br>
-(CH2)o(CHR61)sOCONR33R75;-(CH2)o(CHR61)sNR20CONR33R82.;<br>
-(CH2)o(CHR61)SCOOR57: -(CH2)o(CHR61)sCONR58R59; -(CH2)o(CHR61)sPO(OR60)2;<br>
-(CH2)o(CHR61)s SO2R62; or -(CH2)0(CHR61)sC6H4R8;<br>
R16 is alkyl; alkenyl; -(CH2)O(CHR61)sOR55; -(CH2)O(CHR61)SSR56;<br>
-(CH2)O(CHR61)sNR33R34;<br>
-(CH2)o(CHR61)sOCONR33R75;-(CH2)o(CHR61)sNR20CONR33R82;<br>
-(CH2)o(CHR61)sCOOR57;-(CH2)o(CHR61)sCONR58R59; -(CH2)o(CHR61)sPO(OR60)2;<br>
-(CH2)o(CHR61)s SO2R62; or -(CH2)o(CHR61)sC6H4R8;<br>
R17 is alkyl; alkenyl; -(CH2)q(CHR61)sOR55; -(CH2)q(CHR61)sSR56;<br>
-(CH2)q(CHR61)sNR33R34;<br>
-(CH2)q(CHR61)sOCONR33R75;-(CH2)q(CHR61)sNR20CONR33R82;<br>
-(CH2)q(CHR61)sCOOR57;-(CH2)q(CHR61)sCONR58R59; -(CH2)q(CHR61)sPO(OR60)2;<br>
-(CH2)q(CHR61)s SO2R62; or -(CH2)q(CHR61)sC6H4R8;<br>
R18 is alkyl; alkenyl; -(CH2)p(CHR61)sOR55; -(CH2)p(CHR61)sSR56;<br>
-(CH2)p(CHR61)sNR33R34;<br>
-(CH2)p(CHR61)sOCONR33R75;-(CH2)p(CHR61)sNR20CONR33R82;<br>
-(CH2)p(CHR61)sCOOR57;-(CH2)p(CHR61)sCONR58R59; -(CH2)p(CHR61)sPO(OR60)2;<br>
-(CH2)p(CHR61)s SO2R62; or -(CH2)o(CHR61)sC6H4R8; R19 is lower alkyl; -(CH2)P(CHR61)sOR55; -(CH2)P(CHR61)sSR56: -(CH2)p(CHR61)sNR33R34;<br>
-(CH2)p(CHR61)sOCONR33R75;-(CH2)p(CHR61)sNR20CONR33R82;<br>
-(CH2)p(CHR61)sCOOR57;-(CH2)p(CHR6l)sCONR58R59;-(CH2)p(CHR61)sPO(OR60)2;<br>
-(CH2)p(CHR61)s SO2R62; or-(CH2)0(CHR61)s,C6H4R8; or<br>
R18 and R19 taken together can form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-;<br>
R20 is	H; allvyl; alkenyl; or aryl-lower alkyl;<br><br>
R21 is H; alkyl; alkenyl; -(CH2)0(CHR61)sOR55; -(CH2)o(CHR61)sSR56:<br>
-(CH2)o(CHR61)sNR33R34;<br>
-(CH2)o(CHR61)sOCONR33R75; -(CH2)o(CHR61)sNR20CONR33R82;<br>
-(CH2)o(CHR61)sCOOR57:-(CH2)o(CHR61)sCONR58R59;-(CH2)o(CHR61)sPO(OR60)2;<br>
-(CH2)o(CHR61)s SO2R62; or-(CH2)o(CHR61)sC6H4R8;<br>
R22 is H; alkyl; alkenyl; -(CH2)0(CHR61)sOR55; -(CH2)o(CHR61)sSR56:<br>
-(CH2)o(CHR61)sNR33R34;<br>
-(CH2)o(CHR61)sOCONR33R75; -(CH2)o(CHR61)sNR20CONR33R82;<br>
-(CH2)o(CHR61)sCOOR57:-(CH2)o(CHR61)sCONR58R59;-(CH2)o(CHR61)sPO(OR60)2;<br>
-(CH2)o(CHR61)s SO2R62; or-(CH2)o(CHR61)sC6H4R8;<br>
R23 is alkyl; alkenyl; -(CH2)o(CHR61)sOR55; -(CH2)o(CHR61)sSR56;<br>
-(CH2)o(CHR61)sNR33R34;<br>
-(CH2)o(CHR61)sOCONR33R75;-(CH2)o(CHR61)sNR20CONR33R82;<br>
-(CH2)o(CHR61)sCOOR57; -(CH2)o(CHR61)sCONR58R59; -(CH2)o(CHR61)sPO(OR60)2;<br>
-(CH2)o(CHR61)s SO2R62; or-(CH2)o(CHR61)sC6H4R8;<br>
R24 is alkyl; alkenyl.; -(CH2)0(CHR61)sOR55; -(CH2)o(CHR61)sSR56;<br>
-(CH2)o(CHR61)sNR33R34;<br>
-(CH2)o(CHR61)sOCONR33R75;-(CH2)o(CHR61)sNR20CONR33R82;<br>
-(CH2)o(CHR6l)sCOOR57;-(CH2)o(CHR61)sCONR58R59;-(CH2)o(CHR6l)sPO(OR60)2;<br>
-(CH2)o(CHR6l)s SO2R62; or-(CH2)o(CHR61)sC6H4R8;<br>
R25 is H;alkyl; alkenyl.; -(CH2)m(CHR61)sOR55; -(CH2)o(CHR61)sSR56;<br>
-(CH2)m(CHR61)sNR33R34;-(CH2)m(CHR61)sOCONR33R75;<br>
-(CH2)m(CHR61)sNR20CONR33R82;-(CH2)o(CHR61)sCOOR57<br>
-(CH2)o(CHR6l)sCONR58R59;-(CH2)o(CHR6l)sPO(OR60)2;<br>
-(CH2)o(CHR6l)s SO2R62; or-(CH2)o(CHR61)sC6H4R8;<br>
R26 is H; alkyl; alkenyl; -(CH2)m(CHR61)sOR55; -(CH2)m(CHR61)sSR56;<br>
-(CH2)m(CHR61)sNR33R34;-(CH2)m(CHR61)sOCONR33R75;<br>
-(CH2)m(CHR61)sNR20CONR33R82;-(CH2)o(CHR61)sCOOR57;<br>
-(CH2)o(CHR61)sCONR58R59;-(CH2)o(CHR61)sPO(OR60)2;<br>
-(CH2)o(CHR61)s SO2R62; or -(CH2)o(CHR61)sC6H4R8; or<br>
R25 and R26 taken together can form: -(CH2)2-6-; -(CH2)rO(CH2)r; -(CH2)rS(CH2)r-; or<br>
-(CH2)rNR57(CH2)r-;<br><br>
R27 is H; alkyl; alkenyl; -(CH2)o(CHR61)sOR55; -(CH2)o(CHR61)sSR56;<br>
-(CH2)o(CHR61)sNR33R34;<br>
-(CH2)o(CHR6I)sCOOR57;-(CH2)o(CHR61)sCONR58R59;<br>
-(CH2)o(CHR61)sOCONR33R75;<br>
-(CH2)o(CHR61)sNR20CONR33R82;-(CH2)o(CHR61)sPO(OR60)2;<br>
-(CH2)o(CHR61)s SO2R62; or -(CH2)o(CHR61)sC6H4R8;<br>
R28 is alkyl; alkenyl; -(CH2)o(CHR61)s-OR55; -(CH2)o(CHR61)s SR56; -(CH2)o(CHR61)s<br>
NR33R34;<br>
-(CH2)o(CHR61)sOCONR33R75;-(CH2)o(CHR61)sNR20CONR33R82;<br>
-(CH2)o(CHR61)s COOR57; -(CH2)o(CHR61)s CONR58R59; -(CH2)o(CHR61)s<br>
PO(OR60)2;<br>
-(CH2)o(CHR61)s SO2R62; or -(CH2)o(CHR61)s C6H4R8;<br>
R29 is alkyl; alkenyl; -(CH2)o(CHR61)sOR55; -(CH2)o(CHR61)sSR56;<br>
-(CH2)o(CHR61)sNR33R34;<br>
-(CH2)o(CHR61)sOCONR33R75;-(CH2)o(CHR61)sNR20CONR33R82;<br>
-(CH2)o(CHR61)sCOOR57;-(CH2)o(CHR61)sCONR58R59;-(CH2)o(CHR61)sPO(OR60)2;<br>
-(CH2)o(CHR61)s SO2R62; or-(CH2)o(CHR61)sC6H4R8;<br>
R30 is H; alkyl; alkenyl; or aryl-lower alkyl;<br>
R31 is H; alkyl; alkenyl; -(CH2)P(CHR61)SOR55; -(CH2)P(CHR61)s-NR33R34;<br>
-(CH2)p(CHR61)sOCONR33R75;-(CH2)p(CHR61)sNR20CONR33R82;<br>
-(CH2)o(CHR61)sCOOR57;-(CH2)o(CHR6l)sCONR58R59;-(CH2)o(CHR61)sPO(OR60)2:<br>
-(CH2)o(CHR61)sSO2R62; or-(CH2)O(CHR61)s C6H4R8;<br>
R32 is H; lower alkyl; or aryl-lower alkyl;<br>
R33 is H; alkyl, alkenyl; -(CH2)m(CHR61)sOR55; -(CH2)m(CHR61)sNR34R63;<br>
-(CH2)m(CHR61)sOCONR75R82;-(CH2)m(CHR61)sNR20CONR78R82;<br>
-(CH2)o(CHR6l)sCOR61;-(CH2)o(CHR61)s-CONR58R59,-(CH2)o(CHR61)sPO(OR60)2;<br>
-(CH,)o(CHR61)., SO2R62; or -(CH2)o(CHR61)sC6H4R8;<br>
R34 is H; lower alkyl; aryl, or aryl-lower alkyl;<br>
R33 and R34 taken together can form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-;<br>
R35 is H; alkyl; alkenyl; -(CH2)m(CHR61)sOR55; -(CH2)m(CHR61)sNR33R34;<br>
-(CH2)m(CHR61)sOCONR33R75;-(CH2)m(CHR61)sNR20CONR33R82;<br><br>
-(CH2)p(CHR61)sCOOR57;-(CH3)p(CHR6l)sCONR58R59;-(CH2)p(CHR61)sPO(OR60)2;<br>
-(CH2)p(CHR61)sSO2R62; or -(CH2)p(CHR61)S C6H4R8;<br>
R36 is H, alkyl; alkenyl; -(CH2)o(CHR61)sOR55; -(CH2)p(CHR61)sNR33R34;<br>
-(CH2)p(CHR61)sOCONR33R75;-(CH2)p(CHR61)sNR20CONR33R82;<br>
-(CH2)p(CHR61)sCOOR57;-(CH2)p(CHR61)sCONR58R59:-(CH2)p(CHR6l)sPO(OR60)2;<br>
-(CH2)p(CHR61)sSO2R62; or -(CH2)o(CHR61)s C6H4R8;<br>
R37 is H; F; Br; Cl; NO2; CF3; lower alkyl; -(CH2)p(CHR61)sOR55; -(CH2)p(CHR61)sNR33R34;<br>
-(CH2)p(CHR61)sOCONR33R75;-(CH2)p(CHR61)sNR20CONR33R82;<br>
-(CH2)o(CHR61)sCOOR57;-(CH2)o(CHR61)sCONR58R59;-(CH2)o(CHR61)sPO(OR60)2;<br>
-(CH2)o(CHR61)sS02R62; or -(CH2)o(CHR61)s C6H4R8:<br>
R38 is H; F; Br; Cl; NO2; CF3; alkyl; alkenyl; -(CH2)p(CHR61)sOR55:<br>
-(CH2)p(CHR61)sNR33R34;<br>
-(CH2)p(CHR61)sOCONR33R75:-(CH2)p(CHR61)sNR20CONR33R82;<br>
-(CH2)o(CHR61)sCOOR57;-(CH2)o(CHR61)sCONR58R59;-(CH2)o(CHR61)sPO(OR60)2;<br>
-(CH2)o(CHR61)sSO2R62; or -(CH2)o(CHR61)sC6H4R8;<br>
R39 is H: alkyl; alkenyl; or aryl-lower alkyl;<br>
R40 is H; alkyl; alkenyl; or aryl-lower alkyl;<br>
R41 is H; F; Br; Cl; NO2; CF3; alkyl; alkenyl; -(CH2)p(CHR61)sOR55;<br>
-(CH2)p(CHR61)sNR33R34;<br>
--(CH2)p(CHR61)sOCONR33R75;-(CH2)p(CHR61)sNR20CONR33R82;<br>
-(CH2)o(CHR61)sCOOR57;-(CH2)o(CHR61)sCONR58R59;-(CH2)o(CHR61)sPO(OR60)2;<br>
-(CH2)o(CHR61)sSO2R62; or-(CH2)o(CHR61)s C6H4R8;<br>
R42 is H; F; Br; Cl; NO2; CF3; alkyl; alkenyl; -(CH2)p(CHR61)sOR55;<br>
-(CH2)p(CHR61)sNR33R34;<br>
-(CH2)p(CHR61)sOCONR33R75; -(CH2)p(CHR61)sNR20CONR33R82;<br>
-(CH2)o(CHR61)sCOOR57;-(CH2)o(CHR61)sCONR58R59;-(CH2)o(CHR61)sPO(OR60))2;<br>
-(CH2)o(CHR61)sSO2R62; or -(CH2)o(CHR61)s C6H4R8;<br>
R43 is H; alkyl; alkenyl; -(CH2)m(CHR61)sOR55; -(CH2)m(CHR61)sNR33R34;<br>
-(CH2)m(CHR61)sOCONR33R75; -(CH2)m(CHR61)sNR20CONR33R82;<br>
-(CH2)o(CHR61)sCOOR57;-(CH2)o(CHR61)sCONR58R59;-(CH2)o(CHR61)sPO(OR60)2;<br>
-(CH2)o(CHR61)sSO2R62; or -(CH2)o(CHR61)s C6H4R8;<br>
R44 is alkyl; alkenyl; -(CH2)r(CHR61)sOR55; -(CH2)r(CHR61)sSR56;-(CH2)r(CHR61)sNR33R34;<br>
-(CH2)r(CHR61)sOCONR33R75; -(CH2)r(CHR61)sNR20CONR33R82;<br><br>
-(CH2)r(CHR61)sCOOR57;-(CH2)r(CHR61)sCONR58R59;-(CH2)r(CHR61)sPO(OR60)2;<br>
-(CH2)r(CHR61)s SO2R62; -(CH2)r(CHR61)sC6H4R8;<br>
R45 is H; alkyl; alkenyl; -(CH2)o(CHR61)sOR55; -(CH2)o(CHR61)sSR56;<br>
-(CH2)o(CHR61)sNR33R34;<br>
-(CH2)o(CHR61)sOCONR33R75;-(CH2)o(CHR61)sNR20CONR33R82;<br>
-(CH2)o(CHR61)sC00R57;-(CH2)s(CHR61)sCONR58R59;-(CH2)s(CHR61)sPO(OR60)2;<br>
-(CH2)s(CHR61)s SO2R62; or -(CH2)s(CHR61)sC6H4R8;<br>
R46 is H; alkyl; alkenyl; or -(CH2)o(CHR61)pC6H4R8;<br>
R47 is H; alkyl; alkenyl; -(CH2)o(CHR61)sOR55;<br>
R48 is H; lower alkyl; lower alkenyl; or aryl-lower alkyl;<br>
R49 is H; alkyl; alkenyl; -(CHR61)sCOOR57; (CHR61)sCONR58R59; (CHR6l)sPO(OR60)2;<br>
-(CHR61)sSOR62; or -(CHR6)sC6H4R8;<br>
R50 is H; lower alkyl; or aryl-lower alkyl;<br>
R51 is H; alkyl; alkenyl; -(CH2)m(CHR61)sOR55; -(CH2)m(CHR61)sSR56;<br>
-(CH2)m(CHR61)sNR33R34;-(CH2)m(CHR61)sOCONR33R75;<br>
-(CH2)m(CHR61)sNR20CONR33R82;-(CH2)o(CHR61)sCOOR57:<br>
-(CH2)o(CHR61)sCONR58R59;-(CH2)o(CHR61)pPO(OR60)2;<br>
-(CH2)p(CHR61)s SO2R62; or -(CH2)p(CHR61)sC6H4R8;<br>
R52 is H; alkyl; alkenyl; -(CH2)m(CHR61)sOR55; -(CH2)m(CHR61)sSR56;<br>
-(CH2)m(CHR61)sNR33R34;-(CH2)m(CHR61)sOCONR33R75;<br>
-(CH2)m(CHR61)sNR20CONR33R82;-(CH2)o(CHR61)sCOOR57;<br>
-(CH2)o(CHR61)sCONR58R59;-(CH2)o(CHR61)pPO(OR60)2;<br>
-(CH2)p(CHR61)s SO2R62; or -(CH2)p(CHR61)sC6H4R8;<br>
R53 is H; alkyl; alkenyl; -(CH2)m(CHR61)sOR53; -(CH2)m(CHR61)sSR56;<br>
-(CH2)m(CHR61)sNR33R34;-(CH2)m(CHR61)sOCONR33R75;<br>
-(CH2)m(CHR61)sNR20CONR33R82; -(CH2)o(CHR61)sCOOR57;<br>
-(CH2)o(CHR61)sCONR58R59;-(CH2)o(CHR61)pPO(OR60)2;<br>
-(CH2)p(CHR61)s SO2R62; or -(CH2)P(CHR61)sC6H4R8;<br>
R54 is H; alkyl; alkenyl: -(CH2)m(CHR61)sOR55; -(CH2)m(CHR61)sNR33R34;<br>
-(CH2)m(CHR61)sOCONR33R75;-(CH2)m(CHR61)sNR20CONR33R82;<br>
-(CH2)o(CHR61)COOR57: -(CH2)o(CHR61)sCONR58R59; or -(CH2)o(CHR61)s C6H4R8;<br>
R55 is H; lower alkyl; lower alkenyl; aryl-lower alkyl; -(CH2)m(CHR61)sOR57;<br>
-(CH2)m(CHR61)sNR34R63;-(CH2)m(CHR61)sOCONR75R82;<br><br>
-(CH2)m(CHR61)sNR20CONR78R82;-(CH2)o(CHR61)s-COR64;-(CH2)o(CHR61)COOR57;<br>
or<br>
-(CH2)o(CHR61)sCONR58R59;<br>
R56 is H; lower alkyl; lower alkenyl; aryl-lower alkyl; -(CH2)m(CHR61)sOR57;<br>
-(CH2)m(CHR61)sNR34R63;-(CH2)m(CHR61)sOCONR75R82;<br>
-(CH2)m(CHR61)sNR20CONR78R82; -(CH2)o(CHR61)s-COR64; or<br>
-(CH2)o(CHR61)sCONR58R59:<br>
R57 is H; lower alkyl; lower alkenyl; aryl lower alkyl; or heteroaryl lower alkyl:<br>
R58 is H; lower alkyl; lower alkenyl; aryl; heteroaryl; aryl-lower alkyl; or heteroaryl-lower<br>
alkyl;<br>
R59 is H; lower alkyl; lower alkenyl; aryl; heteroaryl; aryl-lower alkyl; or heteroaryl-lower<br>
alkyl; or<br>
R58 and R59 taken together can form: -(CH2)2-6-; -(CH2)2O(CH2)2-: -(CH2)2S(CH2)2-; or<br>
-(CH2)2NK57(CH2)2-;<br>
R60 is H; lower alkyl; lower alkenyl; aryl; or aryl-lower alkyl;<br>
R61 is H, alkyl; alkenyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; -<br>
(CH2)POR55;<br>
-(CH2)PNR33R34: -(CH2)POCONR75R82; -(CH2)PNR20CONR78R82; -(CH2)oCOOR57;<br>
or -(CH2)oPO(COR60)2;<br>
R62 is lower alkyl; lower alkenyl; aryl, heteroaryl; or aryl-lower alkyl;<br>
R63 is H; lower alkyl; lower alkenyl; aryl, heteroaryl; aryl-lower alkyl; heteroaryl-lower<br>
alkyl;<br>
-COR64; -COOR57; -CONR58R59; -SO2R62; or -PO(OR60);<br>
R34and R63 taken together can form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-;<br>
R64 is H; lower alkyl; lower alkenyl: aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower<br>
alkyl; -(CH2)p(CHR61)sOR65: -(CH2)p(CHR61)sSR66; or-(CH2)p(CHR61)sNR34R63;<br>
-(CH2)p(CHR61)sOCONR75R82;-(CH2)p(CHR61)sNR20CONR78R82;<br>
R65 is H; lower alkyl; lower alkenyl; aryl, aryl-lower alkyl: heteroaryl-lower alkyl; -COR57;<br>
-COOR57; or -CONR58R59;<br>
R66 is H; lower alkyl; lower alkenyl; aryl; aryl-lower alkyl; heteroaryl-lower alkyl; or -<br>
CONR58R59;<br>
m is 2-4; o is 0-4; p is 1-4; q is 0-2; r is 1 or 2; s is 0 or 1;<br><br>
R67 being H; Cl; Br; F; NO2; -NR34COR57; lower alkyl; or lower alkenyl:<br>
R68 being H; Cl; Br; F; NO2; -NR34COR57; lower alkyl; or lower alkenyl;<br>
R09 being H; Cl; Br; F; NO2; -NR34COR57; lower alkyl; or lower alkenyl: and<br>
R70 being H; Cl; Br; F; NO2; -NR34COR57; lower alkyl; or lower alkenyl;<br>
with the proviso that at least two of R67, R68, R69 and R70 are H; and<br>
Z is a chain of 12 α-amino acid residues, the positions of said amino acid residues in said<br>
chain being counted starting from the N-terminal amino acid, whereby these amino acid<br>
residues are, depending on their position in the chain, Gly or Pro, or of formula -A-CO-, or of<br>
formula -B-CO-, or of one of the types<br>
C:	-NR20CH(R72)CO;<br>
D:	-NR20CH(R73)CO-;<br>
E:	-NR20CH(R74)CO-;<br>
F:	-NR20CH(R84)CO-;<br>
H: -NR20-CH(CO-)-(CH2)4.7-CH(CO-)-NR20-;<br>
-NR20-CH(CO-)-(CH2)pSS(CH2)p-CH(CO-)-NR20-;<br>
-NR20-CH(CO-)-(-(CH2)pNR20CO(CH2)p-CH(CO-)-NR20-;and<br>
-NR20-CH(CO-)-(-(CH2)pNR20CONR20(CH2)p-CH(CO-)-NR20-;<br>
R71 is H; lower alkyl; lower alkenyl; -(CX2)P(CHR61)sOR75; -(CX2)p(CHR61)sSR75;<br>
-(CX2)p(CHR61)sNR33R34;-(CX2)P(CXR61)sOCONR33R75;<br>
-(CX2)p(CHR61)sNR20CONR33R82;<br>
-(CX2)o(CHR61)sCOOR75; -(CX2)pCONR58R59; -(CX2)PPO(OR62)2; -(CX2)pSO2R62; or<br>
-(CX2)o-C6R67R68R69R70R76;<br>
R72 is H; lower alkyl; lower alkenyl: -(CX2)p(CHR86)sOR85; or<br>
-(CX2)P(CHR86)sSR85:<br>
R73 is -(CX2)oR77; -(CX2)rO(CH2)oR77; -(CX2)rS(CH2)oR77; or<br>
-(CX2)rNR20(CH2)oR77;<br>
R74 is -(CX2)pNR78R79; -(CX2)pNR77R80; -(CX2)pC(=NR80)NR78R79; -<br>
(CX2)pC(=NOR50)NR78R79;<br>
-(CX2)pC(=NNR78R79)NR78R79;-(CX2)pNR80C(=NR80)NR78R79;<br><br>
-(CX2)pN=C(NR78R80)NR79R8V(CX2)pC6H4NR78R79;-(CX2)pC6H4NR77R80;<br>
-(CX2)pC6H4C(=NR80)NR78R79;-(CX2)pC6H4C(=NOR50)NR78R79;<br>
-(CX2)pC6H4C(=NNR78R79)NR78R79;-(CX2)pC6H4NR80C(=NR80)NR78R79;<br>
-(CX2)PC6H4N=C(NR78R80)NR79R80;-(CX2)rO(CX2)mNR78R79;-(CX2)rO(CX2)mNR77R80;<br>
-(CX2)rO(CX2)pC(=NR80)NR78R79;-(CX2)rO(CX2)pC(=NOR50)NR78R79;<br>
-(CX2)rO(CX2)pC(=NNR78R79)NR78R79;-(CX2)rO(CH2)mNR80C(-NR80)NR78R79;<br>
-(CX2)rO(CX2)mN=C(NR78R80)NR79R80; -(CX2)rO(CX2)pC6H4CNR78R79;<br>
-(CX2)rO(CX2)pC6H4C(=NR80)NR78R79;-(CX2)rO(CX2)pC6H4C(=NOR50)NR78R79;<br>
-(CX2)rO(CX2)pC6H4C(=NNR78R79)NR78R79;<br>
-(CX2)rO(CX2)pC6H4NR80C(=NR80)NR78R79;-(CX2)rS(CX2)mNR78R79;<br>
-(CX2)rS(CX2)mNR77R80;-(CX2)rS(CX2)pC(=NR80)NR78R79;<br>
-(CX2)rS(CX2)pC(=NOR50)NR78R79;-(CX2)rS(CX2)pC(=NNR78R79)NR78R79;<br>
-(CX2)rS(CX2)mNR80C(=NR80)NR78R79;-(CX2)rS(CX2)mN=C(NR78R80)NR79R80;<br>
-(CX2)rS(CX2)pC6H4CNR78R79;-(CX2)rS(CX2)pC6H4C(=NR80)NR78R79;<br>
-(CX2)rS(CX2)pC6H4C(=NOR50)NR78R79;-(CX2)rS(CX2)pC6H4C(=NNR78R79)NR78R79;<br>
-(CX2)rS(CX2)pC6H4NR80C(=NR80)NR78R79;-(CX2)pNR80COR64;-(CX2)pNR80COR77;<br>
-(CX2)PNR80CONR78R79; -(CX2)PC6H4NR80CONR78R79; or -(CX2)p-NR20CO-[(CX2)u-<br>
XX]tCH3 where XX is -O-; -NR20-, or -S-; u is 1-3, and t is 1-6;<br>
R75 is lower alkyl; lower alkenyl: or aryl-lower alkyl;<br>
R33 and R75 taken together can form: -(CX2)2-6-; -(CX2)2O(CX2)2-; -(CX2)2S(CX2)2-; or<br>
-(CX2)2NR57-(CX2)2-;<br>
R75 and R82 taken together can form: -(CX2)2-6-; -(CX2)2O(CX2)2-; -(CX2)2S(CX2)2-; or<br>
-(CX2)2NR57(CX2)2-;<br>
R76 isH; lower alkyl; lower alkenyl; aryl-lower alkyl; -(CX2)oOR72; -(CX2)oSR72;<br>
-(CX2)ONR33R34; -(CX2)oOCONR33R75; -(CX2)oNR20CONR33R82;<br>
-(CX2)OCOOR75; -(CX2)oCONR58R59; -(CX2)oPO(OR60)2; -(CX2)pSO2R62; or<br>
-(CX2)oCOR64:<br>
R77 is	-C6R67R68R69R70R76; or a heteroaryl group of one of the formulae<br><br><br><br><br>
R78 is	H; lower alkyl; aryl; or aryl-lower alkyl;<br>
R78 and R82 taken together can form: -(CX2)2-6-; -(CX2)2O(CX2)2-; -(CX2)2S(CX2)2-; or<br>
-(CX2)2NR57(CX2)2-;<br>
R79 is	H; lower alkyl; aryl; or aryl-lower alkyl; or<br>
R78 and R79, taken together, can be -(CX2)2-7-; -(CX2)2O(CX2)2-; or -(CX2)2NR57(CX2)2-;<br>
R80 is	H; or lower alkyl;<br>
R81 is	H; lower alkyl; or aryl-lower alkyl;<br><br>
R82 is H; lower alkyl; aryl; heteroaryl; or aryl-lower alkyl;<br>
R33 and R82 taken together can form: -(CX2)2-6-; -(CX2)2O(CX2)2-; -(CX2)2S(CX2)2-: or<br>
-(CX2)2NR57(CX2)2-;<br>
R83 is H; lower alkyl; aryl; or -NR78R79;<br>
R84 is -(CX2)m(CHR61)sOH; -(CX2)PCONR78R79; -(CX2)PNR80CONR78R79;<br>
-(CX2)PC6H4CONR78R79; or -(CX2)PC6H4NR80CONR78R79;<br>
R85 is lower alkyl; or lower alkenyl;<br>
R86 is H, alkyl; alkenyl; -(CX2)POR85;-(CX2)PSR85<br>
R87 is H; alkyl; alkenyl; heteroaryl, aryl-lower alkyl; -(CX2)POR55; -(CX2)pOCONR75R82;<br>
-(CX2)PNR20CONR78R82; -(CX2)PCOOR57, or -(CX2)PPO(OR60)2;<br>
X is H; or optionally halogen:<br>
with the proviso that in said chain of 12 α-amino acid residues Z the amino acid residues in<br>
positions 1 to 12 are, in a preferred embodiment:<br>
P1:	of type C or of type D or of type E or of type F, or the residue is<br>
Pro:<br>
P2:	of type D or of type E;<br>
P3:	of type C or of type D, or the residue is Gly or Pro;<br>
P4:	of type C or of type E or of type F, or the residue is Gly or Pro;<br>
P5:	of type E or of type D or of type C, or the residue is Gly or Pro;<br>
P6:	of type E or of type F or of type C or of formula -A-CO-, or the<br>
residue is Gly or Pro;<br>
P7:	of type C or of type E or of type F or of formula -B-CO-;<br>
P8:	of type D or of type C, or of Type F, or the residue is Pro;<br>
P9:	of type C or of type E or of type D or of type F;<br>
P10: of type E;<br>
P11: of type C or of type F, or the residue is Pro or Gly ; and<br>
P12: of type C or of type D or of type E or of type F, or the residue is<br>
Pro; or<br>
P4 and P9 and/or P2 and P11, taken together, can form a group of type H;<br>
and<br>
at P6, P10 and P1 1 also D-isomers being possible;<br>
or, alternatively, but in a less preferred embodiment:<br><br>
P1:	of type C or of type D or of type E or of type F, or the residue is<br>
Pro;<br>
P2:	of type C or of type F, or the residue is Pro or Gly ;<br>
P3:	of type E;<br>
P4:	of type C or of ty pe E or of type D or of type F;<br>
P5:	of type D or of type C, or of type F, or the residue is Pro;<br>
P6:	of type C or of type E or of type For of formula -B-CO-;<br>
P7:	of type E or of type F or of type C or of formula -A-CO-, or the<br>
residue is Gly or Pro;<br>
P8:	of type E or of type D or of type C, or the residue is Gly or Pro;<br>
P9:	of type C or of type E or of type F; or the residue is Gly or Pro;<br>
P 10:	of type C or of type D, or the residue is Gly or Pro;<br>
P11:	of type D or of type E; and<br>
P12:	of type C or of type D or of type E or of type F.. or the residue is<br>
Pro; or<br>
P4 and P9 and/or P2 and P1 1, taken together, can form a group of type H;<br>
and<br>
at P2, P3, and P7	also D-isomers being possible;<br>
and pharmaceutically acceptable salts thereof.<br>
In accordance with the present invention these β-hairpin peptidomimetics can be prepared by<br>
a process which comprises<br>
(a)	coupling an appropriately functionalized solid support with an appropriately<br>
N-protccted derivative of that amino acid which in the desired end-product is in position 5, 6<br>
or 7. any functional group which may be present in said N-protected amino acid derivative<br>
being likewise appropriately protected,<br>
(b)	removing the N-protecting group from the product thus obtained;<br>
(c)	coupling the product thus obtained with an appropriately N-protected<br>
derivative of that amino acid which in the desired end-product is one position nearer the N-<br>
terminal amino acid residue, any functional group which may be present in said N-protccted<br>
amino acid derivative being likewise appropriately protected:<br><br>
(d)	removing the N-protecting group from the product thus obtained;<br>
(e)	repeating steps (c) and (d) until the N-terminal amino acid residue has been<br>
introduced;<br>
(f)	coupling the product thus obtained with a compound of the general formula<br><br>
is to be group (a1) or (a2), above, alternatively<br>
(fa)	coupling the product obtained in step (e) with an appropriately N-protected<br>
derivative of an amino acid of the general formula<br>
HOOC-B-H	III	or HOOC-A-H	IV<br>
wherein B and A are as defined above, any functional group which may be present in<br>
said N-protected amino acid derivative being likewise appropriately protected;<br>
(jjj)	removing the N-protecting group from the product thus obtained; and<br>
(kkk)	coupling the product thus obtained with an appropriately N-protected<br>
derivative of an amino acid of the above general formula IV and, respectively, III,<br>
any functional group which may be present in said N-protected amino acid derivative<br>
being likewise appropriately protected;<br>
(g)	removing the N-protecting group from the product obtained in step (f) or (fc);<br>
(h)	coupling the product thus obtained with an appropriately N-protected<br>
derivative of that amino acid which in the desired end-product is in position 12, any<br><br>
functional group which may be present in said N-protected amino acid derivative being<br>
likewise appropriately protected;<br>
(i)	removing the N-protecting group from the product thus obtained;<br>
(j)	coupling the product thus obtained with an appropriately N-protected<br>
derivative of that amino acid which in the desired end-product is one position farther away<br>
from position 12, any functional group which may be present in said N-protected amino acid<br>
derivative being likewise appropriately protected;<br>
(k)	removing the N-protecting group from the product thus obtained;<br>
(1)	repeating steps (j) and (k) until all amino acid residues have been introduced;<br>
(m)	if desired, selectively deprotecting one or several protected functional<br>
group(s) present in the molecule and appropriately substituting the reactive group(s) thus<br>
liberated;<br>
(o)	detaching the product thus obtained from the solid support;<br>
(p)	cyclizing the product cleaved from the solid support;<br>
(q)	if desired, forming one or two interstrand linkage(s) between side-chains of<br>
appropriate amino acid residues at opposite positions of the p-strand region;<br>
(r)	removing any protecting groups present on functional groups of any<br>
members of the chain of amino acid residues and, if desired, any protecting group(s) which<br>
may in addition be present in the molecule; and<br>
(s)	if desired, converting the product thus obtained into a pharmaceutically<br>
acceptable salt or converting a pharmaceutically acceptable, or unacceptable, salt thus<br>
obtained into the corresponding free compound of formula I or into a different,<br>
pharmaceutically acceptable, salt.<br>
Alternatively, the peptidomimetics of the present invention can be prepared by<br>
(a1)	coupling an appropriately functionalized solid support with a compound of<br>
the general formula<br><br><br><br>
is to be group (a1) or (a2), above, alternatively<br>
(a'a) coupling said appropriately functionalized solid support with an<br>
appropriately N-protected derivative of an amino acid of the general formula<br>
HOOC-B-H	III	or HOOC-A-H	IV<br>
wherein B and A are as defined above, any functional group which may be present in<br>
said N-protected amino acid derivative being likewise appropriately protected;<br>
(a'b) removing the N-protecting group from the product thus obtained; and<br>
(a'c) coupling the product thus obtained with an appropriately N-protected<br>
derivative of an amino acid of the above general formula IV and, respectively, III,<br>
any functional group which may be present in said N-protected amino acid derivative<br>
being likewise appropriately protected;<br>
(b')	removing the N-protecting group from the product obtained in step (a1) or<br>
(a'c);<br>
(c')	coupling the product thus obtained with an appropriately N-protected<br>
derivative of that amino acid which in the desired end-product is in position 12, any<br>
functional group which may be present in said N-protected amino acid derivative being<br>
likewise appropriately protected;<br>
(d')	removing the N-protecting group from the product thus obtained;<br>
(e')	coupling the product thus obtained with an appropriately N-protected<br>
derivative of that amino acid which in the desired end-product is one position farther away<br>
from position 12, any functional group which may be present in said N-protected amino acid<br>
derivative being likewise appropriately protected;<br>
(f')	removing the N-protecting group from the product thus obtained;<br><br>
(g')	repeating steps (e1) and (f) until all amino acid residues have been<br>
introduced;<br>
(h')	if desired, selectively deprotecting one or several protected functional<br>
group(s) present in the molecule and appropriately substituting the reactive group(s) thus<br>
liberated;<br>
(i')	detaching the product thus obtained from the solid support;<br>
(j')	cyclizing the product cleaved from the solid support;<br>
(k')	if desired forming one or two interstrand linkage(s) between side-chains of<br>
appropriate amino acid residues at opposite positions of the p-strand region;<br>
(l')	removing any protecting groups present on functional groups of any<br>
members of the chain of amino acid residues and, if desired, any protecting group(s) which<br>
may in addition be present in the molecule; and<br>
(m')	if desired, converting the product thus obtained into a pharmaceutically<br>
acceptable salt or converting a pharmaceutically acceptable, or unacceptable, salt thus<br>
obtained into the corresponding free compound of formula I or into a different,<br>
pharmaceutically acceptable, salt.<br>
The peptidomimetics of the present invention can also be enantiomers of the compounds of<br>
formula I. These enantiomers can be prepared by a modification of the above processes in<br>
which enantiomers of all chiral starting materials are used.<br>
As used in this description, the term "alkyl", taken alone or in combinations, designates<br>
saturated, straight-chain or branched hydrocarbon radicals having up to 24, preferably up to<br>
12, carbon atoms, ioptionally substituted with halogen. Similarly, the term "alkenyl"<br>
designates straight chain or branched hydrocarbon radicals having up to 24, preferably up to<br>
12, carbon atoms and containing at least one or, depending on the chain length, up to four<br>
olefinic double bonds, optionally substituted with halogen. The term "lower" designates<br>
radicals and compounds having up to 6 carbon atoms. Thus, for example, the term "lower<br>
alkyl" designates saturated, straight-chain or branched hydrocarbon radicals having up to 6<br>
carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert.-<br>
butyl and the like. The term "aryl" designates aromatic carbocyclic hydrocarbon radicals<br>
containing one or two six-membered rings, such as phenyl or naphthyl, which may be<br>
substituted by up to three substituents such as Br, C1, F, CF3, NO2, lower alkyl or lower<br><br>
alkenyl. The term "heteroaryl" designates aromatic heterocyclic radicals containing one or<br>
two five- and/or six-membered rings, at least one of them containing up to three heteroatoms<br>
selected from the group consisting of O, S and N and said ring(s) being optionally<br>
substituted; representative examples of such optionally substituted heteroaryl radicals are<br>
indicated hereinabove in connection with the definition of R77.<br>
The structural element -A-CO- designates amino acid building blocks which in combination<br>
with the structural element -B-CO- form templates (a1) and (a2). Templates (a) through (p)<br>
constitute building blocks which have an N-terminus and a C-terminus oriented in space in<br>
such a way that the distance between those two groups may lie between 4.0-5.5A. A peptide<br>
chain Z is linked to the C-terminus and the N-terminus of the templates (a) through (p) via<br>
the corresponding N- and C-termini so that the template and the chain form a cyclic structure<br>
such as that depicted in formula I. In a case as here where the distance between the N- and C-<br>
termini of the template lies between 4.0-5.5A the template will induce the H-bond network<br>
necessary for the formation of a P-hairpin conformation in the peptide chain Z. Thus template<br>
and peptide chain form a β-hairpin mimetic.<br>
The P-hairpin conformation is highly relevant for the anti-bacterial activity of the P-hairpin<br>
mimetics of the present invention. The p-hairpin stabilizing conformational properties of the<br>
templates (a) through (p) play a key role not only for the selective antibacterial activity but<br>
also for the synthetic processes defined hereinabove, as incorporation of the templates at the<br>
beginning or near the middle of the linear protected peptide precursors enhances cyclization<br>
yields significantly.<br>
Building blocks A1-A69 belong to a class of amino acids wherein the N-terminus is a<br>
secondary amine forming part of a ring. Among the genetically encoded amino acids only<br>
proline falls into this class. The configuration of building block Al through A69 is (D), and<br>
they are combined with a building block -B-CO- of (L)-configuration. Preferred<br>
combinations for templates (al) are-DAl-CO-LB-CO-to DA69-CO-LB-CO-. Thus, for<br>
example, DPro-LPro constitutes the prototype of templates (al). Less preferred, but possible<br>
are combinations-LA1-CO-DB-CO- to LA69-CO-DB-CO- forming templates (a2). Thus, for<br>
example, LPro-DPro constitutes the prototype of template (a2).<br><br>
It will be appreciated that building blocks -A1-C0- to -A69-CO- in which A has (D)-<br>
configuration, are carrying a group R1 at the α-position to the N-terminus. The preferred<br>
values for R1 are H and lower alkyl with the most preferred values for R1 being H and<br>
methyl. It will be recognized by those skilled in the art, that A1-A69 are shown in (D)-<br>
configuration which, for R1 being H and methyl, corresponds to the (R)-configuration.<br>
Depending on the priority of other values for R1 according to the Cahn, Ingold and Prelog-<br>
rules, this configuration may also have to be expressed as (S).<br>
In addition to R1 building blocks -A1-C0- to -A69-CO- can carry an additional substituent<br>
designated as R2 to R17. This additional substituent can be H, and if it is other than H, it is<br>
preferably a small to medium-sized aliphatic or aromatic group. Examples of preferred<br>
values for R2 to R17 are:<br>
-R2: H; lower alkyl; lower alkenyl; (CH2)mOR55 (where R55: lower alkyl; or lower<br>
alkenyl); (CH2)mSR56 (where R56: lower alkyl; or lower alkenyl); (CH2)mNR33R34 (where R33:<br>
lower alkyl; or lower alkenyl; R34: H; or lower alkyl; R33 and R34 taken together form:<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; R57: H; or lower<br>
alkyl); (CH2)mOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower alkyl;<br>
or R33 and R75 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)mNR20CONR33R82 (where R20: H;<br>
or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33<br>
and R82 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oN(R20)COR64(where: R20: H; or<br>
lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)oCOOR57 (where R57: lower alkyl; or<br>
lower alkenyl); -(CH2)oCONR58R59 (where R58: lower alkyl; or lower alkenyl; and R59: H; or<br>
lower alkyl; or R58 and R59 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-;<br>
-(CH2)2S(CH2)2-; or -(CH2)2NR57-(CH2)2-; where R57: H; or lower alkyl); -(CH2)oPO(OR60)2<br>
(where R60: lower alkyl; or lower alkenyl); -(CH2)oSO2R62 (where R62: lower alkyl; or lower<br>
alkenyl); or -(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower<br>
alkoxy).<br>
-R3: H; lower alkyl; lower alkenyl; -(CH2)mOR55 (where R55: lower alkyl; or lower<br>
alkenyl); -(CH2)mSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)mNR33R34 (where<br><br>
R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form:<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57-(CH2)2-; where R57: H; or<br>
lower alkyl); -(CH2)mOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75:<br>
lower alkyl; or R33 and R75 taken together form: -(CH2)2-6-; -(CH2)2O-(CH2)2-;<br>
-(CH2)2S-(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)mNR20CONR33R82 (where R20: H;<br>
or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33<br>
and R82 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oN(R20)COR64 (where: R20: H; or<br>
lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)oCOOR57 (where R57: lower alkyl; or<br>
lower alkenyl); -(CH2)oCONR58R59 (where R58: lower alkyl; or lower alkenyl; and R59: H;<br>
lower alkyl; or R58 and R59 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-;<br>
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); (CH2)oPO(OR60)2<br>
(where R60: lower alkyl; or lower alkenyl); -(CH2)oSO2R62 (where R52: lower alkyl; or lower<br>
alkenyl); or -(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower<br>
alkoxy).<br>
R4: H; lower alkyl; lower alkenyl; -(CH2)mOR55 (where R55: lower alkyl; or lower<br>
alkenyl); -(CH2)mSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)mNR33R34 (where<br>
R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form:<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or-(CH2)2NR57(CH2)2-; where R57: H; or<br>
lower alkyl); -(CH2)mOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75:<br>
lower alkyl; or R33 and R75 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-<br>
;or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)mNR20CONR33R82 (where R20: H;<br>
or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33<br>
and R82 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)mN(R20)COR64(where: R20: H; or<br>
lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)oCOOR57 (where R57: lower alkyl; or<br>
lower alkenyl); -(CH2)oCONR58R59 (where R58: lower alkyl; or lower alkenyl; and R59: H; or<br>
lower alkyl; or R58 and R59 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-;<br>
-(CH2)2S(CH2)2-; or -(CH2)2NR57-(CH2)2-; where R57: H; or lower alkyl); -(CH2)oPO(OR60)2<br>
(where R60: lower alkyl; or lower alkenyl); -(CH2)oSO2R62 (where R62: lower alkyl; or lower<br>
alkenyl); or -(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl;or lower<br><br>
alkoxy).<br>
R5: lower alkyl; lower alkenyl; -(CH2)oOR55 (where R55: lower alkyl; or lower<br>
alkenyl); -(CH2)oSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)oNR33R34 (where R33:<br>
lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form:<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or<br>
lower alkyl); -(CH2)oOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower<br>
alkyl; or R33 and R75 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; R57: where H; or lower alkyl); (CH2)oNR20CONR33R82 (where R20: H; or<br>
lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33 and<br>
R82 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); (CH2)oN(R20)COR64(where: R20: H; or<br>
lower alkyl; R64: alkyl; alkenyl; aryl; and aryl-lower alkyl; heteroaryl-lower alkyl);<br>
-(CH2)oCOOR57 (where R57: lower alkyl; or lower alkenyl); -(CH2)oCONR58R59 (where R58:<br>
lower alkyl; or lower alkenyl; and R59: H; or lower alkyl; or R58 and R59 taken together form:<br>
-(CH2)2-6-;-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or<br>
lower alkyl); -(CH2)oPO(OR60)2 (where R60: lower alkyl; or lower alkenyl); -(CH2)oSO2R62<br>
(where R62: lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower<br>
alkyl; lower alkenyl; or lower alkoxy).<br>
R6: H; lower alkyl; lower alkenyl; -(CH2)oOR55 (where R55: lower alkyl; or lower<br>
alkenyl); -(CH2)oSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)oNR33R34 (where<br>
R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form:<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or-(CH2)2NR57(CH2)2-; where R57: H; or<br>
lower alkyl); -(CH2)oOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower<br>
alkyl; or R33 and R75 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oNR20CONR33R82 (where R20: H;<br>
or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33<br>
and R82 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oN(R20)COR64 (where: R20: H; or<br>
lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)oCOOR57 (where R57: lower alkyl; or<br>
lower alkenyl); -(CH2)oCONR58R59 (where R58: lower alkyl; or lower alkenyl; and R59: H; or<br>
lower alkyl; or R58 and R59 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-;<br>
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oPO(OR60)2<br>
(where R60: lower alkyl; or lower alkenyl); -(CH2)oSO2R62 (where R62: lower alkyl; or lower<br><br>
alkenyl); or -(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower<br>
alkoxy).<br>
R7: lower alkyl; lower alkenyl; -(CH2)qOR55 (where R55: lower alkyl; or lower<br>
alkenyl); -(CH2)qSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)qNR33R34 (where<br>
R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form:<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or<br>
lower alkyl); -(CH2)qOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower<br>
alkyl; or R33 and R75 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); (CH2)qNR20CONR33R82 (where R20: H; or<br>
lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33 and<br>
R82 taken together form: -(CH2)2-6-; -(CH2)2O-(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)qN(R20)COR64(where: R20: H; or<br>
lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)COOR57 (where R57: lower alkyl; or<br>
lower alkenyl); -(CH2)qCONR58R59 (where R58: lower alkyl; or lower alkenyl; and R59: H; or<br>
lower alkyl; or R58 and R59 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-;<br>
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)rPO(OR60)2<br>
(where R60 : lower alkyl; or lower alkenyl); (CH2)rSO2R62 (where R62: lower alkyl; or lower<br>
alkenyl); or -(CH2)qC6H4R8(where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl;or lower<br>
alkoxy).<br>
R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; -(CH2)oOR55 (where R55: lower alkyl;<br>
or lower alkenyl); (CH2)oSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)oNR33R34<br>
(where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken<br>
together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where<br>
R57: H; or lower alkyl); -(CH2)oOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl;<br>
R75: lower alkyl; or R33 and R75 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-;<br>
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl);<br>
-(CH2)oNR20CONR33R82 (where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower<br>
alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2)2-6-;<br>
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl);<br>
-(CH2)oN(R20)COR64 (where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl);<br>
-(CH2)oCOOR57 (where R57 : lower alkyl; or lower alkenyl); -(CH2)oCONR58R59 (where R58:<br>
lower alkyl; or lower alkenyl; and R59: H; or lower alkyl; or R58 and R59 taken together form:<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S-(CH2)2-; or -(CH2)2NR57-(CH2)2-; where R57: H; or<br><br>
lower alkyl); -(CH2)oPO(OR60)2 (where R60: lower alkyl; or lower alkenyl); -(CH2)oSO2R62<br>
(where R62: lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower<br>
alkyl; lower alkenyl; or lower alkoxy).<br>
R9: lower alkyl; lower alkenyl; -(CH2)oOR55 (where R55: lower alkyl; or lower<br>
alkenyl); -(CH2)oSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)oNR33R34 (where R33:<br>
lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form:<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or<br>
lower alkyl); -(CH2)oOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower<br>
alkyl; or R33 and R75 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)mNR20CONR33R82 (where R20: H;<br>
or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33<br>
and R82 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oN(R20)COR64(where: R20: H; or<br>
lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)oCOOR57 (where R57: lower alkyl; or<br>
lower alkenyl); -(CH2)oCONR58R59 (where R58: lower alkyl; or lower alkenyl; and R59: H; or<br>
lower alkyl; or R58 and R59 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-;<br>
-(CH2)2S(CH2)2-; or -(CH2)2NR57-(CH2)2-; where R57: H; or lower alkyl); -(CH2)oPO(OR60)2<br>
(where R60: lower alkyl; or lower alkenyl); -(CH2)oSO2R62 (where R62: lower alkyl; or lower<br>
alkenyl); or -(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower<br>
alkoxy).<br>
R10: lower alkyl; lower alkenyl; -(CH2)oOR55 (where R55: lower alkyl; or lower<br>
alkenyl); -(CH2)oSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)oNR33R34 (where R33:<br>
lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form:<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2-NR57-(CH2)2-; where R57: H; or<br>
lower alkyl); -(CH2)oOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower<br>
alkyl; or R33 and R75 taken together form: -(CH2)2-6-; -(CH2)2O-(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oNR20CONR33R82 (where R20: H;<br>
or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33<br>
and R82 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oN(R20)COR64(where: R20: H; or<br>
lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)oCOOR57 (where R57: lower alkyl; or<br>
lower alkenyl); -(CH2)oCONR58R59 (where R58: lower alkyl; or lower alkenyl; and R59: H;<br>
lower alkyl; or R58 and R59 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-;<br><br>
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oPO(OR60)2<br>
(where R60: lower alkyl; or lower alkenyl); -(CH2)oSO2R62 (where R62: lower alkyl; or lower<br>
alkenyl); or -(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower<br>
alkoxy).<br>
R11:H; lower alkyl; lower alkenyl; -(CH2)mOR55 (where R55: lower alkyl; or lower<br>
alkenyl); -(CH2)mSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)mNR33R34 (where<br>
R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form:<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or<br>
lower alkyl); -(CH2)mOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75:<br>
lower alkyl; or R33 and R75 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-;<br>
-(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)mNR20CONR33R82 (where R20: H;<br>
or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33<br>
and R82 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)mN(R20)COR64 (where: R20: H; or<br>
lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)oC0OR57 (where R57: lower alkyl; or<br>
lower alkenyl); -(CH2)oCONR58R59 (where R58: lower alkyl; or lower alkenyl; and R59: H;<br>
lower alkyl; or R58 and R59 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-;<br>
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oPO(OR60)2<br>
(where R60: lower alkyl; or lower alkenyl); -(CH2)oSO2R62 (where R62: lower alkyl; or lower<br>
alkenyl); or -(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower<br>
alkoxy).<br>
R12: H; lower alkyl; lower alkenyl; -(CH2)mOR55 (where R55: lower alkyl; or lower<br>
alkenyl); -(CH2)mSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)mNR33R34 (where<br>
R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form:<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or<br>
lower alkyl); -(CH2)mOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75:<br>
lower alkyl; or R33 and R75taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-<br>
;or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)mNR20CONR33R82 (where R20: H;<br>
or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33<br>
and R82 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)mN(R20)COR64 (where: R20: H; or<br><br>
lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)rCOOR57 (where R57: lower alkyl; or<br>
lower alkenyl); -(CH2)rCONR58R59 (where R58: lower alkyl; or lower alkenyl; and R59: H; or<br>
lower alkyl; or R58 and R59 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-;<br>
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)rPO(OR60)2<br>
(where R60: lower alkyl; or lower alkenyl); -(CH2)oSO2R62 (where R62: lower alkyl; or lower<br>
alkenyl); or -(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower<br>
alkoxy).<br>
R13: lower alkyl; lower alkenyl; -(CH2)qOR55 (where R55: lower alkyl; or lower<br>
alkenyl); -(CH2)qSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)qNR33R34 (where R33:<br>
lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form:<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or-(CH2)2NR57(CH2)2-; where R57: H; or<br>
lower alkyl); -(CH2)qOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower<br>
alkyl; or R33 and R75 taken together form: -(CH2)2-6-; --(CH2)2O-(CH2)2-; -(CH2)2S(CH2)2-; Or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)qNR20CONR33R82 (where R20: H;<br>
or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33<br>
and R82 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2-; or<br>
-(CH2)2NR57-(CH2)2-; where R57: H; or lower alkyl); -(CH2)qN(R20)COR64 (where: R20: H; or<br>
lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)rCOO57 (where R57: lower alkyl; or<br>
lower alkenyl); -(CH2)qCONR58R59 (where R58: lower alkyl; or lower alkenyl; and R59: H; or<br>
lower alkyl;or R58 and R59 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-<br>
; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)rPO(OR60)2 (where R60: lower<br>
alkyl; or lower alkenyl); -(CH2)rSO2R62 (where R62: lower alkyl; or lower alkenyl); or<br>
-(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy).<br>
R14: H; lower alkyl; lower alkenyl; -(CH2)mOR55 (where R55: lower alkyl; or lower<br>
alkenyl); -(CH2)mSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)mNR33R34 (where<br>
R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form:<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or<br>
lower alkyl); -(CH2)mOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75:<br>
lower alkyl; or R33 and R75 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -<br>
(CH2)2S-(CH2)2-; or<br>
-(CH2)2NR57-(CH2)2-; where R57: H; or lower alkyl); -(CH2)mNR20CONR33R82 (where R20: H;<br>
or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33<br>
and R82 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br><br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)mN(R20)COR64 (where: R20: H;<br>
lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)oCOOR57 (where R57: lower alkyl; or<br>
lower alkenyl); -(CH2)oCONR58R59 (where R58: lower alkyl; or lower alkenyl; and R59: H; or<br>
lower alkyl; or R58 and R59 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-;<br>
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oPO(OR60)2<br>
(where R60: lower alkyl; or lower alkenyl); -(CH2)oS02R62 (where R62: lower alkyl; or lower<br>
alkenyl); -(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower<br>
alkoxy).<br>
R15: lower alkyl; lower alkenyl; -(CH2)oOR55 (where R55: lower alkyl; or lower<br>
alkenyl); -(CH2)oSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)oNR33R34 (where R33:<br>
lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form:<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or<br>
lower alkyl); -(CH2)oOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower<br>
alkyl; or R33 and R75 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oNR20CONR33R82 (where R20: H;<br>
or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33<br>
and R82 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); (CH2)oN(R20)COR64 (where: R20: H; or<br>
lower alkyl; R64: lower alkyl; or lower alkenyl); particularly favoured are NR20COlower alkyl<br>
(R20=H; or lower alkyl); -(CH2)oCOOR57 (where R57: lower alkyl; or lower alkenyl);<br>
-(CH2)oCONR58R39 (where R58: lower alkyl, or lower alkenyl; and R59: H; lower alkyl; or R58<br>
and R59 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60 : lower<br>
alkyl; or lower alkenyl); -(CH2)oSO2R62 (where R62: lower alkyl; or lower alkenyl); or<br>
-(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy).<br>
R16: lower alkyl; lower alkenyl; -(CH2)oOR55 (where R55: lower alkyl; or lower<br>
alkenyl); -(CH2)oSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)oNR33R34 (where R33:<br>
lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form:<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or<br>
lower alkyl); -(CH2)oOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower<br>
alkyl; or R33 and R73 taken together form: -(CH2)2-6-; -(CH2)2O-(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oNR20CONR33R82 (where R20: H;<br>
or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33<br><br>
and R82 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oN(R20)COR64 (where: R20: H; or<br>
lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)oCOOR57 (where R57: lower alkyl; or<br>
lower alkenyl); -(CH2)oCONR58R59 (where R58: lower alkyl; or lower alkenyl; and R59: H; or<br>
lower alkyl; or R58 and R59 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-;<br>
-(CH2)2S(CH2)2-; or --(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oPO(OR60)2<br>
(where R60: lower alkyl; or lower alkenyl); -(CH2)oSO2R62 (where R62: lower alkyl; or lower<br>
alkenyl); or -(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower<br>
alkoxy).<br>
R17: lower alkyl; lower alkenyl; -(CH2)qOR55 (where R55: lower alkyl; or lower<br>
alkenyl); -(CH2)qSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)qNR33R34 (where R33:<br>
lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form:<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NIR57(CH2)2-; where R57: H; or<br>
lower alkyl); -(CH2)qOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower<br>
alkyl; or R33 and R75 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)qNR20CONR33R82 (where R20: H;<br>
or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33<br>
and R82 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)qN(R20)COR64(where: R20: H; or<br>
lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)rCOOR57 (where R57: lower alkyl; or<br>
lower alkenyl); -(CH2)qCONR58R59 (where R58: lower alkyl; or lower alkenyl; and R59: H;<br>
lower alkyl; or R58 and R59 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-;<br>
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)rPO(OR60)2<br>
(where R60: lower alkyl; or lower alkenyl); -(CH2)rSO2R62 (where R62: lower alkyl; or lower<br>
alkenyl); or -(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower<br>
alkoxy).<br>
Among the building blocks A1 to A69 the following are preferred: A5 with R2 being H, A8,<br>
A22, A25, A38 with R2 being H, A42, A47, and A50. Most preferred are building blocks of<br>
type A8':<br><br><br>
wherein R20 is H or lower alkyl; and R64 is alkyl; alkenyl; aryl; aryl-lower alkyl; or<br>
heteroaryl-lower alkyl; especially those wherein R64 is n-hexyl (A8'-l); n-heptyl (A8'-2); 4-<br>
(phenyl)benzyl (A8'-3); diphenylmethyl (A8'-4); 3-amino-propyl (A8'-5); 5-amino-pentyl<br>
(A8'-6); methyl (A8'-7); ethyl (A8'-8); isopropyl (A8'-9); isobutyl (A8'-10); n-propyl (A81-<br>
11); cyclohexyl (A8'-12); cyclohexylmethyl (A8'-13); n-butyl (A8'-14); phenyl (A8'-15);<br>
benzyl (A8'-16); (3-indolyl)methyl (A8'-17); 2-(3-indolyl)ethyl (A8'-18); (4-phenyl)phenyl<br>
(A8'-19); and n-nonyl (A8'-20).<br>
Building block A70 belongs to the class of open-chain a-substituted α-amino acids, building<br>
blocks A71 and A72 to the corresponding p-amino acid analogues and building blocks A73-<br>
A104 to the cyclic analogues of A70. Such amino acid derivatives have been shown to<br>
constrain small peptides in well defined reverse turn or U-shaped conformations (C. M.<br>
Venkatachalam, Biopolymers, 1968, 6, 1425-1434; W. Kabsch, C Sander, Biopolymers 1983,<br>
22, 2577). Such building blocks or templates are ideally suited for the stabilization of β-<br>
hairpin conformations in peptide loops (D. Obrecht, M. Altorfer, J. A. Robinson, "Novel<br>
Peptide Mimetic Building Blocks and Strategies for Efficient Lead Finding", Adv. Med<br>
Chem. 1999, Vol.4, 1-68; P. Balaram, "Non-standard amino acids in peptide design and<br>
protein engineering", Curr. Opin. Struct. Biol. 1992,2, 845-851; M. Crisma, G. Valle, C.<br>
Toniolo, S. Prasad, R. B. Rao, P. Balaram, "p-turn conformations in crystal structures of<br>
model peptides containing α,α- disubstituted amino acids", Biopolymers 1995, 35, 1-9; V. J.<br>
Hruby, F. Al-Obeidi, W. Kazmierski, Biochem. J. 1990, 268, 249-262).<br>
It has been shown that both enantiomers of building blocks -A70-CO- to A104-CO- in<br>
combination with a building block -B-CO- of L-configuration can efficiently stabilize and<br>
induce β-hairpin conformations (D. Obrecht, M. Altorfer, J. A. Robinson, "Novel Peptide<br>
Mimetic Building Blocks and Strategies for Efficient Lead Finding", Adv. Med Chem. 1999,<br>
Vo1.4, 1-68; D. Obrecht, C. Spiegler, P. Schönholzer, K. Müller, H. Heimgartner, F. Stierli,<br><br>
Helv. Chim. Acta 1992, 75, 1666-1696; D. Obrecht, U. Bohdal, J. Daly, C. Lehmann, P.<br>
Schönholzer, K. Müller, Tetrahedron 1995,51, 10883-10900; D. Obrecht, C. Lehmann, C.<br>
Ruffieux, P. SchSnholzer, K. Mailer, Helv. Chim. Acta 1995, 78,1567-1587; D. Obrecht, U.<br>
Bohdal, C. Broger, D. Bur, C. Lehmann, R. Ruffieux, P. Schfinholzer, C. Spiegler, Helv.<br>
Chim. Acta 1995, 78, 563-580; D. Obrecht, H. Karajiannis, C. Lehmann, P. Schonholzer, C.<br>
Spiegler, Helv. Chim. Acta 1995, 78,703-714).<br>
Thus, for the purposes of the present invention templates (al) can also consist of-A70-CO-<br>
to A104-CO- where building block A70 to A104 is of either (D)- or (L)-configuration, in<br>
combination with a building block -B-CO- of (L)- configuration.<br>
Preferred values for R20 in A70 to A104 are H or lower alkyl with methyl being most<br>
preferred. Preferred values for R18, R19 and R21-R29 in building blocks A70 to A104 are the<br>
following:<br>
R18: lower alkyl.<br>
R19: lower alkyl; lower alkenyl; -(CH2)pOR55 (where R55: lower alkyl; or lower<br>
alkenyl); -(CH2)pSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)PNR33R34 (where R33:<br>
lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form:<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57-(CH2)2-; where R57: H; or<br>
lower alkyl); -(CH2)pOCONR33R75(where R33: H; or lower alkyl; or lower alkenyl; R75: lower<br>
alkyl; or R33 and R75 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)pNR20CONR33R82 (where R20: H;<br>
or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33<br>
and R82 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57-(CH2)2-; where R57: H; or lower alkyl); -(CH2)pN(R20)COR64 (where: R20: H; or<br>
lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)pCOOR57 (where R57: lower alkyl; or<br>
lower alkenyl); -(CH2)pCONR58R59 (where R58: lower alkyl; or lower alkenyl; and R59: H; or<br>
lower alkyl; or R58 and R59 taken together form: -(CH2)2-6-; -(CH2)2O-(CH2)2-;<br>
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oPO(OR60)2<br>
(where R60: lower alkyl; or lower alkenyl); -(CH2)pSO2R62 (where R62: lower alkyl; or lower<br>
alkenyl); or -(CH2)oC6H4R8 (where R8: H; F; C1; CF3; lower alkyl; lower alkenyl; or lower<br>
alkoxy).<br><br>
R21: H; lower alkyl; lower alkenyl; -(CH2)oOR55 (where R55: lower alkyl; or lower<br>
alkenyl); -(CH2)oSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)oNR33R34 (where R33:<br>
lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form:<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or<br>
lower alkyl); -(CH2)oOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower<br>
alkyl; or R33 and R75 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oNR20CONR33R82 (where R20: H;<br>
or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33<br>
and R82 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oN(R20)COR64 (where: R20: H; or<br>
lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)oCOOR57 (where R57: lower alkyl; or<br>
lower alkenyl); -(CH2)oCONR58R59 (where R58: lower alkyl, or lower alkenyl; and R59: H;<br>
lower alkyl; or R58 and R59 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-;<br>
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oPO(OR60)2<br>
(where R60: lower alkyl; or lower alkenyl); (CH2)oSO2R62 (where R62: lower alkyl; or lower<br>
alkenyl); or -(CH2)2qC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower<br>
alkoxy).<br>
R22: lower alkyl; lower alkenyl; -(CH2)oOR55 (where R55: lower alkyl; or lower<br>
alkenyl); -(CH2)oSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)oNR33R34 (where R33:<br>
lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form:<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or<br>
lower alkyl); -(CH2)oOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower<br>
alkyl; or R33 and R75 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oNR20CONR33R82 (where R20: H;<br>
or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33<br>
and R82 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oN(R20)COR64(where: R20: H; or<br>
lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)oCOOR57 (where R57: lower alkyl; or<br>
lower alkenyl); -(CH2)oCONR58R59 (where R58: lower alkyl, or lower alkenyl; and R59: H;<br>
lower alkyl; or R58 and R59 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-;<br>
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oPO(OR60)2<br>
(where R60: lower alkyl; or lower alkenyl); -(CH2)oSO2R62 (where R62: lower alkyl; or lower<br><br>
alkenyl); or -(CH2)2qC6H4R8 (where R8: H; F; C1; CF; lower alkyl; lower alkenyl; or lower<br>
alkoxy).<br>
R23: H; lower alkyl; lower alkenyl; -(CH2)oOR55 (where R55: lower alkyl; or lower<br>
alkenyl); -(CH2)oSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)oNR33R34 (where R33:<br>
lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form:<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57-(CH2)2-; where R57: H; or<br>
lower alkyl); -(CH2)oOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower<br>
alkyl; or R33 and R75 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oNR20CONR33R82 (where R20: H;<br>
or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33<br>
and R82 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oN(R20)COR64 (where: R20: H; or<br>
lower alkyl; R64: lower alkyl; or lower alkenyl); particularly favoured are NR20COlower alkyl<br>
(R20=H; or lower alkyl); -(CH2)oCOOR57 (where R57: lower alkyl; or lower alkenyl);<br>
-(CH2)oCONR58R59 (where R58: lower alkyl, or lower alkenyl; and R59: H; lower alkyl; or R58<br>
and R59 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60: lower<br>
alkyl; or lower alkenyl); -(CH2)oSO2R62 (where R62: lower alkyl; or lower alkenyl); or<br>
-(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy);<br>
R24: lower alkyl; lower alkenyl; -(CH2)oOR55 (where R55: lower alkyl; or lower<br>
alkenyl); -(CH2)oSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)oNR33R34 (where R33:<br>
lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form:<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or<br>
lower alkyl); -(CH2)oOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower<br>
alkyl; or R33 and R75 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oNR20CONR33R82 (where R20: H;<br>
or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33<br>
and R82 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oN(R20)COR64 (where: R20: H; or<br>
lower alkyl; R64: lower alkyl; or lower alkenyl); particularly favoured are NR20COlower alkyl<br>
(R20=H ; or lower alkyl); -(CH2)oCOOR57 (where R57: lower alkyl; or lower alkenyl);<br>
-(CH2)oCONR58R59 (where R58: lower alkyl, or lower alkenyl; and R59: H; lower alkyl; or R58<br>
and R59 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br><br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60: lower<br>
alkyl; or lower alkenyl); -(CH2)oSO2R62 (where R62: lower alkyl; or lower alkenyl); or<br>
-(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy);<br>
R25: H; lower alkyl; lower alkenyl; -(CH2)mOR55 (where R55: lower alkyl; or lower<br>
alkenyl); -(CH2)mNR33R34 (where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl;<br>
or R33 and R34 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)mOCONR33R75 (where R33: H; or<br>
lower alkyl; or lower alkenyl; R75: lower alkyl; or R33 and R75 taken together form: -(CH2)2-6-;<br>
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl);<br>
-(CH2)mNR20CONR33R82 (where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower<br>
alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2)2-6-;<br>
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl);<br>
-(CH2)mN(R20)COR64 (where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl);<br>
-(CH2)oCOOR57 (where R57: lower alkyl; or lower alkenyl); -(CH2)oCONR58R59 (where R58:<br>
lower alkyl; or lower alkenyl; and R59: H; lower alkyl; or R58 and R59 taken together form:<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or<br>
lower alkyl); -(CH2)oPO(OR60)2 (where R60: lower alkyl; or lower alkenyl); -(CH2)oSO2R62<br>
(where R62: lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower<br>
alkyl; lower alkenyl; or lower alkoxy).<br>
X26: H; lower alkyl; lower alkenyl; -(CH2)mOR55 (where R55: lower alkyl; or lower<br>
alkenyl); -(CH2)mNR33R34 (where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl;<br>
or R33 and R34 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)mOCONR33R75 (where R33: H; or<br>
lower alkyl; or lower alkenyl; R75: lower alkyl; or R33 and R75 taken together form: -(CH2)2-6-;<br>
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl);<br>
-(CH2)mNR20CONR33R82 (where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower<br>
alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2)2-6-;<br>
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl);<br>
-(CH2)mN(R20)COR64(where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl);<br>
-(CH2)oCOOR57 (where R57: lower alkyl; or lower alkenyl); -(CH2)oCONR58R59 (where R58:<br>
lower alkyl; or lower alkenyl; and R59: H; lower alkyl; or R58 and R59 taken together form:<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or<br>
lower alkyl); -(CH2)oPO(OR60)2 (where R60: lower alkyl; or lower alkenyl); -(CH2)oSO2R62<br><br>
(where R62: lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower<br>
alkyl; lower alkenyl; or lower alkoxy).<br>
Alternatively, R25 and R26 taken together can be -(CH2)2-6-; -(CH2)2O(CH2)2-;<br>
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl).<br>
R27: H; lower alkyl; lower alkenyl; -(CH2)oOR55 (where R55: lower alkyl; or lower<br>
alkenyl); -(CH2)oSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)oNR33R34 (where R33:<br>
lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form:<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or<br>
lower alkyl); -(CH2)oOCONR33R75(where R33: H; or lower alkyl; or lower alkenyl; R75: lower<br>
alkyl; or R33 and R75 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oNR20CONR33R82 (where R20: H;<br>
or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33<br>
and R82 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oN(R20)COR64 (where: R20: H; or<br>
lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)oCOOR57 (where R57: lower alkyl; or<br>
lower alkenyl); -(CH2)oCONR58R59 (where R58: lower alkyl, or lower alkenyl; and R59: H;<br>
lower alkyl; or R58 and R59 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-;<br>
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oPO(OR60)2<br>
(where R60: lower alkyl; or lower alkenyl); -(CH2)oSO2R62 (where R62: lower alkyl; or lower<br>
alkenyl); or -(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower<br>
alkoxy).<br>
R28: lower alkyl; lower alkenyl; -(CH2)oOR55 (where R55: lower alkyl; or lower<br>
alkenyl); -(CH2)oSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)oNR33R34 (where R33:<br>
lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form:<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or<br>
lower alkyl); -(CH2)oOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower<br>
alkyl; or R33 and R75 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oNR20CONR33R82 (where R20: H;<br>
or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33<br>
and R82 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57-(CH2)2-; where R57: H; or lower alkyl); -(CH2)oN(R20)COR64(where: R20: H; or<br>
lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)oCOOR57 (where R57: lower alkyl; or<br>
lower alkenyl); -(CH2)oCONR58R59 (where R58: lower alkyl, or lower alkenyl; and R59: H;<br><br>
lower alkyl; or R58 and R59 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-;<br>
-(CH2)2S-(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oPO(OR60)2<br>
(where R60: lower alkyl; or lower alkenyl); -(CH2)oSO2R62 (where R62: lower alkyl; or lower<br>
alkenyl); or -(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower<br>
alkoxy).<br>
R29: lower alkyl; lower alkenyl; -(CH2)oOR55 (where R55: lower alkyl; or lower<br>
alkenyl); -(CH2)oSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)oNR33R34 (where R33:<br>
lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form:<br>
-(CH2)2-6-;-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or<br>
lower alkyl); -(CH2)oOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower<br>
alkyl; or R33 and R75 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oNR20CONR33R82 (where R20: H;<br>
or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33<br>
and R82 taken together form: -(CH2)M-; -(CH2)z0(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR37(CH2)2-; where R57: H; or lower alkyl); -(CH2)oN(R20)COR64(wto;re: R20. :OR<br>
lower alkyl; R64: lower alkyl; or lower alkenyl); particularly favored are NR20COlower-alkyl<br>
(R20=H; or lower alkyl); -(CH2)0COOR57 (where R57: lower alkyl; or lower alkenyl);<br>
-(CH2)0CONR58R59 (where R58: lower alkyl, or lower alkenyl; and R59: H; lower alkyl; or R58<br>
and R59 taken together form: -(CH2)2-6 -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60: lower<br>
alkyl; or lower alkenyl); -(CH2)oSO2R62 (where R62: lower alkyl; or lower alkenyl); or<br>
-(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy).<br>
For templates (b) to (p), such as (b1) and (cl), the preferred values for the various symbols<br>
are the following:<br>
R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; -(CH2)oOR55 (where R55: lower alkyl;<br>
or lower alkenyl); -(CH2)oSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)oNR33R34<br>
(where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken<br>
together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where<br>
R57: H; or lower alkyl); -(CH2)oOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl;<br>
R75: lower alkyl; or R33 and R75 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-;<br>
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl);<br>
-(CH2)oNR20CONR33R82 (where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower<br><br>
alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2)2-6-;<br>
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl);<br>
-(CH2)oN(R20)COR64 (where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl);<br>
-(CH2)oCOOR57 (where R57: lower alkyl; or lower alkenyl); -(CH2)oCONR58R59 (where R58:<br>
lower alkyl; or lower alkenyl; and R59: H; or lower alkyl; or R58 and R59 taken together form:<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or<br>
lower alkyl); -(CH2)oPO(OR60)2 (where R60: lower alkyl; or lower alkenyl); -(CH2)oSO2R62<br>
(where R62: lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower<br>
alkyl; lower alkenyl; or lower alkoxy).<br>
R20: or lower alkyl.<br>
R30: H, methyl.<br>
R31: H; lower alkyl; lower alkenyl; -(CH2)pOR55 (where R55: lower alkyl; or lower<br>
alkenyl); -(CH2)pNR33R34 (where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or<br>
R33 and R34 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)pOCONR33R75 (where R33: H; or<br>
lower alkyl; or lower alkenyl; R75: lower alkyl; or R33 and R75 taken together form: -(CH2)2-6-;<br>
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl);<br>
-(CH2)pNR20CONR33R82 (where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower<br>
alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2)2-6-;<br>
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl);<br>
-(CH2)pN(R20)COR64 (where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl);<br>
-(CH2)oCOOR57 (where R57: lower alkyl; or lower alkenyl); (-CH2)oCONR58R59 (where R58:<br>
lower alkyl, or lower alkenyl; and R59: H; lower alkyl; or R58 and R59 taken together form:<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or<br>
lower alkyl); -(CH2)oPO(OR60)2 (where R60: lower alkyl; or lower alkenyl); -(CH2)oSO2R62<br>
(where R62: lower alkyl; or lower alkenyl); or -(CH2)rC6H4R8 (where R8: H; F; Cl; CF3; lower<br>
alkyl; lower alkenyl; or lower alkoxy); most preferred is -CH2CONR58R59 (R58: H; or lower<br>
alkyl; R59: lower alkyl; or lower alkenyl).<br>
R32: II, methyl.<br>
R33: lower alkyl; lower alkenyl; -(CH2)mOR55 (where R53: lower alkyl; or lower<br>
alkenyl); -(CH2)mNR34R63 (where R34: lower alkyl; or lower alkenyl; R63: H; or lower alkyl;<br>
or R34 and R63 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)mOCONR75R82(where R75: lower<br><br>
alkyl; or lower alkenyl; R82: H; or lower alkyl; or R75 and R82 taken together form: -(CH2)2-6-;<br>
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl);<br>
-(CH2)mNR20CONR78R82 (where R20: H; or lower lower alkyl; R78: H; or lower alkyl; or lower<br>
alkenyl; R82: H; or lower alkyl; or R78 and R82 taken together form: -(CH2)2-6-;<br>
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl);<br>
-(CH2)mN(R20)COR64 (where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl);<br>
-(CH2)oCOOR57 (where R57: lower alkyl; or lower alkenyl); -(CH2)oCONR58R59 (where R58:<br>
lower alkyl; or lower alkenyl; and R59: H; lower alkyl; or R58 and R59 taken together form:<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or<br>
lower alkyl).<br>
R34:H; or lower alkyl.<br>
R35: H; lower alkyl; lower alkenyl; -(CH2)mOR55 (where R55: lower alkyl; or lower<br>
alkenyl); -(CH2)mNR33R34 (where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl;<br>
or R33 and R34 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)mOCONR33R75 (where R33: H; or<br>
lower alkyl; or lower alkenyl; R75: lower alkyl; or R33 and R75 taken together form: -(CH2)2-6-;<br>
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl);<br>
-(CH2)mNR20CONR33R82 (where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower<br>
alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2)2-6-;<br>
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl);<br>
-(CH2)mN(R20)COR64 (where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl);<br>
-(CH2)oCOOR57 (where R57: lower alkyl; or lower alkenyl); -(CH2)oCONR58R59 (where R58:<br>
lower alkyl; or lower alkenyl; and R59: H; lower alkyl; or R58 and R59 taken together form:<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or<br>
lower alkyl).<br>
R36: lower alkyl; lower alkenyl; or aryl-Iower alkyl.<br>
R37: H; lower alkyl; lower alkenyl; -(CH2)pOR55 (where R55: lower alkyl; or lower<br>
alkenyl); -(CH2)pNR33R34 (where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or<br>
R33 and R34 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)pOCONR33R75 (where R33: H; or<br>
lower alkyl; or lower alkenyl; R75: lower alkyl; or R33 and R75 taken together form: -(CH2)2-6-;<br>
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl);<br>
-(CH2)pNR20CONR33R82 (where R20: H; or lower alkyl; R33: H; or lower alkyl; or lower<br><br>
alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2)2-6-;<br>
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57-(CH2)2-; where R57: H; or lower alkyl);<br>
-(CH2)pN(R20)COR64 (where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl);<br>
-(CH2)oCOOR57 (where R57 : lower alkyl; or lower alkenyl); -(CH2)oCONR58R59 (where R58:<br>
lower alkyl, or lower alkenyl; and R59: H; lower alkyl; or R58 and R59 taken together form:<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or-(CH2)2NR57(CH2)2-; where R57: H; or<br>
lower alkyl); -(CH2)oPO(OR60)2 (where R60: lower alkyl; or lower alkenyl); -(CH2)oSO2R62<br>
(where R62; lower alky; or lower alkenyl); or -(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower<br>
alkyl; lower alkenyl; or lower alkoxy).<br>
R38: H; lower alkyl; lower alkenyl; -(CH2)pOR55 (where R55: lower alkyl; or lower<br>
alkenyl); -(CH2)pNR33R34 (where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or<br>
R33 and R34 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)pOCONR33R75 (where R33: H; or<br>
lower alkyl; or lower alkenyl; R75: lower alkyl; or R33 and R78 taken together form: -(CH2)2-6-;<br>
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl);<br>
-(CH2)pNR20CONR33R82(where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower<br>
alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2)2-6-;<br>
-(CH2)2O(CH2)2; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl);<br>
-(CH2)pN(R20)COR64 (where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl);<br>
-(CH2)oCOOR57 (where R57: lower alkyl; or lower alkenyl); -(CH2)oCONR58R59 (where R58:<br>
lower alkyl, or lower alkenyl; and R59: H; lower alkyl; or R58 and R59 taken together form:<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57-(CH2)2-; where R57: H; or<br>
lower alkyl); -(CH2)oPO(OR60)2 (where R60: lower alkyl; or lower alkenyl); -(CH2)oSO2R62<br>
(where R62: lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower<br>
alkyl; lower alkenyl; or lower alkoxy).<br>
R39: H; lower alkyl; lower alkenyl; -(CH2)mOR55 (where R55: lower alkyl; or lower<br>
alkenyl); -(CH2)mN(R20)COR64 (where: R20: H; or lower alkyl; R64: lower alkyl; or lower<br>
alkenyl); -(CH2)oCOOR57 (where R57: lower alkyl; or lower alkenyl); -(CH2)oCONR58R59<br>
(where R58: lower alkyl; or lower alkenyl; and R59: H; lower alkyl; or R58 and R59 taken<br>
together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-;or -(CH2)2NR57(CH2)2-; where<br>
R57: H; or lower alkyl).<br>
R40: lower alkyl; lower alkenyl; or aryl-lower alkyl.<br><br>
R41: H; lower alkyl; lower alkenyl; -(CH2)pOR55 (where R55: lower alkyl; or lower<br>
alkenyl); -(CH2)pNR33R34 (where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or<br>
R33 and R34 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)pOCONR33R75 (where R33: H; or<br>
lower alkyl; or lower alkenyl; R75: lower alkyl; or R33 and R75 taken together form: -(CH2)2-6-;<br>
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl);<br>
-(CH2)pNR20CONR33R82 (where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower<br>
alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2)2-6-;<br>
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl);<br>
-(CH2)pN(R20)COR64 (where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl);<br>
-(CH2)oCOOR57 (where R57: lower alkyl; or lower alkenyl); -(CH2)oCONR58R59 (where R58:<br>
lower alkyl, or lower alkenyl; and R59: H; lower alky; or R58 and R59 taken together form:<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or<br>
lower alkyl); -(CH2)oPO(OR60)2 (where R60: lower alkyl; or lower alkenyl); -(CH2)oSO2R62<br>
(where R62: lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower<br>
alkyl; lower alkenyl; or lower alkoxy).<br>
R42: H; lower alkyl; lower alkenyl; -(CH2)pOR55 (where R55: lower alkyl; or lower<br>
alkenyl); -(CH2)pNR33R34 (where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or<br>
R33 and R34 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)pOCONR33R75 (where R33: H; or<br>
lower alkyl; or lower alkenyl; R75: lower alkyl; or R33 and R75 taken together form: -(CH2)2-6-;<br>
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl);<br>
-(CH2)pNR20CONR33R82 (where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower<br>
alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2)2-6-;<br>
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl);<br>
-(CH2)pN(R20)COR64 (where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl);<br>
-(CH2)oCOOR57 (where R57: lower alkyl; or lower alkenyl); -(CH2)oCONR58R59 (where R58:<br>
lower alkyl, or lower alkenyl; and R59: H; lower alkyl; or R58 and R59 taken together form:<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or-(CH2)2NR57(CH2)2-; where R57: H; or<br>
lower alkyl); -(CH2)oPO(OR60)2 (where R60: lower alkyl; or lower alkenyl); -(CH2)oSO2R62<br>
(where R62: lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower<br>
alkyl; lower alkenyl; or lower alkoxy).<br><br>
R13: H; lower alkyl; lower alkenyl; -(CH2)mOR55 (where R55: lower alkyl; or lower<br>
alkenyl); -(CH2)mSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)mNR33R34 (where<br>
R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form:<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or<br>
lower alkyl); -(CH2)mOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75:<br>
lower alkyl; or R33 and R75 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -<br>
(CH2)2S(CH2)2-; <br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)mNR20CONR33R82 (where R20: H;<br>
or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33<br>
and R82 taken together form: -(CH2)2NR57(CH2)2-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)mN(R20)COR64 (where: R20: H; or<br>
lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)oCOOR57 (where R57: lower alkyl; or<br>
lower alkenyl); -(CH2)oCONR58R59 (where R58: lower alkyl; or lower alkenyl; and R59: H;<br>
lower alkyl; or R58 and R59 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-;<br>
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oPO(OR60)2<br>
(where R60: lower alkyl; or lower alkenyl); -(CH2)oSO2R62 (where R62: lower alkyl; or lower<br>
alkenyl); or -(CH2)qC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower<br>
alkoxy).<br>
R44: lower alkyl; lower alkenyl; -(CH2)pOR55 (where R55: lower alkyl; or lower<br>
alkenyl); -(CH2)pSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)pNR33R34 (where R33:<br>
lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form:<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or<br>
lower alkyl); -(CH2)pOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower<br>
alkyl; or R33 and R78 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)pNR20CONR33R82 (where R20: H;<br>
or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33<br>
and R82 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; (CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)pN(R20)COR64 (where: R20: H; or<br>
lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)pCOOR57 (where R57: lower alkyl; or<br>
lower alkenyl); -(CH2)pCONR58R59 (where R58: lower alkyl; or lower alkenyl; and R59: H;<br>
lower alkyl; or R58 and R59 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-;<br>
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); or -(CH2)oC6H4R8<br>
(where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy).<br><br>
R45: H; lower alkyl; lower alkenyl; -(CH2)oOR55 (where R55: lower alkyl; or lower<br>
alkenyl); -(CH2)oSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)oNR33R34 (where R33:<br>
lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form:<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or<br>
lower alkyl); -(CH2)sOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower<br>
alkyl; or R33 and R75 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oNR20CONR33R82 (where R20: H;<br>
or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33<br>
and R82 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)oN(R20)COR64 (where: R20: H; or<br>
lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)oCOOR57 (where R57: lower alkyl; or<br>
lower alkenyl); -(CH2)oCONR58R59 (where R58: lower alkyl; or lower alkenyl; and R59: H;<br>
lower alkyl; or R58 and R59 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-;<br>
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); or -(CH2)sC6H4R8<br>
(where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy).<br>
R46: H; lower alkyl; lower alkenyl; -(CH2)sOR55 (where R55: lower alkyl; or lower<br>
alkenyl); -(CH2)sSR56 (where R56: lower alkyl; or lower alkenyl); -(CH2)sNR33R34 (where R33:<br>
lower alkyl; or lower alkenyl; R34: H; or lower alkyl; or R33 and R34 taken together form:<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or<br>
lower alkyl); -(CH2)sOCONR33R75 (where R33: H; or lower alkyl; or lower alkenyl; R75: lower<br>
alkyl; or R33 and R75 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)sNR20CONR33R82 (where R20: H;<br>
or lower lower alkyl; R33: H; or lower alkyl; or lower alkenyl; R82: H; or lower alkyl; or R33<br>
and R82 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)sN(R20)COR64 (where: R20: H; or<br>
lower alkyl; R64: lower alkyl; or lower alkenyl); -(CH2)oCOOR57 (where R57: lower alkyl; or<br>
lower alkenyl); -(CH2)oCONR58R59 (where R58: lower alkyl; or lower alkenyl; and R59: H;<br>
lower alkyl; or R58 and R59 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-;<br>
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); or -(CH2)sC6H4R8<br>
(where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy).<br>
R47: H; or OR55 (where R55: lower alkyl; or lower alkenyl).<br>
R48:H; or lower alkyl.<br><br>
R49: H;lower alkyl; -(CH2)oCOOR57 (where R57: lower alkyl; or lower alkenyl);<br>
-(CH2)oCONR58R59 (where R58: lower alkyl; or lower alkenyl; and R59: H; lower alkyl; or R58<br>
and R59 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); or (CH2)sC6H4R8 (where R8: H; F; Cl;<br>
CF3; lower alkyl; lower alkenyl; or lower alkoxy).<br>
R50: H; methyl.<br>
R51: H; lower alkyl; lower alkenyl; -(CH2)mOR55 (where R55: lower alkyl; or lower<br>
alkenyl); -(CH2)NR33R34 (where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl;<br>
or R33 and R34 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); (CH2)mOCONR33R75 (where R33: H; or<br>
lower alkyl; or lower alkenyl; R75: lower alkyl; or R33 and R75 taken together form: -(CH2)2-6-; <br>
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl);<br>
-(CH2)mNR20CONR33R82 (where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower<br>
alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2)2-6-;<br>
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl);<br>
-(CH2)mN(R20)COR64 (where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl);<br>
-(CH2)pCOOR57 (where R57: lower alkyl; or lower alkenyl); -(CH2)pCONR58R59 (where R58:<br>
lower alkyl; or lower alkenyl; and R59: H; lower alkyl; or R58 and R59 taken together form:<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or<br>
lower alkyl); or -(CH2)rC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower<br>
alkoxy).<br>
R52: H; lower alkyl; lower alkenyl; -(CH2)mOR55 (where R55: lower alkyl; or lower<br>
alkenyl); -(CH2)mNR33R34 (where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl;<br>
or R33 and R34 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)mOCONR33R75 (where R33: H; or<br>
lower alkyl; or lower alkenyl; R75: lower alkyl; or R33 and R75 taken together form: -(CH2)2-6-;<br>
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl);<br>
-(CH2)mNR20CONR33R82 (where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower<br>
alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; R57: H; or lower alkyl);<br>
-(CH2)mN(R20)COR64 (where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl);<br>
-(CH2)pCOOR57 (where R57: lower alkyl; or lower alkenyl); -(CH2)pCONR58R59 (where R58:<br>
lower alkyl; or lower alkenyl; and R59: H; lower alkyl; or R58 and R59 taken together form:<br><br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or<br>
lower alkyl); or -(CH2)rC6H4R8 (where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower<br>
alkoxy).<br>
R53: H; lower alkyl; lower alkenyl; -(CH2)mOR55 (where R55: lower alkyl; or lower<br>
alkenyl); -(CH2)mNR33R34 (where R33: lower alkyl; or lower alkenyl; R34: H; or lower alkyl;<br>
or R33 and R34 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl); -(CH2)mOCONR33R75 (where R33: H; or<br>
lower alkyl; or lower alkenyl; R75: lower alkyl; or R33 and R75 taken together form: -(CH2)2-6-;<br>
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl);<br>
-(CH2)mNR20CONR33R82 (where R20: H; or lower lower alkyl; R33: H; or lower alkyl; or lower<br>
alkenyl; R82: H; or lower alkyl; or R33 and R82 taken together form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower alkyl);<br>
-(CH2)mNR20COR64 (where: R20: H; or lower alkyl; R64: lower alkyl; or lower alkenyl);<br>
-(CH2)pCOOR57 (where R57: lower alkyl; or lower alkenyl); -(CH2)pCONR58R59 (where R58:<br>
lower alkyl; or lower alkenyl; and R59: H; lower alkyl; or R58 and R59 taken together form:<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or<br>
lower alkyl); or -(CH2)rC6H4R8(where R8: H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower<br>
alkoxy).<br>
R54: lower alkyl; lower alkenyl; or aryl-lower alkyl.<br>
Among the building blocks A70 to A104 the following are preferred: A74 with R22 being H,<br>
A75, A76, A77 with R22 being H, A78 and A79.<br>
The building block -B-CO- within templates (al) and (a2) designates an L-amino acid<br>
residue. Preferred values for B are: -NR20CH(R71)- and enantiomers of groups A5 with R2<br>
being H, A8, A22, A25, A38 with R2 being H, A42, A47, and A50. Most preferred are<br>
Ala	L-Alanine<br>
Arg	L-Arginine<br>
Asn	L-Asparagine<br>
Cys	L-Cysteine<br>
Gln	L-Glutamine<br>
Gly	Glycine<br>
His	L-Histidine<br>
Ile	L-Isoleucine<br><br>
Leu	L-Leucine<br>
Lys	L-Lysine<br>
Met	L-Methionine<br>
Phe	L-Phenylalanine<br>
Pro	L-Proline<br>
Pro(5RPhe)	(2S,5R)-5-phenylpyrrrolidine-2-carbocyclic acid<br>
Ser	L-Serine<br>
Thr	L-Threonine<br>
Trp	L-Tryptophan<br>
Tyr	L-Tyrosine<br>
Val	L-Valine<br>
Cit	L-Citrulline<br>
Orn	L-Ornithine<br>
tBuA	L-t-Butylalanine<br>
Sar	Sarcosine<br>
t-BuG	L-tert-Butylglycine<br>
4AmPhe	L-para-Aminophenylalanine<br>
3AmPhe	L-meta-Aminophenylalanine<br>
2AmPhe	L-ortho-Aminophenylalanine<br>
Phe(mC(NH2)=NH) L-meta-Amidinophenylalanine<br>
Phe(pC(NH2)=NH) L-para-Amidinophenylalanine<br>
Phe(mNHC(NH2)=NH)L-meta-Guanidinophenylalanine<br>
Phe(pNHC (NH2)=NH) L-para-Guanidinophenylalanine<br>
Phg	L-Phenylglycine<br>
Cha	L-Cyclohexylalanine<br>
C4al	L-3-Cyclobutylalanine<br>
C5al	L-3-Cyclopentylalanine<br>
Nle	L-Norleucine<br>
2-Nal	L-2-Naphthylalanine<br>
1-Nal	L-1-Naphthylalanine<br>
4C1-Phe	L-4-Chlorophenylalanine<br>
3C1-Phe	L-3-Chlorophenylalanine<br>
2C1-Phe	L-2-Chlorophenylalanine<br><br>
3,4C12-Phe	L-3,4-Dichlorophenylalanine<br>
4F-Phe	L-4-Fluorophenylalanine<br>
3F-Phe	L-3-Fluorophenylalanine<br>
2F-Phe	L-2-Fluorophenylalanine<br>
Tic	L-l,2,3,4-Tetrahydroisoquinoline-3-carboxylic acid<br>
Thi	L-β-2-Thienylalanine<br>
Tza	L-2-Thiazolylalanine<br>
Mso	L-Methionine sulfoxide<br>
AcLys	L-N-Acetyllysine<br>
Dpr	L-2,3-Diaminopropionic acid<br>
A2Bu	L-2,4-Diaminobutyric acid<br>
Dbu	(S)-2,3-Diaminobutyric acid<br>
Abu	γ-Aminobutyric acid (GABA)<br>
Aha	8-Aminohexanoic acid<br>
Aib	α-Aminoisobutyric acid<br>
Y(Bzl)	L-O-Benzyltyrosine<br>
Bip	L-Biphenylalanine<br>
S(Bzl)	L-O-Benzylserine<br>
T(Bzl)	L-O-Benzylthreonine<br>
hCha	L-Homo-cyclohexylalanine<br>
hCys	L-Homo-cysteine<br>
hSer	L-Homo-serine<br>
bArg	L-Homo-arginine<br>
hPhe	L-Homo-phenylalanine<br>
Bpa	L-4-Benzoylphenylalanine<br>
Pip	L-Pipecolic acid<br>
OctG	L-Octylglycine<br>
MePhe	L-N-Methylphenylalanine<br>
MeNle	L-N-Methylnorleucine<br>
MeAla	L-N-Methylalanine<br>
Melle	L-N-Methylisoleucine<br>
MeVal	L-N-Methvaline<br><br>
MeLeu	L-N-Methylleucine<br>
In addition, the most preferred values for B also include groups of type A8" of (L)-<br>
configuration:<br><br>
wherein R20 is H or lower alkyl and R64 is alkyl; alkenyl; -[(CH2)u-X]t-CH3 (where X is<br>
-O-; -NR20-, or -S-; u = 1-3, and t = 1-6), aryl; aryl-lower alkyl; or heteroaryl-lower<br>
alkyl; especially those wherein R64 is n-hexyl (A8"-21); n-heptyl (A8"-22); 4-<br>
(phenyl)benzyl (A8"-23); diphenylmethyl (A8"-24); 3-amino-propyl (A8"-25); 5-<br>
amino-pentyl (A8"-26); methyl (A8"-27); ethyl (A8"-28); isopropyl (A8"-29); isobutyl<br>
(A8"-30); n-propyl (A8"-31); cyclohexyl (A8"-32); cyclohexylmethyl (A8"-33); n-<br>
butyl (A8"-34); phenyl (A8"-35); benzyl (A8"-36); (3-indolyl)methyl (A8"-37); 2-(3-<br>
indolyl)ethyl (A8"-38); (4-phenyl)phenyl (A8"-39); n-nonyl (A8"-40); CH3-OCH2CH2-<br>
OCH2- (A8"-41) and CH3-(OCH2CH2)2-OCH2- (A8"-42).<br>
The peptidic chain Z of the P-hairpin mimetics described herein is generally defined in terms<br>
of amino acid residues belonging to one of the following groups:<br>
Group C -NR20CH(R72)CO-; "hydrophobic: small to medium-sized"<br>
Group D -NR20CH(R73)CO-; "hydrophobic: large aromatic or<br>
heteroaromatic"<br>
Group E -NR20CH(R74)CO-; "polar-cationic" and "urea-derived"<br>
Group F -NR20CH(R84)CO-; "polar-non-charged or anionic"<br>
Group H -NR20-CH(CO-)-(CH2)4-7-CH(CO-)-NR20-;<br>
-NR20-CH(CO-)(CH2)pSS(CH2)p-CH(CO-)-NR20-;<br>
-NR20-CH(CO-)-(-(CH2)pNR20CO(CH2)p-CH(CO-)-NR20-;and<br>
-NR20-CH(CO-)-(-(CH2)pNR20CONR20(CH2)p-CH(CO-)-NR20-;<br>
"interstrand linkage"<br><br>
Furthermore, the amino acid residues in chain Z can also be of formula -A-CO- or of formula<br>
-B-CO- wherein A and B are as defined above. Finally, Gly can also be an amino acid residue<br>
in chain Z, and Pro can be an amino acid residue in chain Z, too, with the exception of<br>
positions where interstrand linkages (H) are possible.<br>
Group C comprises amino acid residues with small to medium-sized hydrophobic side chain<br>
groups according to the general definition for substituent R72. A hydrophobic residue refers to<br>
an amino acid side chain that is uncharged at physiological pH and that is repelled by<br>
aqueous solution. Furthermore these side chains generally do not contain hydrogen bond<br>
donor groups, such as (but not limited to) primary and secondary amides, primary and<br>
secondary amines and the corresponding protonated salts thereof, thiols, alcohols,<br>
phosphonates, phosphates, ureas or thioureas. However, they may contain hydrogen bond<br>
acceptor groups such as ethers, thioethers, esters, tertiary amides, alkyl- or aryl phosphonates<br>
and phosphates or tertiary amines. Genetically encoded small-to-medium-sized amino acids<br>
include alanine, isoleucine, leucine, methionine and valine.<br>
Group D comprises amino acid residues with aromatic and heteroaromatic side chain groups<br>
according to the general definition for substituent R73. An aromatic amino acid residue refers<br>
to a hydrophobic amino acid having a side chain containing at least one ring having a<br>
conjugated π-electron system (aromatic group). In addition they may contain hydrogen bond<br>
donor groups such as (but not limited to) primary and secondary amides, primary and<br>
secondary amines and the corresponding protonated salts thereof, thiols, alcohols,<br>
phosphonates, phosphates, ureas or thioureas, and hydrogen bond acceptor groups such as<br>
(but not limited to) ethers, thioethers, esters, tetriary amides, alkyl- or aryl phosphonates -and<br>
phosphates or tertiary amines. Genetically encoded aromatic amino acids include<br>
phenylalanine and tyrosine.<br>
A heteroaromatic amino acid residue refers to a hydrophobic amino acid having a side chain<br>
containing at least one ring having a conjugated π-system incorporating at least one<br>
heteroatom such as (but not limited to) O, S and N according to the general definition for<br>
substituent R77. In addition such residues may contain hydrogen bond donor groups such as<br>
(but not limited to) primary and secondary amides, primary and secondary amines and the<br><br>
corresponding protonated salts thereof, tfaiols, alcohols, phosphonates, phosphates, ureas or<br>
thioureas, and hydrogen bond acceptor groups such as (but not limited to) ethers, thioethers,<br>
esters, tetriary amides, alkyl- or aryl phosphonates -and phosphates or tertiary amines.<br>
Genetically encoded heteroaromatic atnino acids include tryptophan and histidine.<br>
Group E comprises amino acids containing side chains with polar-cationic, acylamino- and<br>
urea-derived residues according to the general definition for substituen R74. Polar-cationic<br>
refers to a basic side chain which is protonated at physiological pH. Genetically encoded<br>
polar-cationic amino acids include arginine, lysine and histidine. Citrulline is an example for<br>
an urea derived amino acid residue.<br>
Group F comprises amino acids containing side chains with polar-non-charged or anionic<br>
residues according to the general definition for substituent R84. A polar-non-charged or<br>
anionic residue refers to a hydrophilic side chain that is uncharged and, respectively anionic<br>
at physiological pH (carboxylic acids being included), but that is not repelled by aqueous<br>
solutions. Such side chains typically contain hydrogen bond donor groups such as (but not<br>
limited to) primary and secondary amides, carboxyclic acids and esters, primary and<br>
secondary amines, thiols, alcohols, phosphonates, phosphates, ureas or thioureas. These<br>
groups can form hydrogen bond networks with water molecules. In addition they may also<br>
contain hydrogen bond acceptor groups such as (but not limited to) ethers, thioethers, esters,<br>
tetriary amides, carboxylic acids and carboxylates, alkyl- or aryl phosphonates -and<br>
phosphates or tertiary amines. Genetically encoded polar-non-charged amino acids include<br>
asparagine, cysteine, glutamine, serine and threonine, but also aspartic acid and glutamic<br>
acid.<br>
Group H comprises side chains of preferably (L)-amino acids at opposite positions of the β-<br>
strand region that can form an interstrand linkage. The most widely known linkage is the<br>
disulfide bridge formed by cysteines and homo-cysteines positioned at opposite positions of<br>
the β-strand. Various methods are known to form disulfide linkages including those described<br>
by: J. P. Tarn et al. Synthesis 1979, 955-957; Stewart et al., Solid Phase Peptide Synthesis,<br>
2d Ed., Pierce Chemical Company, III., 1984; Ahmed et al. J. Biol. Chem. 1975, 250, 8477-<br>
8482; and Pennington et al., Peptides, pages 164-166, Giralt and Andreu, Eds., ESCOM<br><br>
Leiden, The Netherlands, 1990. Most advantageously, for the scope of the present invention,<br>
disulfide linkages can be prepared using acetamidomethyl (Acm)- protective groups for<br>
cysteine. A well established interstrand linkage consists in linking ornithines and lysines,<br>
respectively, with glutamic and aspartic acid residues located at opposite β-strand positions<br>
by means of an amide bond formation. Preferred protective groups for the side chain amino-<br>
groups of ornithine and lysine are allyloxycarbonyl (Alloc) and allylesters for aspartic and<br>
glutamic acid. Finally, interstrand linkages can also be established by linking the amino<br>
groups of lysine and ornithine located at opposite β-strand positions with reagents such as<br>
N,N-carbonylimidazole to form cyclic ureas.<br>
As mentioned earlier, positions for interstrand linkages are positions P4 and P 9 and/or P2<br>
and P1 1 taken together. Such interstrand linkages are known to stabilize the β-hairpin<br>
conformations and thus constitute an important structural element for the design of β-hairpin<br>
mimetics.<br>
Most preferred amino acid residues in chain Z are those derived from natural a-amino acids.<br>
Hereinafter follows a list of amino acids which, or the residues of which, are suitable for the<br>
purposes of the present invention, the abbreviations corresponding to generally adopted usual<br>
practice:<br>
three letter code	one letter code<br>
Ala	L-Alanine	A<br>
Arg	L-Arginine	R<br>
Asn	L-Asparagine	N<br>
Asp	L-Aspartic acid	D<br>
Cys	L-Cysteine	C<br>
Glu	L-Glutamic acid	E<br>
Gln	L-Glutamine	Q<br>
Gly	Glycine	G<br>
His	L-Histidine	H<br>
Ile	L-Isoleucine	I<br><br>
Leu	L-Leucine	L<br>
Lys	L-Lysine	K<br>
Met	L-Methionine	M<br>
Phe	L-Phenylalanine	F<br>
Pro	L-Proline	P<br>
DPro	D-Proline	DP<br>
Ser	L-Serine	S<br>
Thr	L-Threonine	T<br>
Trp	L-Tryptophan	W<br>
Tyr	L-Tyrosine	Y<br>
Val	L-Valine	V<br>
Other α-amino acids which, or the residues of which, are suitable for the purposes of the<br>
present invention include:<br>
Cit	L-Citrulline<br>
Orn	L-Ornithine<br>
tBuA	L-t-Butylalanine<br>
Sar	Sarcosine<br>
Pen	L-Penicillamine<br>
t-BuG	L-tert.-Butylglycine<br>
4AmPhe	L-para-Aminophenylalanine<br>
3AmPhe	L-meta-Aminophenylalanine<br>
2AmPhe	L-ortho-Aminophenylalanine<br>
Phe(mC(NH2)=NH) L-meta-Amidinophenylalanine<br>
Phe(pC(NH2)=NH)	L-para-Amidinophenylalanine<br>
Phe(mNHC (NH2)=NH) L-meta-Guanidinophenylalanine<br>
Phe(pNHC (NH2)=NH) L-para-Guanidinophenylalanine<br>
Phg	L-Phenylglycine<br>
Cha	L-Cyclohexylalanine<br>
C4al	L-3-Cyclobutylalanine<br>
C5al	L-3-Cyclopentylalanine<br>
Nle	L-Norleucine<br><br>
2-Nal	L-2-Naphthylalanine<br>
1-NaI	L-1-Naphthylalanine<br>
4C1-Phe	L-4-Chlorophenylalanine<br>
3C1-Phe	L-3-ChlorophenylaIanine<br>
2C1-Phe	L-2-Chlorophenylalanine<br>
3,4C12-Phe	L-3,4-Dichlorophenylalanine<br>
4F-Phe	L-4-Fluorophenylalanine<br>
3F-Phe	L-3-Fluorophenylalanine<br>
2F-Phe	L-2-Fluorophenylalanine<br>
Tic	l,2,3,4-Tetrahydroisoquinoline-3-carboxylic acid<br>
Thi	L-β-2-Thienylalanine<br>
Tza	L-2-Thiazolylalanine<br>
Mso	L-Methionine sulfoxide<br>
AcLys	N-Acetyllysine<br>
Dpr	2,3-Diaminopropionic acid<br>
A2Bu	2,4-Diaminobutyric acid<br>
Dbu	(S)-2,3-Diaminobutyric acid<br>
Abu	γ-Aminobutyric acid (GABA)<br>
Aha	ε-Aminohexanoic acid<br>
Aib	α-Aminoisobutyric acid<br>
Y(Bzl)	L-O-Benzyltyrosine<br>
Bip	L-(4-phenyl)phenylalanine<br>
S(Bzl)	L-O-Benzylserine<br>
T(Bzl)	L-O-Benzylthreogine<br>
hCha	L-Homo-cyclohexylalanine<br>
hCys	L-Homo-cysteine<br>
hSer	L-Homo-serine<br>
hArg	L-Homo-arginine<br>
hPhe	L-Homo-phenylalanine<br>
Bpa	L-4-Benzoylphenylalanine<br>
4-AmPyrrl	(2S,4S)-4-Amino-pyrrolidine-L-carboxylic acid<br>
4-AmPyrr2	(2S,4R)-4-Amino-pyrrolidine-L-carboxylic acid<br><br>
4-PhePyrrl	(2S,5R)-4-Phenyl-pyrrolidine-L-carboxylic acid<br>
4-PhePyrr2	(2S,5S)-4-Phenyl-pyrrolidine-L-carboxylic acid<br>
5-PhePyrrl	(2S,5R)-5-Phenyl-pyrrolidine-L-carboxylic acid<br>
5-PhePyrr2	(2S,5S)-5-Phenyl-pyrrolidine-L-carboxylic acid<br>
Pro(4-OH)1	(4S)-L-Hydroxyproline<br>
Pro(4-OH)2	(4R)-L-Hydroxyproline<br>
Pip	L-Pipecolic acid<br>
DPip	D-Pipecolic acid<br>
OctG	L-Octylglycine<br>
NGly	N-Methylglycine<br>
MePhe	L-N-Methylphenylalanine<br>
MeNle	L-N-Methylnorleucine<br>
MeAIa	L-N-Methylalanine<br>
Melle	L-N-Methylisoleucine<br>
MeVal	L-N-Methylvaline<br>
MeLeu	L-N-Methylleucine<br>
DimK	L-(N',N'Dimethyl)-lysine<br>
Lpzp	L-Piperazinic acid<br>
Dpzp	D-Piperazinic acid<br>
Isorn	L-(N',N'-diisobutyl)-ornithine<br>
PipAla	L-2-(4'-piperidinyl)-alanine<br>
PirrAla	L-2-(3'-pyrrolidinyl)-alanine<br>
Ampc	4-Amino-piperidine-4-carboxylic acid<br>
NMeR	L-N-Methylarginine<br>
NMeK	L-N-Methyllysine<br>
NMePhe	L-N-Methylphenylalanine<br>
IPegK	L-2-Amino-6-{2-[2-(2-methoxy-<br>
ethoxy)ethoxy]acetylamino}-hexanoic acid<br>
SPegK	L-2-Amino-6-[2-(2methoxy-ethoxy)-acetylamino]-<br>
hexanoic acid<br>
Dab	L-2,4-Diamino-butyric acid<br>
IPegDab	L-2-Amino-4{2-[2-(2-methoxy-ethoxy)-ethoxyl-<br><br>
acetylamino}-butyric acid<br>
SPegDab	L-2-Amino-4[2-(2-methoxy-ethoxy)-acetylamino]<br>
butyric acid<br>
4-PyrAla	L-2-(4'Pyridyl)-alanine<br>
OrnPyr	L-2-Amino-5-[(2' carbonylpyrazine)]amino-pentanoic<br>
acid<br>
BnG	N-Benzylglycine<br>
AlloT	Allo-Threonin<br>
Aoc	2-(S)-Aminooctanoic acid<br>
Cpa	L-Cyclo-Propylalanine<br>
Particularly preferred residues for group C are:<br>
Ala	L-Alanine<br>
Ile	L-Isoleucine<br>
Leu	L-Leucine<br>
Met	L-Methionine<br>
Val	L-Valine<br>
tBuA	L-t-Butylalanine<br>
t-BuG	L-tert.-Butylglycine<br>
Cha	L-Cyclohexylalanine<br>
C4al	L-3-Cyclobutylalanine<br>
C5al	L-3-Cyclopentylalanine<br>
Nle	L-Norleucine<br>
hCha	L-Homo-cyclohexylalanine<br>
OctG	L-Octylglycine<br>
MePhe	L-N-Methylphenylalanine<br>
MeNle	L-N-Methylnorleucine<br>
MeAla	L-N-Methylalanine<br>
Melle	L-N-Methylisoleucine<br>
MeVal	L-N-Methylvaline<br>
MeLeu	L-N-Methylleucine<br>
Aoc	2-(S)-Aminooctanoic acid<br><br>
Cpa	L-Cyclo-Propylalanine<br>
Particularly preferred residues for group D are:<br>
His	L-Histidine<br>
Phe	L-Phenylalanine<br>
Trp	L-Tryptophan<br>
Tyr	L-Tyrosine<br>
Phg	L-Phenylglycine<br>
2-NaI	L-2-Naphthylalanine<br>
1-Nal	L-1-Naphthylalanine<br>
4C1-Phe	L-4-Chlorophenylalanine<br>
3C1-Phe	L-3-Chlorophenylalanine<br>
2C1-Phe	L-2-Chlorophenylalanine<br>
3,4C12-Phe	L-3,4-Dichlorophenylalanine<br>
4F-Phe	L-4-Fluorophenylalanine<br>
3F-Phe	L-3-Fluorophenylalanine<br>
2F-Phe	L-2-Fluorophenylalanine<br>
Thi	L-β-2-Thienylalanine<br>
Tza	L-2-Thiazolylalanine<br>
Y(Bzl)	L-O-Benzyltyrosine<br>
Bip	L-Biphenylalanine<br>
S(Bzl)	L-O-Benzylserine<br>
T(Bzl)	L-O-Benzylthreonine<br>
hPhe	L-Homo-phenylalanine<br>
Bpa	L-4-Benzoylphenylalanine<br>
PirrAla	L-2-(3'-pyrrolidinyl)-alanine<br>
NMePhe	L-N-Methylphenylalanine<br>
4-PyrAla	L-2-(4'Pyridyl)-alanine<br>
Particularly preferred residues for group E are<br>
Arg	L-Arginine<br><br>
Lys	L-Lysine<br>
Orn	L-Ornithine<br>
Dpr	L-2,3-Diaminopropionic acid<br>
A2Bu	L-2S4-Diaminobutyric acid<br>
Dbu	(S)-2,3-Diaminobutyric acid<br>
Phe(pNH2)	L-para-Aminophenylalanine<br>
Phe(mNH2)	L-meta-Aminophenylalanine<br>
Phe(oNH2)	L-ortho-Aminophenylalanine<br>
hArg	L-Homo-arginine<br>
Phe(mC(NH2)=NH) L-meta-Amidinophenylalanine<br>
Phe(pC(NH2)=NH) L-para-Amidinophenylalanine<br>
PheCmNHC(NH2)=NH)L-meta-Guanidinophenylalanine<br>
Phe(pNHC (NH2)=NH) L-para-Guanidinophenylalanine<br>
DimK	L-(N',N'Dimethyl)-lysine<br>
Isorn	L-(N',N'-diisobutyl)-ornithine<br>
NMeR	L-N-Methylarginine<br>
NMeK	L-N-Methyllysine<br>
IPegK	L-2-Amino-6-{2-[2-(2-methoxy-<br>
ethoxy)ethoxy]acetylamino}-hexanoic acid<br>
SPegK L-2-Amino-6-[2-(2methoxy-ethoxy)-acetylamino]-hexanoic acid<br>
Dab	L-2,4-Diamino-butyric acid<br>
IPegDab	L-2-Amino-4{2-[2-(2-methoxy-ethoxy)-ethoxy]-<br>
acetylamino}-butyric acid<br>
SPegDab	L-2-Amino-4[2-(2-methoxy-ethoxy)-acetylamino]<br>
butyric acid<br>
OrnPyr	L-2-Amino-5-[(2' carbonylpyrazine)]aminopentanoic<br>
PipAla	L-2-(4'-piperidinyl)-alanine<br>
30 Particularly preferred residues for group F are<br>
Asn	L-Asparagine<br>
Asp	L-Aspartic acid<br><br>
Cys	L-Cysteine<br>
Gin	L-Glutamine<br>
Glu	L-Glutamic acid<br>
Ser	L-Serine<br>
Thr	L-Threonine<br>
AlloThr	Allo Threonine<br>
Cit	L-Citrulline<br>
Pen	L-Penicillamine<br>
AcLys	L-Nε-Acetyllysine<br>
hCys	L-Homo-cysteine<br>
hSer	L-Homo-serine<br>
Generally, the peptidic chain Z within the β-hairpin mimetics of the invention comprises 12<br>
amino acid residues. The positions P1 to P12 of each amino acid residue in the chain Z are<br>
unequivocally defined as follows: P1 represents the first amino acid in the chain Z that is<br>
coupled with its N-terminus to the C-terminus of the templates (b)-(p), or of group -B-CO- in<br>
template (al), or of group -A-CO- in template (a2); and P12 represents the last amino acid in<br>
the chain Z that is coupled with its C-terminus to the N-terminus of the templates (b)-(p). or<br>
of group -A-CO- in template (al), or of group -B-CO- in template (a2). Each of the positions<br>
P1 to P12 will preferably contain an amino acid residue belonging to one of the above types<br>
C, D, E, F, H, or of formula -A-CO- or of formula -B-CO-, or being Gly, or Pro as follows:<br>
The a-amino acid residues in positions 1 to 12 of the chain Z are preferably:<br>
P1:	of type C or of type Dor of type E or of type F;<br>
P2:	of type D;<br>
P3:	of type C, or the residue is Gly or Pro;<br>
P4:	of type Cor of type E or of type F, or the residue is Gly or Pro;<br>
P5:	of type E, or the residue is Gly or Pro;<br>
P6:	of type E, of type C or of type F or of formula-A-CO-, or the<br>
residue is Gly or Pro;<br>
P7:	of type Cor of type E or of type For of formula-B-CO-;<br><br>
P8: of type D, or of type F;<br>
P9: of type E or of type For of type C;<br>
P10: of type E;<br>
P11: of type F or of type C, or the residue is Gly or Pro; and<br>
P12: of type C or of type Dor of type E, or of type F; or<br>
P4 and P9 and/or P2 and P11, taken together, can form a group of type H;<br>
and<br>
at P6, P10 and P1 1 also D-isomers being possible;<br>
or, alternatively, within the less preferred embodiment mentioned earlier herein above:<br>
P1:	of type Cor of type Dor of type E, or of type F;<br>
P2:	of type F or of type C, or the residue is Gly or Pro;<br>
P3: of type E;<br>
P4:	of type E or of type F or of type C;<br>
P5:	of type D, or of Type F;<br>
P6: of type Cor of type E or of type For of formula-B-CO-;<br>
P7:	of type C or of type F or of formula -A-CO-, or the residue is Gly<br>
or Pro;<br>
P8:	of type E, or the residue is Gly or Pro;<br>
P9:	of type C or of type E or of type F, or the residue is Gly or Pro;<br>
P10: of type C, or the residue is Gly or Pro;<br>
Pll: of type D;and<br>
P12: of type C or of type D or of type E or of type F; or<br>
P4 and P9 and/or P2 and Pll, taken together, can form a group of type H;<br>
and<br>
at P2, P3, and P7 also D-isomers being possible.<br>
If n is 12, the α-amino acid residues in positions 1 to 12 are most preferably:<br>
P1:	Ala, Cit, Thr, Thr, Asp, Glu;<br>
P2:	Trp, Tyr;<br>
P3: Ile,Val,Nle,Chg,Cha;<br>
P4: Dab, Lys, Gln;<br>
P5: Lys, Dab, Orn;<br><br>
P6: Dab, DDab; Lys;<br>
P7: His, Lys, Gln, Dab;<br>
P8:	Tyr, Trp, Ser;<br>
P9	Dab, Lys;<br>
P10: Dab, Lys;<br>
P11: Ala,Abu,Thr,Gly,Pro,Hse,Ile,Nva,DAla,DVal,Aib,Nle,Chg,<br>
Cha, Gln, Asp, Glu, Cpa, t-BuG, Leu, Val, Asn;<br>
P12: Dab, Lys, Gln, Ser;<br>
at P6, P10 and P1 1 are D-Isomers being possible.<br>
Particularly preferred P-hairpin peptidomimetics of the invention include those described in<br>
Examples 1, 2, 6, 16, 19,22, 24, 25, 28, 29, 32, 35, 40, 41,49, 50.<br>
The processes of the invention can advantageously be carried out as parallel array syntheses<br>
to yield libraries of template-fixed β-hairpin peptidomimetics of the above general formula I.<br>
Such parallel syntheses allow one to obtain arrays of numerous (normally 24 to 192, typically<br>
96) compounds of general formula I in high yields and defined purities, minimizing the<br>
formation of dimeric and polymeric by-products. The proper choice of the functionalized<br>
solid-support (i.e. solid support plus linker molecule), templates and site of cyclization play<br>
thereby key roles.<br>
The functionalized solid support is conveniently derived from polystyrene crosslinked with,<br>
preferably 1-5%, divinylbenzene; polystyrene coated with polyethyleneglycol spacers<br>
(TentagelR); and polyacrylamide resins (see also Obrecht, D.; Villalgordo, J.-M, "Solid-<br>
Supported Combinatorial and Parallel Synthesis of Small-Molecular-Weight Compound<br>
Libraries", Tetrahedron Organic Chemistry Series, Vol. 17, Pergamon, Elsevier Science,<br>
1998).<br>
The solid support is functionalized by means of a linker, i.e. a bifunctional spacer molecule<br>
which contains on one end an anchoring group for attachment to the solid support and on the<br>
other end a selectively cleavable functional group used for the subsequent chemical<br>
transformations and cleavage procedures. For the purposes of the present invention two types<br>
of linkers are used:<br><br>
Type 1 linkers are designed to release the amide group under acidic conditions (Rink H,<br>
Tetrahedron Lett. 1987,28, 3783-3790). Linkers of this kind form amides of the carboxyl<br>
group of the amino acids; examples of resins functionalized by such linker structures include<br>
4-[(((2,4-dimethoxyphenyl)Fmoc-aminomethyl)phenoxyacetamido) aminomethyl] PS resin,<br>
4-[(((2,4-dimethoxyphenyl)Fmoc-aminomethyl)phenoxyacetamido)aminomethyl]-4-<br>
methylbenzydrylamine PS resin (Rink amide MBHA PS Resin), and 4-[(((2,4-<br>
dimethoxyphenyl)Fmoc-aminomethyl)phenoxyacetamido) aminomethyl] benzhydrylamine<br>
PS-resin (Rink amide BHA PS resin). Preferably, the support is derived from polystyrene<br>
crosslinked with, most preferably 1-5%, divinylbenzene and functionalized by means of the<br>
4- (((2,4-dimethoxyphenyl)Fmoc-aminomethyl)phenoxyacetamido) linker.<br>
Type 2 linkers are designed to eventually release the carboxyl group under acidic conditions.<br>
Linkers of this kind form acid-labile esters with the carboxyl group of the amino acids,<br>
usually acid-labile benzyl, benzhydryl and trityl esters; examples of such linker structures<br>
include 2-methoxy-4-hydroxymethylphenoxy (SasrinR linker), 4-(2,4-dimethoxyphenyl-<br>
hydroxymethyl)-phenoxy (Rink linker), 4-(4-hydroxymethyl-3-methoxyphenoxy)butyric acid<br>
(HMPB linker), trityl and 2-chlorotrityl. Preferably, the support is derived from polystyrene<br>
crosslinked with, most preferably 1-5%, divinylbenzene and functionalized by means of the<br>
2-chlorotrityl linker.<br>
When carried out as parallel array syntheses the processes of the invention can be<br>
advantageously carried out as described herein below but it will be immediately apparent to<br>
those skilled in the art how these procedures will have to be modified in case it is desired to<br>
synthesize one single compound of the above formula I.<br>
A number of reaction vessels (normally 24 to 192, typically 96), equal to the total number of<br>
compounds to be synthesized by the parallel method, are loaded with 25 to 1000 mg,<br>
preferably 100 mg, of the appropriate functionalized solid support, preferably 1 to 3% cross-<br>
linked polystyrene or Tentagel resin.<br><br>
The solvent to be used must be capable of swelling the resin and includes, but is not limited<br>
to, dichloromethane (DCM), dimethylformamide (DMF), N-methylpyrrolidone (NMP),<br>
dioxane, toluene, tetrahydrofuran (THF), ethanol (EtOH), trifluoroethanol (TFE),<br>
isopropylalcohol and the like. Solvent mixtures containing as at least one component a polar<br>
solvent (e. g. 20% TFE/DCM, 35% THF/NMP) are beneficial for ensuring high reactivity<br>
and solvation of the resin-bound peptide chains (Fields, G. B., Fields, C. G., J. Am. Chem.<br>
Soc. 1991,113,4202-4207).<br>
With the development of various linkers that release the C-terminal carboxylic acid group<br>
under mild acidic conditions, not affecting acid-labile groups protecting functional groups in<br>
the side chain(s), considerable progresses have been made in the synthesis of protected<br>
peptide fragments. The 2-methoxy-4-hydroxybenzylalcohol-derived linker (SasrinR linker,<br>
Mergler et al., Tetrahedron Lett. 1988, 29 4005-4008) is cleavable with diluted trifluoroacetic<br>
acid (0.5-1% TFA in DCM) and is stable to Fmoc deprotection conditions during the peptide<br>
synthesis, Boc/tBu-based additional protecting groups being compatible with this protection<br>
scheme. Other linkers which are suitable for the process of the invention include the super<br>
acid labile 4-(2,4-dimethoxyphenyl-hydroxymethyl)-phenoxy linker (Rink linker, Rink, H.<br>
Tetrahedron Lett. 1987,28, 3787-3790), where the removal of the peptide requires 10%<br>
acetic acid in DCM or 0.2% trifluoroacetic acid in DCM; the 4-(4-hydroxymethyl-3-<br>
methoxyphenoxy)butyric acid-derived linker (HMPB-linker, Flörsheimer &amp; Riniker, Peptides<br>
1991,1990 131) which is also cleaved with 1%TFA/DCM in order to yield a peptide fragment<br>
containing all acid labile side- chain protective groups; and, in particular, the 2-<br>
chlorotritylchloride linker (Barlos et al., Tetrahedron Lett. 1989, 30, 3943-3946), which<br>
allows the peptide detachment using a mixture of glacial acetic acid/trifluoroethanol/DCM<br>
(1:2:7) for 30 min.<br>
Suitable protecting groups for amino acids and, respectively, for their residues are, for<br>
example,<br>
for the amino group (as is present e. g. also in the side-chain of lysine)<br>
Cbz	benzyloxycarbonyl<br>
Boc	tert-butyloxycarbonyl<br>
Fmoc	9-fluorenylmethoxycarbonyl<br><br>
Alloc	allyloxycarbonyl<br>
Teoc	trimethylsilylethoxycarbonyl<br>
Tcc	trichloroethoxycarbonyl<br>
Nps	o-nitrophenylsulfonyl;<br>
Trt	triphenymethyl or trityl<br>
for the carboxyl group (as is present e. g. also in the side-chain of aspartic<br>
and glutamic acid) by conversion into esters with the alcohol components<br>
tBu	tert-butyl<br>
Bn	benzyl<br>
Me	methyl<br>
Ph	phenyl<br>
Pac	Phenacyl<br>
Allyl<br>
Tse	trimethylsilylethyl<br>
Tce	trichloroethyl;<br>
for the guanidino group (as is present e. g. in the side-chain of arginine)<br>
Pmc	2,2,5,7,8-pentamethylchroman-6-sulfonyl<br>
Ts	tosyl (i. e. p-toluenesulfonyl)<br>
Cbz	benzyloxycarbonyl<br>
Pbf	pentamethyldihydrobenzofuran-5-sulfonyl<br>
for the hydroxy group (as is present e. g. in the side-chain of threonine and<br>
serine)<br>
tBu	tert.-butyl<br>
Bn	benzyl<br>
Trt	trityl<br>
and for the mercapto group (as is present e. g. in the side-chain of cysteine)<br><br>
Acm	acetamidomethyl<br>
tBu	tert.-butyl<br>
Bn	benzyl<br>
Trt	trityl<br>
Mtr	4-methoxytrityl..<br>
The 9-fluorenylmethoxycarbonyl- (Fmoc)-protected amino acid derivatives are preferably<br>
used as the building blocks for the construction of the template-fixed p-hairpin loop mimetics<br>
of formula I. For the deprotection, i. e. cleaving off of the Fmoc group, 20% piperidine in<br>
DMF or 2% DBU/2% piperidine in DMF can be used.<br>
The quantity of the reactant, i. e. of the amino acid derivative, is usually 1 to 20 equivalents<br>
based on the milliequivalents per gram (meq/g) loading of the functionalized solid support<br>
(typically 0.1 to 2.85 meq/g for polystyrene resins) originally weighed into the reaction tube.<br>
Additional equivalents of reactants can be used, if required, to drive the reaction to<br>
completion in a reasonable time. The reaction tubes, in combination with the holder block<br>
and the manifold, are reinserted into the reservoir block and the apparatus is fastened<br>
together. Gas flow through the manifold is initiated to provide a controlled environment, for<br>
example, nitrogen, argon, air and the like. The gas flow may also be heated or chilled prior to<br>
flow through the manifold. Heating or cooling of the reaction wells is achieved by heating the<br>
reaction block or cooling externally with isopropanol/dry ice and the like to bring about the<br>
desired synthetic reactions. Agitation is achieved by shaking or magnetic stirring (within the<br>
reaction tube). The preferred workstations (without, however, being limited thereto) are<br>
Labsource's Combi-chem station and MultiSyn Tech's-Syro synthesizer.<br>
Amide bond formation requires the activation of the α-carboxyl group for the acylation step.<br>
When this activation is being carried out by means of the commonly used carbodiimides such<br>
as dicyclohexylcarbodiimide (DCC, Sheehan &amp; Hess, J. Am. Chem. Soc. 1955, 77, 1067-<br>
1068) or diisopropylcarbodiimide (DIC, Sarantakis et al Biochem. Biophys. Res.<br>
Commun.1976, 73, 336-342), the resulting dicyclohexylurea and diisopropylurea is insoluble<br>
and, respectively, soluble in the solvents generally used. In a variation of the carbodiimide<br>
method 1-hydroxybenzotriazole (HOBt, König &amp; Geiger, Chem. Ber 1970,103,788-798) is<br><br>
included as an additive to the coupling mixture. HOBt prevents dehydration, suppresses<br>
racemization of the activated amino acids and acts as a catalyst to improve the sluggish<br>
coupling reactions. Certain phosphonium reagents have been used as direct coupling<br>
reagents, such as benzotriazol-l-yl-oxy-tris-(dimethylamino)-phosphonium<br>
hexafluorophosphate (BOP, Castro et al., Tetrahedron Lett. 1975,14, 1219-1222; Synthesis,<br>
1976,751-752), or benzotriazol-1-yl-oxy-tris-pyrrolidino-phosphonium hexaflurophoshate<br>
(Py-BOP, Coste et al., Tetrahedron Lett. 1990,31,205-208), or 2-(lH-benzotriazol-l-yl-<br>
)l,l,3,3-tetramethyluronium terafluoroborate (TBTU), or hexafluorophosphate (HBTU,<br>
Knorr et al., Tetrahedron Lett. 1989,30,1927-1930), or 1-benzotriazol-l-<br>
[bis(dimethylamino)methylene]-5-chloro-hexafluorophosphate-l,3-oxide(HCTU); these<br>
phosphonium reagents are also suitable for in situ formation of HOBt esters with the<br>
protected amino acid derivatives. More recently diphenoxyphosphoryl azide (DPPA) or O-(7-<br>
aza-benzotriazol-l-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate (TATU) or O-(7-aza-<br>
benzotriazol-l-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU)/7-aza-l-<br>
hydroxy benzotriazole (HOAt, Carpino et al., Tetrahedron Lett. 1994, 35,2279-2281) have<br>
also been used as coupling reagents.<br>
Due to the fact that near-quantitative coupling reactions are essential, it is desirable to have<br>
experimental evidence for completion of the reactions. The ninhydrin test (Kaiser et al., Anal.<br>
Biochemistry 1970, 34, 595), where a positive colorimetric response to an aliquot of resin-<br>
bound peptide indicates qualitatively the presence of the primary amine, can easily and<br>
quickly be performed after each coupling step. Fmoc chemistry allows the<br>
spectrophotometric detection of the Fmoc chromophore when it is released with the base<br>
(Meienhofer et al., Int. J. Peptide Protein Res. 1979,13, 35-42).<br>
The resin-bound intermediate within each reaction tube is washed free of excess of retained<br>
reagents, of solvents, and of by-products by repetitive exposure to pure solvent(s) by one of<br>
the two following methods:<br>
1)	The reaction wells are filled with solvent (preferably 5 ml), the reaction<br>
tubes, in combination with the holder block and manifold, are immersed and agitated for 5 to<br>
300 minutes, preferably 15 minutes, and drained by gravity followed by gas pressure applied<br>
through the manifold inlet (while closing the outlet) to expel the solvent;<br><br>
2)	The manifold is removed from the holder block, aliquots of solvent<br>
(preferably 5 ml) are dispensed through the top of the reaction tubes and drained by gravity<br>
through a filter into a receiving vessel such as a test tube or vial.<br>
Both of the above washing procedures are repeated up to about 50 times (preferably about 10<br>
times), monitoring the efficiency of reagent, solvent and by-product removal by methods<br>
such as TLC, GC, or inspection of the washings.<br>
The above described procedure of reacting the resin-bound compound with reagents within<br>
the reaction wells followed by removal of excess reagents, by-products and solvents is<br>
repeated with each successive transformation until the final resin-bound fully protected linear<br>
peptide has been obtained.<br>
Before this fully protected linear peptide is detached from the solid support, it is possible, if<br>
desired, to selectively deprotect one or several protected functional group(s) present in the<br>
molecule and to appropriately substitute the reactive group(s) thus liberated. To this effect,<br>
the functional group(s) in question must initially be protected by a protecting group which<br>
can be selectively removed without affecting the remaining protecting groups present. Alloc<br>
(allyloxycarbonyl) is an example for such an amino protecting group which can be selectively<br>
removed, e.g. by means of Pd° and phenylsilane in CH2C12, without affecting the remaining<br>
protecting groups, such as Fmoc, present in the molecule. The reactive group thus liberated<br>
can then be treated with an agent suitable for introducing the desired substituent Thus, for<br>
example, an amino group can be acylated by means of an acylating agent corresponding to<br>
the acyl substituent to be introduced. For the formation of pegylated amino acids such as<br>
IPegK, or SPegK, preferably a solution of 5 equivalents of HATU (N-[(dimethylamino)-lH-<br>
l,2,3-triazolo[4,5-b]pyridin-l-ylmethyIene]-N-methylmethanaminiumhexafluorophosphate<br>
N-oxide) in dry DMF and a solution of 10 equivalents of DIPEA (Diisopropyl ethaylamine)<br>
in dry DMF and 5 equivalents of 2-[2-(2-methoxyethoxy)ethoxy] acetic acid (IPeg) and,<br>
respectively, 2-(2-methoxyethoxy)acetic acid (sPeg), is applied to the liberated amino group<br>
of the appropiate amino acid side chain for 3 h. The procedure is thereafter repeated for<br>
another 3h with a fresh solution of reagents after filtering and washing the resin.<br><br>
Before this fully protected linear peptide is detached from the solid support, it is also<br>
possible, if desired, to form (an) interstrand linkage(s) between side-chains of appropriate<br>
amino acid residues at opposite positions of the β-strand region.<br>
Interstrand linkages and their formation have been discussed above, in connection with the<br>
explanations made regarding groups of the type H which can, for example, be disulfide<br>
bridges formed by cysteine and homocysteine residues at opposite positions of the β-strand;<br>
or lactam bridges formed by glutamic and aspartic acid residues linking ornithine and,<br>
respectively, lysine residues, or by glutamic acid residues linking 2,4-diaminobutyric acid<br>
residues located at opposite β-strand positions by amide bond formation. The formation of<br>
such interstrand linkages can be effected by methods well known in the art<br>
For the formation of disulfide bridges preferably a solution of 10 equivalents of iodine<br>
solution is applied in DMF or in a mixture of CH2C12 /MeOH for 1.5 h which is repeated for<br>
another 3h with a fresh iodine solution after filtering of the iodine solution, or in a mixture of<br>
DMSO and acetic acid solution, buffered with 5% with NaHCO3 to pH 5-6 for 4h, or in water<br>
after having been adjusted to pH 8 with ammonium hydroxide solution by stirring for 24h or<br>
ammonium acetate buffer adjusted to pH 8 in the presence of air, or in a solution of NMP and<br>
tri-n- butylphosphine (preferably 50 eq.).<br>
Detachment of the fully protected linear peptide from the solid support is achieved by<br>
immersion of the reaction tubes, in combination with the holder block and manifold, in<br>
reaction wells containing a solution of the cleavage reagent (preferably 3 to 5 ml). Gas flow,<br>
temperature control, agitation and reaction monitoring are implemented as described above<br>
and as desired to effect the detachment reaction. The reaction tubes, in combination with the<br>
holder block and manifold, are disassembled from the reservoir block and raised above the<br>
solution level but below the upper lip of the reaction wells, and gas pressure is applied<br>
through the manifold inlet (while closing the outlet) to efficiently expel the final product<br>
solution into the reservoir wells. The resin remaining in the reaction tubes is then washed 2 to<br>
5 times as above with 3 to 5 ml of an appropriate solvent to extract (wash out) as much of the<br>
detached product as possible. The product solutions thus obtained are combined, taking care<br>
to avoid cross-mixing. The individual solutions/extracts are then manipulated as needed to<br><br>
isolate the final compounds. Typical manipulations include, but are not limited to,<br>
evaporation, concentration, liquid/liquid extraction, acidification, basification, neutralization<br>
or additional reactions in solution.<br>
The solutions containing fully protected linear peptide derivatives which have been cleaved<br>
off from the solid support and neutralized with a base, are evaporated. Cyclization is then<br>
effected in solution using solvents such as DCM, DMF, dioxane, THF and the like. Various<br>
coupling reagents which were mentioned earlier can be used for the cyclization. The duration<br>
of the cyclization is about 6-48 hours, preferably about 16 hours. The progress of the reaction<br>
is followed, e. g. by RP-HPLC (Reverse Phase High Performance Liquid Chromatography).<br>
Then the solvent is removed by evaporation, the fully protected cyclic peptide derivative is<br>
dissolved in a solvent which is not miscible with water, such as DCM, and the solution is<br>
extracted with water or a mixture of water-miscible solvents, in order to remove any excess<br>
of the coupling reagent<br>
Finally, the fully protected peptide derivative is treated with 95% TFA, 2.5% H2O, 2.5% TIS<br>
or another combination of scavengers for effecting the cleavage of protecting groups. The<br>
cleavage reaction time is commonly 30 minutes to 12 hours, preferably about 2.5 hours. The<br>
volatiles are evaporated to dryness and the crude peptide is dissolved in 20% AcOH in<br>
water and extracted with isopropyl ether or other solvents which are suitable therefor.<br>
The aqueous layer is collected and evaporated to dryness, and the fully deprotected<br>
cyclic peptide derivative of formula I is obtained as end-product. Depending on its purity,<br>
this peptide derivative can be used directly for biological assays, or it has to be further<br>
purified, for example by preparative HPLC.<br>
Alternatively the detachment, cyclisation and complete deprotection of the fully protected<br>
peptide from the solid support can be achieved manually in glass vessels.<br>
As mentioned earlier, it is thereafter possible, if desired, to convert a fully deprotected<br>
product of formula I thus obtained into a pharmaceutically acceptable salt or to convert a<br>
pharmaceutically acceptable, or unacceptable, salt thus obtained into the corresponding free<br><br>
compound of formula I or into a different, pharmaceutically acceptable, salt Any of these<br>
operations can be carried out by methods well known in the art.<br>
The template starting materials of formula II used in the processes of the invention, pre-<br>
starting materials therefor, and the preparation of these starting and pre-starting materials are<br>
described in International Application PCT/EP02/01711, published as WO 02/070547 Al.<br>
The β-hairpin peptidomimetics of the invention can be used in a wide range of applications in<br>
order to inhibit the growth of or to kill microorganisms. In particular they can be used to<br>
selectively inhibit the growth of or to kill microorganisms such as Pseudomonas aeruginosa.<br>
They can be used for example as disinfectants or as preservatives for materials such as<br>
foodstuffs, cosmetics, medicaments and other nutrient-containing materials. The β-hairpin<br>
peptidomimetics of the invention can also be used to treat or prevent diseases related to<br>
microbial infection in plants and annuals.<br>
For use as disinfectants or preservatives the β-hairpin peptidomimetics can be added to the<br>
desired material singly, as mixtures of several β-hairpin peptidomimetics or in combination<br>
with other antimicrobial agents. The β-hairpin peptidomimetics may be administered per se<br>
or may be applied as an appropriate formulation together with carriers, diluents or excipients<br>
well known in the art<br>
When used to treat or prevent infections or diseases related to such infections, particularly<br>
infections related to respiratory diseases such as cystic fibrosis, emphysema and asthma;<br>
infections related to skin or soft tissue diseases such as surgical wounds, traumatic wounds<br>
and burn wounds; infections related to gastrointestinal diseases such as epidemic diarrhea,<br>
necrotizing enterocolitis and typhlitis; infections related to eye diseases such as keratitis and<br>
endophthalmitis; infections related to ear diseases such as otitis, infections related to CNS<br>
diseases such as brain abscess and meningitis; infections related to bone diseases such as<br>
osteochondritis and osteomyelitis; infections related to cardiovascular diseases such as<br>
endocartitis and pericarditis; or infections related to gastrourinal diseases such as<br><br>
epididymitis, prostatitis and urethritis; the β-hairpin peptidomimetics can be administered<br>
singly, as mixtures of several β-hairpin peptidomimetics, in combination with other<br>
antimicrobial or antibiotic agents, or anti cancer agents, or antiviral (e. g. anti-HIV) agents, or<br>
in combination with other pharmaceutically active agents. The β-hairpin peptidomimetics can<br>
be administered per se or as pharmaceutical compositions.<br>
Pharmaceutical compositions comprising β-hairpin peptidomimetics of the invention may be<br>
manufactured by means of conventional mixing, dissolving, granulating, coated tablet-<br>
making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.<br>
Pharmaceutical compositions may be formulated in conventional manner using one or more<br>
physiologically acceptable carriers, diluents, excipients or auxiliaries which facilitate<br>
processing of the active β-hairpin peptidomimetics into preparations which can be used<br>
pharmaceutically. Proper formulation depends upon the method of administration chosen.<br>
For topical administration the β-hairpin peptidomimetics of the invention may be formulated<br>
as solutions, gels, ointments, creams, suspensions, etc. as are well-known in the art<br>
Systemic formulations include those designed for administration by injection, e.g.<br>
subcutaneous, intravenous, intramuscular, intrathecal or intraperitoneal injection, as well as<br>
those designed for transdermal, transmucosal, oral or pulmonary administration.<br>
For injections, the β-hairpin peptidomimetics of the invention may be formulated in adequate<br>
solutions, preferably in physiologically compatible buffers such as Hink's solution, Ringer's<br>
solution, or physiological saline buffer. The solution may contain formulatory agents such as<br>
suspending, stabilizing and/or dispersing agents. Alternatively, the β-hairpin peptidomimetics<br>
of the invention may be in powder form for combination with a suitable vehicle, e.g., sterile<br>
pyrogen-free water, before use.<br>
For transmucosal administration, penetrants appropriate to the barrier to be permeated are<br>
used in the formulation as known in the art.<br><br>
For oral administration, the compounds can be readily formulated by combining the active β-<br>
hairpin peptidomimetics of the invention with pharmaceutically acceptable carriers well<br>
known in the ait Such carriers enable the β-hairpin peptidomimetics of the invention to be<br>
formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions etc.,<br>
for oral ingestion of a patient to be treated. For oral formulations such as, for example,<br>
powders, capsules and tablets, suitable excipients include fillers such as sugars, such as<br>
lactose, sucrose, mannitol and sorbitol; cellulose preparations such as maize starch, wheat<br>
starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose,<br>
hydroxypropylmethyl cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone<br>
(PVP); granulating agents; and binding agents. If desired, desintegrating agents may be<br>
added, such as cross-linked polyvinylpyrrolidones, agar, or alginic acid or a salt thereof, such<br>
as sodium alginate. If desired, solid dosage forms may be sugar-coated or enteric-coated<br>
using standard techniques.<br>
For oral liquid preparations such as, for example, suspensions, elixirs and solutions, suitable<br>
carriers, excipients or diluents include water, glycols, oils, alcohols, etc. In addition, flavoring<br>
agents, preservatives, coloring agents and the like may be added.<br>
For buccal administration, the composition may take the form of tablets, lozenges, etc.<br>
formulated as usual.<br>
For administration by inhalation, the β-hairpin peptidomimetics of the invention are<br>
conveniently delivered in form of an aeorosol spray from pressurized packs or a nebulizer,<br>
with the use of a suitable propellant, e.g. dichlorodifluoromethane, trichlorofluromethane,<br>
carbon dioxide or another suitable gas. In the case of a pressurized aerosol the dose unit may<br>
be determined by providing a valve to deliver a metered amount Capsules and cartridges of<br>
e.g. gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of<br>
the p-hairpin peptidomimetics of the invention and a suitable powder base such as lactose or<br>
starch.<br><br>
The compounds may also be formulated in rectal or vaginal compositions such as<br>
suppositories together with appropriate suppository bases such as cocoa butter or other<br>
glycerides.<br>
In addition to the formulations described previously, the β-hairpin peptidomimetics of the<br>
invention may also be formulated as depot preparations. Such long acting formulations may<br>
be administered by implantation (e.g. subcutaneously or intramuscularly) or by intramuscular<br>
injection. For the manufacture of such depot preparations the β-hairpin peptidomimetics of<br>
the invention may be formulated with suitable polymeric or hydrophobic materials (e.g. as an<br>
emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble salts.<br>
In addition, other pharmaceutical delivery systems may be employed such as liposomes and<br>
emulsions well known in the art. Certain organic solvents such as dimethylsulfoxide also may<br>
be employed. Additionally, the β-hairpin peptidomimetics of the invention may be delivered<br>
using a sustained-release system, such as semipermeable matrices of solid polymers<br>
containing the therapeutic agent. Various sustained-release materials have been established<br>
and are well known by those skilled in the art Sustained-release capsules may, depending on<br>
their chemical nature, release the compounds for a few weeks up to over 100 days.<br>
Depending on the chemical nature and the biological stability of the therapeutic agent,<br>
additional strategies for protein stabilization may be employed.<br>
As the β-hairpin pepdidomimetics of the invention may contain charged residues, they may<br>
be included in any of the above-described formulations as such or as pharmaceutically<br>
acceptable salts. Pharmaceutically acceptable salts tend to be more soluble in aqueous and<br>
other protic solvents man are the corresponding free base forms.<br>
The β-hairpin peptidomimetics of the invention, or compositions thereof, will generally be<br>
used in an amount effective to achieve the intended purpose. It is to be understood that the<br>
amount used will depend on a particular application.<br>
For example, for use as a desinfectant or preservative, an antimicrobially effective amount of<br>
a β-hairpin peptidomimetic of the invention, or a composition thereof, is applied or added to<br><br>
the material to be desinfected or preserved. By antimicrobially effective amount is meant an<br>
amount of a p-hairpin peptidomimetic of the invention, or a composition thereof, that inhibits<br>
the growth of, or is lethal to, a target microbe population. While the antimicrobially effective<br>
amount will depend on a particular application, for use as desinfectants or preservatives the<br>
β-hairpin peptidomimetics of the invention, or compositions thereof, are usually added or<br>
applied to the material to be desinfected or preserved in relatively low amounts. Typically,<br>
the β-hairpin peptidomimetics of the invention comprise less than about 5% by weight of a<br>
desinfectant solution or material to be preserved, preferably less than 1% by weight and more<br>
preferably less than 0.1% by weight. An ordinary skilled expert will be able to determine<br>
antimicrobially effective amounts of particular p-hairpin pepdidomimetics of the invention<br>
for particular applications without undue experimentation using, for example, the in vitro<br>
assays provided in the examples.<br>
For use to treat or prevent microbial infections or diseases related to such infections, the β-<br>
hairpin pepidomimetics of the invention, or compositions thereof, are administered or applied<br>
in a therapeutically effective amount. By therapeutically effective amount is meant an amount<br>
effective in ameliorating the symptoms of, or in ameliorating, treating or preventing<br>
microbial infections or diseases related thereto. Determination of a therapeutically effective<br>
amount is well within the capacities of those skilled in the art, especially in view of the<br>
detailed disclosure provided herein.<br>
As in the case of desinfectants and preservatives, for topical administration to treat or prevent<br>
bacterial infections a therapeutically effective dose can be determined using, for example, the<br>
in vitro assays provided in the examples. The treatment may be applied while the infection is<br>
visible, or even when it is not visible. An ordinary skilled expert will be able to determine<br>
therapeutically effective amounts to treat topical infections without undue experimentation.<br>
For systemic administration, a therapeutically effective dose can be estimated initially from<br>
in vitro assays. For example, a dose can be formulated in animal models to achieve a<br>
circulating β-hairpin peptidomimetic concentration range that includes the IC50 as determined<br>
in the cell culture (i.e. the concentration of a test compound that is lethal to 50% of a cell<br>
culture), the MIC, as determined in cell culture (i.e. the concentration of a test compound that<br><br>
is lethal to 100% of a cell culture). Such information can be used to more accurately<br>
determine useful doses in humans.<br>
Initial dosages can also be determined from in vivo data, e.g. animal models, using<br>
techniques that are well known in the art One having ordinary skills in the art could readily<br>
optimize administration to humans based on animal data.<br>
Dosage amount for applications as antimicrobial agents may be adjusted individually to<br>
provide plasma levels of the β-hairpin peptidomimetics of the invention which are sufficient<br>
to maintain the therapeutic effect. Therapeutically effective serum levels may be achieved by<br>
administering multiple doses each day.<br>
In cases of local administration or selective uptake, the effective local concentration of the β-<br>
hairpin peptidomimetics of the invention may not be related to plasma concentration. One<br>
having the skills in the art will be able to optimize therapeutically effective local dosages<br>
without undue experimentation.<br>
The amount of β-hairpin peptidomimetics administered will, of course, be dependent on the<br>
subject being treated, on the subject's weight, the severity of the affliction, the manner of<br>
administration and the judgement of the prescribing physician.<br>
The antimicrobial therapy may be repeated intermittently while infections are detectable or<br>
even when they are not detectable. The therapy may be provided alone or in combination<br>
with other drugs, such as for example antibiotics or other antimicrobial agents.<br>
Normally, a therapeutically effective dose of the β-hairpin peptidomimetics described herein<br>
will provide therapeutic benefit without causing substantial toxicity.<br>
Hemolysis of red blood cells is often employed for assessment of toxicity of related<br>
compounds such as protegrin or tachyplesin. Values are given as %-lysis of red blood cells<br>
observed at a concentration of 100|xg/ml. Typical values determined for cationic peptides<br>
such as protegrin and tachyplesin range between 30-40% with average MIC-values of 1-<br><br>
5μg/ml over a wide range of pathogens. Normally, p-hairpin peptidomimetics of the<br>
invention will show hemolysis in a range of 0.5-10%, often in a range of 1-5%, at activity<br>
levels comparable to those mentioned above for protegrin and tachyplesin. Thus preferred<br>
compounds exhibit low MIC-values and low %-hemolysis of red blood cells observed at a<br>
concentration of 100μ.g/ml.<br>
Toxicity of the β-hairpin peptidomimetics of the invention herein can be determined by<br>
standard pharmaceutical procedures in cell cultures or experimental animals, e.g., by<br>
determining the LD50 (the dose lethal to 50% of the population) or the LD100 (the dose lethal<br>
to 100% of the population). The dose ratio between toxic and therapeutic effect is the<br>
therapeutic index. Compounds which exhibit high therapeutic indices are preferred. The data<br>
obtained from these cell culture assays and animal studies can be used in formulating a<br>
dosage range that is not toxic for use in humans. The dosage of the β-hairpin peptidomimetics<br>
of the invention lies preferably within a range of circulating concentrations that include the<br>
effective dose with little or no toxicity. The dosage may vary within the range depending<br>
upon the dosage form employed and the route of administration utilized. The exact<br>
formulation, route of administration and dose can be chosen by the individual physician in<br>
view of the patient's condition (see, e.g. Fingl et al. 1975, In: The Pharmacological Basis of<br>
Therapeutics, Ch. 1, p. 1).<br>
The following Examples illustrate the invention in more detail but are not intended to limit its<br>
scope in any way. The following abbreviations are used in these Examples:<br>
HBTU: 1-benzotriazol-l-yl-tetramethylurounium hexafluorophosphate<br>
(Knorr et al. Tetrahedron Lett. 1989,30,1927-1930);<br>
HCTU: 1-Benzotriazol l-[bis(dimethylamino)methylene]<br>
-5chloro-hexafluorophosphate-l,3-oxide<br>
HOBt: 1-hydroxybenzotriazole;<br>
DIEA: diisopropylethylamine;<br>
HOAT: 7-aza- 1-hydroxybenzotriazole;<br>
HATU:O-(7-aza-benzotriazole-l-yl)-N,N,N',N'-tetramethyluronoium<br>
hexafluorophosphate (Carpino et al. Tetrahedron Lett. 1994,35,<br>
2279-2281).<br><br>
Examples<br>
1. Peptide synthesis<br>
Coupling of the first protected amino acid residue to the resin<br>
0.5 g of 2-chlorotritylchloride resin (Barlos et al. Tetrahedron Lett. 1989,30, 3943-3946)<br>
(0.83 mMol/g, 0.415 mmol) was filled into a dried flask. The resin was suspended in CH2Cl2<br>
(2.5 ml) and allowed to swell at room temperature under constant stirring for 30 min. The<br>
resin was treated with 0.415 mMol (leq) of the first suitably protected amino acid residue<br>
(see below) and 284 μl (4eq) of diisopropylethylamine (DIEA) in CH2C12 (2.5 ml), the<br>
mixture was shaken at 25°C for 4 hours. The resin was shaken (CH2C12 /MeOH/DIEA:<br>
17/2/1), 30 ml for 30 min; then washed in the following order with CH2C12 (lx), DMF (lx),<br>
CH2Cl2(1x), MeOH (1x), CH2Cl2(1x), MeOH (1x), CH2C12 (2x), Et2O (2x) and dried under<br>
vacuum for 6 hours.<br>
Loading was typically 0.6-0.7 mMol/g.<br>
The following preloaded resin was prepared: Fmoc-Pro-2-chlorotritylresin.<br>
Synthesis of the fully protected peptide fragment<br>
The synthesis was carried out using a Syro-peptide synthesizer (Multisyntech) using<br>
24 to 96 reaction vessels. In each vessel were placed 60 mg (weight of the resin<br>
before loading) of the above resin. The following reaction cycles were programmed<br>
and carried out:<br>
Step	Reagent	Time<br>
1	CH2C12, wash and swell (manual)	3x1 min.<br>
2	DMF, wash and swell	1x5 min<br>
3	40 % piperidine/DMF	2x5 min.<br>
4	DMF, wash	5x2 min.<br>
5	5 equiv. Fmoc amino acid/DMF<br><br>
+ 5 eq. HCTU<br>
+ 5 eq. DIEA	2 x 60 min.<br>
6	DMF, wash	4 x 2 min.<br>
7	CH2Cl2, wash (at the end of the synthesis)	3 x 2 min.<br>
Steps 3 to 6 are repeated to add each amino-acid.<br>
After the synthesis of the fully protected peptide fragment had been terminated, then<br>
subsequently the cleavage, cyclization and work up procedure as described hereinbelow, was<br>
used for the preparation of the peptides.<br>
Analytical methods:<br>
Method 1: Analytical HPLC retention times (RT, in minutes) were determined using an<br>
Jupiter Proteo column (90A, 150x 2.0 mm, cod. 00F4396-B0 - Phenomenex) with the<br>
following solvents A (H2O + 0.1% TFA) and B (CH3CN + 0.1% TFA) and the gradient: 0<br>
min: 95%A, 5%B; 20 min: 40%A 60%B; 21-23 min: 0%A, 100%B; 23.1-30 min: 95% A,<br>
5%B.<br>
Method 2: Analytical HPLC retention times (RT, in minutes) were determined using an<br>
Aquity UPLC BEH C18 column (1.7 μm, 100 x 2.1 mm, cod. 186002352 - Waters) with the<br>
following solvents A (H2O + 0.1% TFA) and B (CH3CN + 0.085% TFA) and the gradient: 0<br>
min: 95%A, 5%B; 0.2 min: 95%A 5%B; 4 min: 35%A, 65%B; 4.2 min: 5% A, 95%B; 4.25<br>
min: 95%A, 5%B; 4.9 min: 95%A, 5%B.<br>
Procedure: Cleavage, cyclization and work up of backbone cyclized peptides<br>
Cleavage, backbone cyclization and purification of the peptide<br>
After assembly of linear peptides, the resin was suspended in 1 ml (0.39 mMol) of 1% TFA<br>
in CH2C12 (v/V) for 3 minutes and filtered, and the filtrate was neutralized with 1m1 (1.17<br>
mMol, 3eq.) of 20% DIEA in CH2C12 (v/V). This procedure was repeated twice to ensure<br>
completion of the cleavage. The resin was washed with 2ml of CH2C12. The CH2C12 layer was<br>
evaporated to dryness.<br><br>
The fully protected linear peptide was solubilised in 8 ml of dry DMF. Then 2 eq. of HATU<br>
in dry DMF (1m1) and 4 eq. of DIPEA in dry DMF (1 ml) were added to the peptide,<br>
followed by stirring for 16 h. The volatiles were evaporated to dryness. The crude cyclic<br>
peptide was dissolved in 7 ml of CH2C12 and extracted with 10% acetonitrile in water (4.5<br>
ml) three times. The CH2CI2 layer was evaporated to dryness. To fully deprotect the peptide,<br>
3 ml of cleavage cocktail TFA:TIS:H2O (95:2.5:2.5) were added, and the mixture was stirred<br>
for 2.5 h. The volatile was evaporated to dryness and the crude peptide was dissolved in 20%<br>
AcOH in water (7 ml) and extracted with diisopropyl ether (4 ml) for three times. The<br>
aqueous layer was collected and evaporated to dryness, and the residue was purified by<br>
preparative reverse phase LC-MS.<br>
After lyophilisation the products were obtained as white powders and analysed by HPLC-<br>
ESI-MS analytical methods as described above. The analytical data comprising purity after<br>
preparative HPLC and ESI-MS are shown in Table 1.<br>
Examples 1-50, are shown in Table 1. The peptides were synthesized starting with the amino<br>
acid L-Pro which was grafted to the resin. Starling resin was Fmoc-Pro-2-chlorotrityl resin,<br>
which was prepared as described above. The linear peptides were synthesized on solid<br>
support according to the procedure described above in the following sequence: Resin-Pro-<br>
DPro-P12-Pl 1-P10-P9-P8-P7-P6-P5-P4-P3-P2-P1. Ex. 1-50, were cleaved from the resin,<br>
cyclized, deprotected and purified as indicated by preparative reverse phase LC-MS.<br>
After lyophilisation the products were obtained as white powders and analysed by HPLC-<br>
ESI-MS methods as described above.<br>
HPLC-retention times (minutes) were determined using the analytical methods as described<br>
above. Examples 1 to 39 were analysed with method 1, for Examples 40-50 method 2 was<br>
used:<br>
Ex. 1 (8.87), Ex. 2 (9.26), Ex. 3 (9.34), Ex. 4 (9.45), Ex. 5 (9.48), Ex. 6 (9.44), Ex. 7 (10.11),<br>
Ex. 8 (9.99), Ex. 9 (10.22), Ex. 10 (9.76), Ex. 11 (10.56), Ex. 12 (11.37), Ex. 13 (9.13), Ex.<br>
14 (9.34), Ex. 15 (8.80), Ex. 16 (9.23); Ex. 17 (9.65), Ex. 18 (9.18), Ex. 19 (8.37), Ex. 20<br>
(8.86), Ex. 21 (8.78), Ex. 22 (9.32), Ex. 23 (9.58), Ex. 24 (9.27), Ex. 25 (9.31), Ex. 26<br>
(9.24), Ex. 27 (9.23), Ex. 28 (9.34), Ex. 29 (9.66), Ex. 30 (9.88), Ex. 31 (9.62), Ex. 32(8.86),<br><br>
Ex. 33 (9.73), Ex. 34 (10.46), Ex. 35 (9.21), Ex. 36 (9.80), Ex. 37 (9.73), Ex. 38 (9.20), Ex.<br>
39 (9.53), Ex. 40 (2.07), Ex 41 (1.77), Ex. 42 (1.66), Ex. 43 (1.67), Ex. 44 (1.81), Ex. 45<br>
(1.87), Ex. 46 (1.81), Ex. 47 (1.83), Ex. 48 (1.79), Ex. 49 (1.88), Ex. 50 (2.17).<br><br><br><br><br><br>
2. Biological methods<br>
2.1.	Preparation of the peptide samples.<br>
Lyophilized peptides were weighed on a Microbalance (Mettler MT5) and dissolved in<br>
sterile water to a final concentration of 1 mg/ml unless stated otherwise. Stock solutions<br>
were kept at +4°C, light protected.<br>
2.2.	Antimicrobial activity of the peptides.<br>
The selective antimicrobial activities of the peptides were determined in 96-well plates<br>
(Nunclon polystyrene) by the standard NCCLS broth microdilution method (see ref 1,<br>
below) with slight modifications. Innocula of the microorganisms were diluted into<br>
Mueller-Hinton (MH) broth + 0.02% BSA and compared with a 0.5 Mcfarland standard<br>
to give appr. 106 colony forming units (CFU)/ml. Aliquots (50 μl) of inoculate were<br>
added to 50 μ1 of MH broth + 0.02% BSA containing the peptide in serial two-fold<br>
dilutions. The following microorganisms were used to determine antibiotic selectivity of<br>
the peptides: Escherichia coli (ATCC 25922), Pseudomonas aeruginosa (P. aeruginosa<br>
ATCC 27853, P8191900, P1021903, P1021913, IMP 1 Livermore 3140). Antimicrobial<br>
activities of the peptides were expressed as the minimal inhibitory concentration (MIC) in<br>
μg/ml at which no visible growth was observed after 18-20 hours of incubation at 37°C.<br>
2.3.	Cytotoxicity assay<br>
The cytotoxicity of the peptides to HELA cells (Acc57) and COS-7 cells (CRL-1651) was<br>
determined using the MTT reduction assay [see ref. 2 and 3, below]. Briefly the method<br>
was as follows: HELA cells and COS-7 cells were seeded at 7.0x103 and, respectively,<br>
4.5x103 cells per well and grown in 96-well microtiter plates for 24 hours at 37°C at 5%<br>
CO2. At this point, time zero (Tz) was determined by MTT reduction (see below).The<br>
supernatant of the remaining wells was discarded, and fresh medium and the peptides in<br>
serial dilutions of 12.5,25 and 50 μM were dispensed into the wells. Each peptide<br>
concentration was assayed in triplicate. Incubation of the cells was continued for 48 hours<br>
at 37°C at 5% CO2. Wells were then washed once with phosphate buffered saline (PBS)<br>
and subsequently 100 μl MTT reagent (0.5 mg/ml in medium RPMI1640 and,<br>
respectively, DMEM) were added to the wells. This was incubated at 37°C for 2 hours<br>
and subsequently the medium was aspirated and 100 μ1 isopropanol were added to each<br>
well. The absorbance at 595 nm of the solubilized product was measured (OD595peptide).<br>
For each concentration averages were calculated from triplicates. The percentage of<br>
growth was calculated as follows: (OD595peptide-OD595Tz-OD595Empty well) / (OD595Tz-<br>
OD595Empty well) x 100% and was plotted for each peptide concentration.<br><br>
The LC 50 values (Lethal Concentration, defined as the concentration that kills 50% of<br>
the cells) were determined for each peptide by using the trend line function of EXCEL<br>
(Microsoft Office 2000) for the concentrations (50,25,12.5 and 0 μM), the<br>
corresponding growth percentages and the value -50, (=TREND(C50:C0,%50:%0,-50)).<br>
The GI 50 (Growth Inhibition) concentrations were calculated for each peptide by using a<br>
trend line function for the concentrations (50,25,12.5 and 0 μg/ml), the corresponding<br>
percentages and the value 50, (=TREND (C50:CO,%50:%O,50).<br>
2.4.	Hemolysis<br>
The peptides were tested for their hemolytic activity against human red blood cells<br>
(hRBC). Fresh hRBC were washed three times with phosphate buffered saline (PBS) by<br>
centrifugation for 10 min at 2000 x g. Peptides at a concentration of 100 μM were<br>
incubated with 20% v/v hRBC for 1 hour at 37°C. The final erythrocyte concentration<br>
was approximately 0.9xl09 cells per ml. A value of 0% and, respectively,. 100% cell lysis<br>
was determined by incubation of the hRBC in the presence of PBS alone and,<br>
respectively, 0.1% Triton X-100 in H2O. The samples were centrifuged, the supernatant<br>
was 20-fold diluted in PBS buffer and the optical density (OD) of the sample at 540 nM<br>
was measured. The 100% lysis value (OD540H2O) gave an OD540 of approximately 1.3-1.8.<br>
Percent hemolysis was calculated as follows: (OD540peptide/OD540H2O) xl00%.<br>
2.5.	Plasma stability<br>
405 μl of plasma/albumin solution were placed in a polypropylene (PP) tube and spiked<br>
with 45 μl of compound from a 100 mM solution B, derived from 135 μl of PBS and 15<br>
111 of 1 mM peptide in PBS, pH 7.4.150 μl aliquots were transferred into individual wells<br>
of the 10 kDa filter plate (Millipore MAPPB 1010 Biomax membrane). For "0 minutes<br>
controls": 270 μl of PBS were placed in a PP tube and 30 μl of stock solution B was<br>
added and mixed. 150 μl of control solution were placed into one well of the filter plate<br>
and served as "filtered control".<br>
Further 150 μl of control solution were placed directly into a receiver well (reserved for<br>
filtrate) and served as "not-filtered control". The entire plate including evaporation lid<br>
was incubated for 60 min at 37°C. Plasma samples (rat plasma: Harlan Sera lab UK,<br>
human plasma: Blutspendezentrum Zürich) were centrifuged at least for 2 h at 4300 rpm<br>
(3500 g) and 15°C in order to yield 100 μl filtrate. For "serum albumin"-samples (freshly<br>
prepared human albumin: Sigma A-4327, rat albumin: Sigma A-6272, all at 40 mg/ml<br>
concentration in PBS) approximately 1 hour of centrifugation was sufficient The filtrates<br><br>
in the receiver PP plate were analysed by LC/MS as follows: Column: Jupiter C18<br>
(Phenomenex), mobile phases: (A) 0.1% formic acid in water and (B) acetonitrile,<br>
gradient: 5%-100% (B) in 2 minutes, electrospray ionization, MRM detection (triple<br>
quadrupole). The peak areas were determined and triplicate values were averaged. The<br>
binding was expressed in percent of the (filtered and not-filtered time point 0 min) control<br>
1 and 2 by: 100-(100 x T60/To). The average from these values was then calculated.<br>
2.6. Pharmacokinetic study (PK)<br>
Pharmacokinetic study after single intravenous, subcutaneous and intraperitoneal<br>
administration in mice<br>
Pharmacokinetic study after single intravenous (i.v.) and subcutaneous (s.c.)<br>
administration was performed for the compound of Example 1 ("Ex. 1"). CD-1 mice (20-<br>
25 g) were used in me study. Physiological saline was used a vehicle. The volume was 2<br>
ml/kg i.v., and 5 ml/kg s.c. and the peptide Ex. 1 was injected to give a final intravenous<br>
dose of 1 mg/kg, and a subcutaneous dose of 5 mg/kg. Approximately 200-230 μl of<br>
blood was removed under light isoflurane anesthesia by cardiac puncture at<br>
predetermined time intervals (0, 5,15, 30 min and 1,2, 3,4 and 5 hours for the i.v. study<br>
and 0,15,30 min and 1,2,4,6,8 and 10 hours for the s.c. study) and added to<br>
heparinized tubes. Plasma was removed from pelleted cells upon centrifugation and<br>
frozen at -80°C prior to HPLC-MS analysis.<br>
Preparation of the plasma calibration samples<br>
"Blank" mouse plasma from untreated animals was used. Aliquots of plasma of 0.2 ml<br>
each were spiked with 50 ng of propranolol (Internal Standard, IS), (sample preparation<br>
by solid phase extraction on OASIS® HLB cartridges (Waters)) and with known amounts<br>
of Ex. 1 in order to obtain 9 plasma calibration samples in the range 10 - 5000 nM. The<br>
OASIS® HLB cartridges were conditioned with 1 ml of methanol and then with 1 ml of<br>
1% NH3 in water. Samples were then diluted with 700 μl of 1% NH3 in water and loaded.<br>
The plate was washed with 1 ml of methanol/1% NH3 in water 5/95. Elution was<br>
performed using 1 ml of 0.1% TFA in methanol.<br>
The plate containing eluates was introduced into the concentrator system and taken to<br>
dryness. The residues were dissolved in 100 μL of formic acid 0.1%/acetonitrile, 95/5<br>
(v/v) and analysed in the HPLC/MS on a reverse phase analytical column (Jupiter C18,<br>
50 x 2.0 mm, 5 μm, Phenomenex), using gradient elution (mobile phases A: 0.1% formic<br>
acid in water, B: Acetonitrile; from 5%B to 100%B in 2 min.).<br><br>
Preparation of plasma samples<br>
Samples coming from animal treatments were pooled in order to obtain an appropriate<br>
volume for the extraction. If the total volume obtained was less than 0.2 ml the<br>
appropriate amount of "blank" mouse plasma was added in order to keep the matrix<br>
identical to the calibration curve. Samples were than spiked with IS and processed as<br>
described for the calibration curve.<br>
Pharmacokinetic evaluation<br>
PK analysis was performed on pooled data (generally n=2 or 3) using the software Win<br>
Nonlin (Pharsight). The area under the curve AUC was calculated by the linear<br>
trapezoidal rule. Elimination half-life was calculated by the linear regression on at least<br>
three data points during the elimination phase. The time intervals selected for the half-life<br>
determinations were evaluated by the correlation coefficient (r2), which should be at least<br>
above 0.85 and most optimally above 0.96. In case of i.v. administration the initial<br>
concentration at tzero was determined by extrapolation of the curve through the first two<br>
time points. Finally bioavailability after i.p. administration was calculated from the<br>
normalised AUCinf_D_obs ration after s.c. versus i.v. administration.<br>
2.7.	In vivo Septicemia Assay<br>
Groups of 6 CD-1 (Cr1.) derived male mice weighing 24 ± 2 g were used. The mice were<br>
each inoculated intravenously (TV) with an LD90-100 of Pseudomonas aeruginosa<br>
(ATCC 27853) (9 x 106 CFU/0.5ml/mouse) in brain heart infusion broth without 5%<br>
mucin. Compound at doses of 5, 2.5, 1, 0.5, 0.25 and 0.1 mg/kg, vehicle (0.9% NaCL, 10<br>
ml/kg) was administered subcutaneously (SC) to test animals at 1hour after bacterial<br>
inoculation. Also, an additional group was treated twice with compound at a dose of<br>
5mg/kg at 1 and 6 hours after bacterial inoculation. Mortality was recorded once daily for<br>
7 days following the bacterial inoculation and an increase of survival of the animals by 50<br>
percent or more (3 50 %) after the bacterial inoculation, relative to vehicle control,<br>
indicates significant antimicrobial effect. The MED (ED50) was determined by nonlinear<br>
regression using Graph-Pad Prism (Graph Pad Software, USA).<br>
2.8.	Results<br>
The results of the experiments described in 2.2,2.3 and 2.4, above, are indicated in Table<br>
2, herein below<br><br><br><br><br><br><br><br><br>
After intravenous administration of Ex. 1 at a dose level of 1 mg/kg body weight, Ex. 1<br>
followed intravenous kinetic characteristics. After PK analysis, Ex 1 showed an<br>
extrapolated Cinitial of 2174 ng/ml and a Cmax observed of 1268 ng/ml at 5 min. Plasma<br>
levels rapidly decreased to 575 and 177 ng/ml at 15 min and 1 hour respectively. From<br><br>
0.5 to 2 h plasma levels decreased with an elimination half-life of 0.53 h to 10.6 ng/ml at<br>
3 h. The AUCINF_obs amounted to 679.5 ng.h/ml.<br>
After subcutaneous administration of Ex. 1 at a dose level of 5 mg/kg body weight,<br>
plasma levels of Ex. 1 increased the first 0.5-1 h and showed a Cmax of 2333 ng/ml. From<br>
0.5 to 8 h plasma levels decreased with an elimination half-life of 0.95 h to 7.3 ng/ml at 8<br>
h. The AUCINF_obs amounted to 4016.5 ng.h/ml.<br>
As compared to the normalized AUC value after i.v. administration (100% absorbed, 679<br>
ng.h/ml) of Ex. 1 absorbed after s.c administration amounted to 118% (803 ng.h/ml). The<br>
value above 100% may partially reflect an impaired reliability caused by the limited<br>
number of points or is caused by a non-linearity in dose.<br>
The results of the experiment described in 2.7 (Septicaemia Assay), above, are indicated<br>
in Table 5-7 herein below.<br>
Septicaemia experiment in mice: LD90-100 of Pseudomonas aeruginosa<br>
(ATCC 27853) (9 x 106 CFU/0.5 ml/mouse IV and after 1 h Ex. 1 s.c.<br><br>
Septicaemia experiment in mice: LD90-100 of Pseudomonas aeruginosa<br>
(ATCC 27853) (9 x 106 CFU/0.5 ml/mouse IV), and after 1 and 5h Ex. 40 s.c.<br><br><br>
References<br>
1.	National Committee for Clinical Laboratory Standards. 1993. Methods for dilution<br>
antimicrobial susceptibility tests for bacteria that grow aerobically, 3rd ed. Approved<br>
standard M7-A3. National Committee for Clinical laboratory standards, Villanova, Pa.<br>
2.	Mossman T. J Immunol Meth 1983,65, 55-63<br>
3.	Berridge MV, Tan AS. Archives of Biochemistry &amp; Biophysics 1993, 303,474-482<br><br><br><br><br><br><br><br><br><br><br><br><br><br><br>
Rl is H; lower alkyl; or aryl-lower alkyl;<br>
R2 is H; alkyl; alkenyl; -(CH2)m(CHR61)sOR55; -(CH2)m(CHR61)sSR56;<br>
-(CH2)m(CHR61)sNR33R34;-(CH2)m(CHR61)sOCONR33R75;<br>
-(CH2)m(CHR61)sNR20CONR33R82; -(CH2)o(CHR61)sCOOR57;<br>
-(CH2)o(CHR61)sCONR58R59; --(CH2)o(CHR61)sPO(OR60)2;<br>
-(CH2)o(CHR61)s SO2R62; or --(CH2)o(CHR61)sC6H4R8;<br>
R3 is H; alkyl; alkenyl; -(CH2)m(CHR61)sOR55; -(CH2)m(CHR61)sSR56;<br>
-(CH2)m(CHR61)sNR33R34;-(CH2)m(CHR61)sOCONR33R75;<br>
-(CH2)m(CHR61)sNR20CONR33R82; -(CH2)o(CHR61)sCOOR57;<br>
-(CH2)o(CHR61)sCONR58R59; -(CH2)o(CHR61)sPO(OR60)2;<br>
-(CH2)o(CHR61)s SO2R62; or -(CH2)o(CHR61)sC6H4R8;<br><br>
R4 is H; alkyl; alkenyl; -(CH2)m(CHR61)sOR55; -(CH2)m(CHR61)sSR56;<br>
-(CH2)m(CHR61)sNR33R34;<br>
-(CH2)m(CHR61)sOCONR33R75; -(CH2)m(CHR61)sNR20CONR33R82;<br>
-(CH2)p(CHR61)sCOOR57; -(CH2)p(CHR61)sCONR58R59;<br>
-(CH2)p(CHR61)sPO(OR60)2;<br>
-(CH2)p(CHR61)s SO2R62; or -(CH2)o(CHR61)sC6H4R8;<br>
R5 is alkyl; alkenyl; -(CH2)o(CHR61)sOR55; -(CH2)o(CHR61)sSR56;<br>
-(CH2)o(CHR61)sNR33R34;<br>
-(CH2)o(CHR61)sOCONR33R75; -(CH2)o(CHR61)sNR20CONR33R82;<br>
-(CH2)o(CHR61)sCOOR57; -(CH2)o(CHR61)sCONR58R59;<br>
-(CH2)o(CHR61)sPO(OR60)2;<br>
--(CH2)o(CHR61)s SO2R62; or -(CH2)o(CHR61)sC6H4R8;<br>
R6 is H; alkyl; alkenyl; -(CH2)o(CHR61)sOR55; -(CH2)o(CHR61)sSR56;<br>
-(CH2)o(CHR61)sNR33R34;<br>
-(CH2)o(CHR61)sOCONR33R75;-(CH2)o(CHR61)sNR20CONR33R82;<br>
-(CH2)o(CHR61)sCOOR57; -(CH2)o(CHR61)sCONR58R59;<br>
-(CH2)o(CHR61)sPO(OR60)2;<br>
-(CH2)o(CHR61)s SO2R62; or -(CH2)o(CHR61)sC6H4R8;<br>
R7 is alkyl; alkenyl; -(CH2)q(CHR61)sOR55; -(CH2)q(CHR61)sNR33R34;<br>
-(CH2)q(CHR61)sOCONR33R75;-(CH2)q(CHR61)sNR20CONR33R82;<br>
-(CH2)r(CHR61)sCOOR57; -(CH2)r(CHR61)sCONR58R59;<br>
-(CH2)r(CHR61)sPO(OR60)2;<br>
--(CH2)r(CHR61)sSO2R62; or -(CH2)r(CHR61)s C6H4R8;<br>
R8 is H; C1; F; CF3; NO2; lower alkyl; lower alkenyl; aryl; aryl-lower alkyl;<br>
-(CH2)o(CHR61)sOR55; -(CH2)o(CHR61)sSR56; -(CH2)o(CHR61)sNR33R34;<br>
-(CH2)o(CHR61)sOCONR33R75; -(CH2)o(CHR61)sNR20CONR33R82;<br>
-(CH2)o(CHR61)sCOOR57; -(CH2)o(CHR61)sCONR58R59;<br>
-(CH2)o(CHR61)sPO(OR60)2;<br>
-(CH2)o(CHR61)sSO2R62; or -(CH2)o(CHR61)sCOR64;<br>
R9 is alkyl; alkenyl; -(CH2)o(CHR61)sOR55; -(CH2)o(CHR61)sSR56;<br>
-(CH2)o(CHR61)sNR33R34;<br>
-(CH2)o(CHR61)sOCONR33R75; -(CH2)o(CHR61)sNR20CONR33R82;<br>
-(CH2)o(CHR61)sCOOR57; -(CH2)o(CHR61)sCONR58R59;<br>
-(CH2)o(CHR61)sPO(OR60)2; <br>
-(CH2)o(CHR61)sSO2R62; or -(CH2)o(CHR61)sC6H4R8;<br><br>
R10 is alkyl; alkenyl; -(CH2)o(CHR61)sOR55; -(CH2)o(CHR61)sSR56;<br>
-(CH2)o(CHR61)sNR33R34;<br>
-(CH2)o(CHR61)sOCONR33R75; -(CH2)o(CHR61)sNR20CONR33R82;<br>
-(CH2)o(CHR61)sCOOR57; -(CH2)o(CHR61)sCONR58R59;<br>
-(CH2)o(CHR61)sPO(OR60)2;<br>
-(CH2)o(CHR61)s SO2R62; or -(CH2)o(CHR61)sC6H4R8;<br>
R11 is H; alkyl; alkenyl; -(CH2)m(CHR61)sOR55; -(CH2)m(CHR61)sNR33R34;<br>
-(CH2)m(CHR61)sOCONR33R75; -(CH2)m(CHR61)sNR20CONR33R82;<br>
-(CH2)o(CHR61)sCOOR57; -(CH2)o(CHR61)sCONR58R59;<br>
-(CH2)o(CHR61)sPO(OR60)2;<br>
--(CH2)o(CHR61)s SO2R62; or -(CH2)o(CHR61)sC6H4R8;<br>
R12 is H; alkyl; alkenyl; -(CH2)m(CHR61)sOR55; -(CH2)m(CHR61)sSR56;<br>
-(CH2)m(CHR61)sNR33R34; -(CH2)m(CHR61)sOCONR33R75;<br>
-(CH2)m(CHR61)sNR20CONR33R82; -(CH2)r(CHR61)sCOOR57;<br>
-(CH2)r(CHR61)sCONR58R59;<br>
 -(CH2)r(CHR61)s PO(OR60)2; or -(CH2)r(CHR61)sSO2R62; or -(CH2)r(CHR61)sC6H4R8;<br>
R13 is alkyl; alkenyl; -(CH2)q(CHR61)sOR55; -(CH2)q(CHR61)sSR56;<br>
-(CH2)q(CHR61)sNR33R34;<br>
-(CH2)q(CHR61)sOCONR33R75; -(CH2)q(CHR61)sNR20CONR33R82;<br>
-(CH2)q(CHR61)sCOOR57; -(CH2)q(CHR61)sCONR58R59;<br>
-(CH2)q(CHR61)sPO(OR60)2;<br>
-(CH2)q(CHR61)s SO2R62; or -(CH2)q(CHR61)sC6H4R8;<br>
R14 is H; alkyl; alkenyl; -(CH2)m(CHR61)sOR55; -(CH2)m(CHR61)sNR33R34;<br>
-(CH2)m(CHR61)sOCONR33R75; -(CH2)m(CHR61)sNR20CONR33R82;<br>
-(CH2)q(CHR61)sCOOR57; -(CH2)q(CHR61)sCONR58R59;<br>
-(CH2)q(CHR61)sPO(OR60)2;<br>
-(CH2)q(CHR61)s SOR62; or -(CH2)q(CHR61)sC6H4R8;<br>
R15 i s alkyl; alkenyl; -(CH2)o(CHR61)sOR55; -(CH2)o(CHR61)sSR56;<br>
-(CH2)o(CHR61)sNR33R34;<br>
-(CH2)o(CHR61)sOCONR33R75; -(CH2)o(CHR61)sNR20CONR33R82;<br>
-(CH2)o(CHR61)sCOOR57; -(CH2)o(CHR61)sCONR58R59;<br>
-(CH2)o(CHR61)sPO(OR60)2; <br>
-(CH2)o(CHR61)sSO2R62; or -(CH2)o(CHR61)sC6H4R8;<br><br>
R16 i s alkyl; alkenyl; -(CH2)o(CHR61)sOR55; -(CH2)o(CHR61)sSR56;<br>
-(CH2)o(CHR61)sNR33R34;<br><br><br><br>
-(CH2)o(CHR61)sOCONR33R75; -(CH2)o(CHR61)sNR20CONR33R82;<br>
-(CH2)o(CHR61)sCOOR57; -(CH2)o(CHR61)sCONR58R59;<br>
-(CH2)o(CHR61)sPO(OR60)2; <br>
-(CH2)o(CHR61)sSO2R62; or -(CH2)o(CHR61)sC6H4R8;<br><br>
R17 is alkyl; alkenyl; -(CH2)q(CHR61)sOR55; -(CH2)q(CHR61)sSR56;<br>
-(CH2)q(CHR61)sNR33R34;<br>
-(CH2)q(CHR61)sOCONR33R75; -(CH2)q(CHR61)sNR20CONR33R82;<br>
-(CH2)q(CHR61)sCOOR57; -(CH2)q(CHR61)sCONR58R59;<br>
-(CH2)q(CHR61)sPO(OR60)2;<br>
-(CH2)q(CHR61)s SO2R62; or -(CH2)q(CHR61)sC6H4R8;<br>
R18 is alkyl; alkenyl; -(CH2)p(CHR61)sOR55; -(CH2)p(CHR61)sSR56;<br>
-(CH2)p(CHR61)sNR33R34;<br>
-(CH2)p(CHR61)sOCONR33R75; -(CH2)p(CHR61)sNR20CONR33R82;<br>
-(CH2)p(CHR61)sCOOR57; -(CH2)p(CHR61)sCONR58R59;<br>
-(CH2)p(CHR61)sPO(OR60)2;<br>
-(CH2)p(CHR61)s SO2R62; or -(CH2)o(CHR61)sC6H4R8; R19 is alkyl; alkenyl; -(CH2)p(CHR61)sOR55; -(CH2)p(CHR61)sSR56;<br>
-(CH2)p(CHR61)sNR33R34;<br>
-(CH2)p(CHR61)sOCONR33R75; -(CH2)p(CHR61)sNR20CONR33R82;<br>
-(CH2)p(CHR61)sCOOR57; -(CH2)p(CHR61)sCONR58R59;<br>
-(CH2)p(CHR61)sPO(OR60)2;<br>
-(CH2)p(CHR61)s SO2R62; or -(CH2)o(CHR61)sC6H4R8;<br>
R18 and R19 taken together can form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-;<br>
R20 is H; alkyl; alkenyl; or aryl-lower alkyl;<br>
R21 is alkyl; alkenyl; -(CH2)o(CHR61)sOR55; -(CH2)o(CHR61)sSR56;<br><br>
-(CH2)o(CHR61)sNR33R34;<br>
-(CH2)o(CHR61)sOCONR33R75; -(CH2)o(CHR61)sNR20CONR33R82;<br>
-(CH2)o(CHR61)sCOOR57; -(CH2)o(CHR61)sCONR58R59;<br>
-(CH2)o(CHR61)sPO(OR60)2;<br>
-(CH2)o(CHR61)s SO2R62; or -(CH2)o(CHR61)sC6H4R8; R22 is alkyl; alkenyl; -(CH2)o(CHR61)sOR55; -(CH2)o(CHR61)sSR56;<br>
-(CH2)o(CHR61)sNR33R34;<br>
-(CH2)o(CHR61)sOCONR33R75; -(CH2)o(CHR61)sNR20CONR33R82;<br><br><br><br>
-(CH2)o(CHR61)sCOOR57; -(CH2)o(CHR61)sCONR58R59;<br>
-(CH2)o(CHR61)sPO(OR60)2;<br>
-(CH2)o(CHR61)s SO2R62; or -(CH2)o(CHR61)sC6H4R8;<br><br>
R23 is alkyl; alkenyl; -(CH2)o(CHR61)sOR55; -(CH2)o(CHR61)sSR56;<br>
-(CH2)o(CHR61)sNR33R34;<br>
-(CH2)o(CHR61)sOCONR33R75; -(CH2)o(CHR61)sNR20CONR33R82;<br>
-(CH2)o(CHR61)sCOOR57; -(CH2)o(CHR61)sCONR58R59;<br>
-(CH2)o(CHR61)sPO(OR60)2;<br>
-(CH2)o(CHR61)s SO2R62; or -(CH2)o(CHR61)sC6H4R8;<br><br>
R24 is alkyl; alkenyl; -(CH2)o(CHR61)sOR55; -(CH2)o(CHR61)sSR56;<br>
-(CH2)o(CHR61)sNR33R34;<br>
-(CH2)o(CHR61)sOCONR33R75; -(CH2)o(CHR61)sNR20CONR33R82;<br>
-(CH2)o(CHR61)sCOOR57; -(CH2)o(CHR61)sCONR58R59;<br>
-(CH2)o(CHR61)sPO(OR60)2;<br>
-(CH2)o(CHR61)s SO2R62; or -(CH2)o(CHR61)sC6H4R8; R25 is H; alkyl; alkenyl; -(CH2)m(CHR61)sOR55; -(CH2)m(CHR61)sSR56;<br>
-(CH2)m(CHR61)sNR33R34; -(CH2)m(CHR61)sOCONR33R75;<br>
-(CH2)m(CHR61)sNR20CONR33R82; -(CH2)o(CHR61)sCOOR57;<br>
-(CH2)o(CHR61)sCONR58R59; -(CH2)o(CHR61)sPO(OR60)2;<br>
-(CH2)o(CHR61)s SO2R62; or -(CH2)o(CHR61)sC6H4R8;<br>
R26 is H; alkyl; alkenyl; -(CH2)m(CHR61)sOR55; -(CH2)m(CHR61)sSR56;<br>
-(CH2)m(CHR61)sNR33R34; -(CH2)m(CHR61)sOCONR33R75;<br>
-(CH2)m(CHR61)sNR20CONR33R82; -(CH2)o(CHR61)sCOOR57;<br>
-(CH2)o(CHR61)sCONR58R59;<br>
-(CH2)o(CHR61)sPO(OR60)2; -(CH2)o(CHR61)s SO2R62; or -(CH2)o(CHR61)sC6H4R8;<br>
or<br>
R25 and R26 taken together can form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-;<br>
-(CH2)rNR57(CH2)r-;<br>
R27 is H; alkyl; alkenyl; -(CH2)o(CHR61)sOR55; -(CH2)o(CHR61)sSR56;<br>
-(CH2)o(CHR61)sNR33R34;<br>
-(CH2)o(CHR61)sCOOR57; -(CH2)o(CHR61)sCONR58R59;<br>
-(CH2)o(CHR61)sOCONR33R75;<br>
-(CH2)o(CHR61)sNR20CONR33R82; -(CH2)o(CHR61)sPO(OR60);<br>
-(CH2)o(CHR61)s SO2R62; or -(CH2)o(CHR61)sC6H4R8;<br><br>
R28 is alkyl; alkenyl; -(CH2)o(CHR61)s-OR55; -(CH2)o(CHR61)s SR56; -(CH2)o(CHR61)s<br>
NR33R34;<br><br>
-(CH2)o(CHR61)sOCONR33R75; -(CH2)o(CHR61)sNR20CONR33R82;<br>
-(CH2)o(CHR61)sCOOR57; -(CH2)o(CHR61)sCONR58R59; -(CH2)o(CHR61)s<br>
PO(OR60)2;<br>
-(CH2)o(CHR61)s SO2R62; or -(CH2)o(CHR61)sC6H4R8;<br>
R29 alkyl; alkenyl; -(CH2)o(CHR61)sOR55; -(CH2)o(CHR61)sSR56;<br>
-(CH2)o(CHR61)sNR33R34;<br>
-(CH2)o(CHR61)sOCONR33R75; -(CH2)o(CHR61)sNR20CONR33R82;<br>
-(CH2)o(CHR61)sCOOR57; -(CH2)o(CHR61)sCONR58R59;<br>
-(CH2)o(CHR61)sPO(OR60)2;<br><br>
R30 is H; alkyl; alkenyl; or aryl-lower alkyl;<br>
R31 is H; alkyl; alkenyl; -(CH2)p(CHR61)sOR55; -(CH2)p(CHR61)sNR33R34; <br>
-(CH2)p(CHR61)sOCONR33R75; -(CH2)p(CHR61)sNR20CONR33R82;<br>
-(CH2)o(CHR61)sCOOR57; -(CH2)o(CHR61)sCONR58R59;<br>
-(CH2)o(CHR61)sPO(OR60)2;<br>
-(CH2)o(CHR61)s SO2R62; or -(CH2)o(CHR61)sC6H4R8;<br>
R32 is H; lower alkyl; or aryl-lower alkyl;<br>
R33 is H; alkyl, alkenyl; H; alkyl; alkenyl; -(CH2)m(CHR61)sOR55; -(CH2)m(CHR61)sNR34R63; <br>
-(CH2)m(CHR61)sOCONR75R82; -(CH2)m(CHR61)sNR20CONR78R82;<br>
-(CH2)o(CHR61)sCOOR64; -(CH2)o(CHR61)sCONR58R59;<br>
-(CH2)o(CHR61)sPO(OR60)2;<br>
-(CH2)o(CHR61)s SO2R62; or -(CH2)o(CHR61)sC6H4R8;<br>
R34 is H; lower alkyl; aryl, or aryl-lower alkyl;<br>
R33 and R34 taken together can form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2;<br>
R35 is H; alkyl; alkenyl; H; alkyl; alkenyl; -(CH2)m(CHR61)sOR55; -(CH2)m(CHR61)sNR33R34; <br>
-(CH2)m(CHR61)sOCONR33R75; -(CH2)m(CHR61)sNR20CONR33R82;<br>
 -(CH2)p(CHR61)sCOOR57; -(CH2)p(CHR61)sCONR58R59;<br>
 -(CH2)p(CHR61)sPO(OR60)2;<br>
-(CH2)p(CHR61)s SO2R62; or -(CH2)p(CHR61)sC6H4R8;<br>
R36 is H; alkyl; alkenyl; H; alkyl; alkenyl; -(CH2)o(CHR61)sOR55; -(CH2)p(CHR61)sNR33R34; <br>
-(CH2)p(CHR61)sOCONR33R75; -(CH2)p(CHR61)sNR20CONR33R82;<br><br>
 -(CH2)p(CHR61)sCOOR57; -(CH2)p(CHR61)sCONR58R59;<br>
 -(CH2)p(CHR61)sPO(OR60)2;<br>
-(CH2)p(CHR61)s SO2R62; or -(CH2)o(CHR61)sC6H4R8;<br>
R37 is H; F; Br; Cl1; NO2; CF3; lower alkyl; -(CH2)P(CHR61)SOR55;<br>
-(CH2)p(CHR61)sNR33R34;<br>
 -(CH2)p(CHR61)sOCONR33R75; -(CH2)p(CHR61)sNR20CONR33R82;<br><br>
 -(CH2)o(CHR61)sCOOR57; -(CH2)o(CHR61)sCONR58R59;<br>
 -(CH2)o(CHR61)sPO(OR60)2;<br><br>
-(CH2)o(CHR61)s SO2R62; or -(CH2)o(CHR61)sC6H4R8;<br>
R38 is H; F; Br; Cl; NO2; CF3; alkyl; alkenyl; -(CH2)p(CHR61)s-OR55;<br>
-(CH2)p(CHR61)sNR33R34;<br>
-(CH2)p(CHR61)sOCONR33R75; -(CH2)p(CHR61)sNR20CONR33R82;<br>
-(CH2)o(CHR61)sCOOR57; -(CH2)o(CHR61)sCONR58R59;<br>
-(CH2)o(CHR61)sPO(OR60)2<br>
-(CH2)o(CHR61)s SO2R62; or -(CH2)o(CHR61)sC6H4R8;<br>
R39 is H; alkyl; alkenyl; or aryl-lower alkyl;<br>
R40 is H; alkyl; alkenyl; or aryl-lower alkyl;<br>
R41 is H; F; Br; C1; NO2; CF3; alkyl; alkeayl; -(CH2)p(CHR61)sOR55;<br>
-(CH2)p(CHR61)sNR33R34;<br>
-(CH2)p(CHR61)sOCONR33R75; -(CH2)p(CHR61)sNR20CONR33R82;<br>
-(CH2)o(CHR61)sCOOR57; -(CH2)o(CHR61)sCONR58R59;<br>
-(CH2)o(CHR61)sPO(OR60)2<br>
-(CH2)o(CHR61)s SO2R62; or -(CH2)o(CHR61)sC6H4R8;<br>
R42 is H; F; Br, C1; NO2; CF3; alkyl; alkenyl; (CH2)p(CHR61)sOR55;<br>
-(CH2)p(CHR61)sNR33R34;<br>
-(CH2)p(CHR61)sOCONR33R75; -(CH2)p(CHR61)sNR20CONR33R82;<br>
-(CH2)o(CHR61)sCOOR57; -(CH2)o(CHR61)sCONR58R59;<br>
-(CH2)o(CHR61)sPO(OR60)2<br>
-(CH2)o(CHR61)s SO2R62; or -(CH2)o(CHR61)sC6H4R8; R43 is H; alkyl; alkenyl; -(CH2)m(CHR61)sOR55; -(CH2)m(CHR61)sNR33R34; <br>
-(CH2)m(CHR61)sOCONR33R75; -(CH2)m(CHR61)sNR20CONR33R82;<br>
-(CH2)o(CHR61)sCOOR57; -(CH2)o(CHR61)sCONR58R59;<br>
-(CH2)o(CHR61)sPO(OR60)2<br>
-(CH2)o(CHR61)s SO2R62; or -(CH2)o(CHR61)sC6H4R8; <br><br>
R44 is alkyl; alkenyl; -(CH2)r(CHR61)sOR55; -(CH2)r(CHR61)sSR56;<br>
-(CH2)r(CHR61)sNR33R34;<br>
-(CH2)r(CHR61)sOCONR33R75; -(CH2)r(CHR61)sNR20CONR33R82;<br>
-(CH2)r(CHR61)sCOOR57; -(CH2)r(CHR61)sCONR58R59;<br>
-(CH2)r(CHR61)sPO(OR60)2;<br>
-(CH2)r(CHR61)s SO2R62; or -(CH2)r(CHR61)sC6H4R8;<br><br>
R45 is H; alkyl; alkenyl; -(CH2)o(CHR61)sOR55; -(CH2)o(CHR61)sSR56;<br>
-(CH2)o(CHR61)sNR33R34;<br>
-(CH2)o(CHR61)sOCONR33R75; -(CH2)o(CHR61)sNR20CONR33R82;<br>
-(CH2)o(CHR61)sCOOR57; -(CH2)s(CHR61)sCONR58R59;<br>
-(CH2)s(CHR61)sPO(OR60)2;<br>
-(CH2)s(CHR61)s SO2R62; or -(CH2)s(CHR61)sC6H4R8;<br><br>
R46 is H; alkyl; alkenyl; or -(CH2)o(CHR61)sC6H4R8;<br>
R47 is H; alkyl; alkenyl; or -(CH2)o(CHR61)sOR55;<br>
R48 is H; lower alkyl; lower alkenyl; or aryl-lower alkyl;<br>
R49 is H; alkyl; alkenyl; -(CHR61)sCOOR57; (CHR61)sCONR58R59; -(CH2)o(CHR61)sPO(OR60)2;<br>
-(CH2)s SOR62; or -(CHR61)sC6H4R8;<br>
R50 is H; lower alkyl; or aryl-lower alkyl;<br>
R51 is H; alkyl; alkenyl; -(CH2)m(CHR61)s-OR55; -(CH2)m(CHR61)s SR56;<br>
-(CH2)m(CHR61)sNR33R34; -(CH2)m(CHR61)sOCONR33R75;<br>
-(CH2)m(CHR61)sNR20CONR33R82;-(CH2)o(CHR61)sCOOR57;<br>
-(CH2)o(CHR61)sCONR58R59; -(CH2)o(CHR61)sPO(OR60)2;<br>
-(CH2)p(CHR61)s SO2R62; or -(CH2)p(CHR61)sC6H4R8;<br>
R52 is H; alkyl; alkenyl; -(CH2)m(CHR61)s-OR55; -(CH2)m(CHR61)s SR56;<br>
-(CH2)m(CHR61)sNR33R34; -(CH2)m(CHR61)sOCONR33R75;<br>
-(CH2)m(CHR61)sNR20CONR33R82;-(CH2)o(CHR61)sCOOR57;<br>
-(CH2)o(CHR61)sCONR58R59; -(CH2)o(CHR61)pPO(OR60)2;<br>
-(CH2)p(CHR61)s SO2R62; or -(CH2)p(CHR61)sC6H4R8;<br>
R53 is H; alkyl; alkenyl; -(CH2)m(CHR61)sOR55; -(CH2)m(CHR61)sSR56;<br>
-(CH2)m(CHR61)sNR33R34;<br>
-(CH2)m(CHR61)sOCONR33R75;<br>
-(CH2)m(CHR61)sNR20CONR33R82;-(CH2)o(CHR61)sCOOR57;<br>
-(CH2)o(CHR61)sCONR58R59; -(CH2)o(CHR61)pPO(OR60)2;<br>
-(CH2)p(CHR61)s SO2R62; or -(CH2)p(CHR61)sC6H4R8;<br>
R54 is H; alkyl; alkenyl; -(CH2)m(CHR61)sOR55; -(CH2)m(CHR61)sNR33R34; <br><br>
-(CH2)m(CHR61)sOCONR33R75; -(CH2)m(CHR61)sNR20CONR33R82;<br>
-(CH2)o(CHR61)sCOOR57; -(CH2)o(CHR61)sCONR58R59; or -(CH2)o(CHR61)s<br>
C6H4R8;<br>
R55 is H; lower alkyl; lower alkenyl; aryl-lower alkyl; -(CH2)m(CHR61)sOR57;<br>
-(CH2)m(CHR61)sNR34R63; -(CH2)m(CHR61)sOCONR75R82;<br>
-(CH2)m(CHR61)sNR20CONR78R82;-(CH2)o(CHR61)s-COR64;<br>
--(CH2)o(CHR61)COOR57;or<br>
-(CH2)o(CHR61)sCONR58R59;<br>
R56 is H; lower alkyl; lower alkenyl; aryl-lower alkyl; -(CH2)m(CHR61)sOR57;<br>
-(CH2)m(CHR61)sNR34R63; -(CH2)m(CHR61)sOCONR75R82;<br>
-(CH2)m(CHR61)sNR20CONR78R82;-(CH2)o(CHR61)s-COR64; or<br>
-(CH2)o(CHR61)sCONR58R59;<br>
R57 is H; lower alkyl; lower alkenyl; aryl lower alkyl; or heteroaryl lower alkyl;<br>
R58 is H; lower alkyl; lower alkenyl; aryl; heteroaryl; aryl-lower alkyl; or heteroaryl-<br>
lower alkyl;<br>
R59 is H; lower alkyl; lower alkenyl; aryl; heteroaryl; aryl-lower alkyl; or heteroaryl-<br>
lower alkyl; or<br>
R58 and R59 taken together can form:-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-;<br>
R60 is H; lower alkyl; lower alkenyl; aryl; or aryl-lower alkyl;<br>
R61 is H, alkyl; alkenyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl;<br>
-(CH2)pOR55;<br>
-(CH2)pNR33R34; -(CH2)pOCONR75R82; -(CH2)pNR20CONR78R82; -(CH2)OCOOR57;<br>
or-(CH2)oPO(OR60)2;<br>
R62 is lower alkyl; lower alkenyl; aryl, heteroaryl; or aryl-lower alkyl;<br>
R63 is H; lower alkyl; lower alkenyl; aryl, heteroaryl; aryl-lower alkyl; heteroaryl-lower<br>
alkyl;<br>
-COR64; -COOR57; -CONR58R59; -SO2R62; or -PO(OR60)2;<br>
R34and R63 taken together can form: -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-;<br>
R64 is H; lower alkyl; lower alkenyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower<br>
alkyl;<br>
-(CH2)p(CHR61)sOR65; -(CH2)p(CHR61)s SR66; or -(CH2)p(CHR61)sNR34R63;<br>
-(CH2)p(CHR61)sOCONR75R82; -(CH2)p(CHR61)sNR20CONR78R82;<br><br>
R65 is H; lower alkyl; lower alkenyl; aryl, aryl-lower alkyl; heteroaryl-lower alkyl; -<br>
COR57;<br>
-COOR57; or -CONR58R59;<br>
R66 is H; lower alkyl; lower alkenyl; aryl; aryl-lower alkyl; heteroaryl-lower alkyl; or -<br>
CONR58R59;<br>
m is 2-4; o is 0-4; p is 1-4; q is 0-2; r is 1 or 2; s is 0 or 1;<br>
R67 being H; C1; Br; F; NO2; -NR34COR57; lower alkyl; or lower alkenyl;<br>
R68 being H; Cl; Br; F; NO2; -NR34COR57; lower alkyl; or lower alkenyl;<br>
R69 being H; Cl; Br; F; NO2; -NR34COR57; lower alkyl; or lower alkenyl; and<br>
R70 being H; Cl; Br; F; NO2; -NR34COR57; lower alkyl; or lower alkenyl;<br>
with the proviso that at least two of R67, R68, R69 and R70 are H; and<br>
Z is a chain of 12 α-amino acid residues, the positions of said amino acid residues in said<br>
chain being counted starting from the N-terminal amino acid, whereby these amino acid<br>
residues are, depending on their position in the chain, Gly or Pro, or of formula -A-CO-,<br>
or of formula -B-CO-, or of one of the types<br>
C: -NR20CH(R72)CO-;<br>
D: -NR20CH(R73)CO-;<br>
E: - NR20CH(R74)CO-;<br>
F: -NR20CH(R84)CO-; and<br>
H: -NR20-CH(CO-)-(CH2)4-7-CH(CO-)-NR20-;<br>
-NR20-CH(CO-)-(CH2)pSS(CH2)p-CH(CO-)-NR20-;<br>
-NR20-CH(CO-)-(CH2)pNR20CO(CH2)p-CH(CO-)-NR20-;and<br>
-NR20-CH(CO-)-(CH2)pNR20CONR20(CH2)p-CH(CO-)-NR20-;<br>
R71 is H; lower alkyl; lower alkenyl; -(CX2)p(CHR61)sOR75; -(CX2)p(CHR61)sSR75;<br>
-(CX2)p(CHR61)sNR33R34;-(CX2)p(CXR61)sOCONR33R75;<br>
-(CX2)p(CHR61)sNR20CONR33R82;<br>
-(CX2)o(CHR61)sCOOR75; -(CX2)PCONR58R59; -(CX2)pPO(OR62)2; -(CX2)pSO2R62; or<br>
-(CX2)o-C6R67R68R69R70R76;<br>
R72 is H; lower alkyl; lower alkenyl; -(CX2)p(CHR86)sNROR85; or<br>
-(CX2)p(CHR86)sSR85;<br>
R73 is -(CX2)oR77; -(CX2)rO(CH2)oR77; -(CX2)rS(CH2)oR77; or<br>
-(CX2)rNR20; -(CH2)oR77;<br><br>
R74 is -(CX2)pNR78R79; -(CX2)pNR77R80; -(CX2)pC(=NR80)NR78R79; -<br>
(CX2)pC(=NOR50)NR78R79;<br>
(CX2)pC(=NNR78R79)NR78R79; -(CX2)pNR80C(=NR80)NR78R79;<br>
-(CX2)pN=C(NR78R80)NR79R80; -(CX2)pC6H4NR78R79; -(CX2)pC6H4NR77R80;<br>
-(CX2)pC6H4C(=NR80)NR78R79;-(CX2)pC6H4C(=NOR50)NR78R79;<br>
-(CX2)pC6H4C(=NNR78R79)NR79R79;--(CX2)pC6H4NR80C(=NR80)NR78R79;<br>
-(CX2)pC6H4C=C(NR78R80)NR79R80;-(CX2)rO(CX2)mNR78R79; -<br>
-(CX2)rO(CX2)mNR77R80;<br>
-(CX2)rO(CX2)pC(=NR80)NR78R79;-(CX2)rO(CX2)pC(=NOR50)NR78R79;<br>
-(CX2)rO(CX2)pC(=NNR78R79)NR78R79;-(CX2)rO(CH2)mNR80C(=NR80)NR78R79;<br>
-(CX2)rO(CX2)mN=C(NR78R80)NR79R80;-(CX2)rO(CX2)pC6H4CNR78R79;<br>
-(CX2)rO(CX2)pC6H4C(=NR80)NR78R79; -(CX2)rO(CX2)pC6H4C(=NOR50)NR78R79;<br>
-(CX2)rO(CX2)pC6H4C(=NNR78R79)NR78R79;<br>
-(CX2)rO(CX2)pC6H4NR80C(=NR80) NR78R79;-(CX2)rS(CX2)mNR78R79;<br>
-(CX2)rS(CX2)mNR77R80;-(CX2)rS(CX2)pC(=NR80)NR78R79;<br>
-(CX2)rS(CX2)pC(=NOR50)NR78R79;-(CX2)rS(CX2)pC(=NNR78R79)NR78R79;<br>
-(CX2)rS(CX2)mNR80C(=NR80)NR78R79;-(CX2)rS(CX2)mN=c(NR78R80)NR79R80;<br>
-(CX2)rS(CX2)pC6H4CNR78R79; -(CX2)rS(CX2)pC6H4C(=NR80)NR78R79;<br>
-(CX2)rS(CX2)pC6H4C(=NOR50)NR78R79;-<br>
-(CX2)rS(CX2)pC6H4C(=NNR78R79)NR78R79;<br>
-(CX2)rS(CX2)pC6H4NR80C(=NR80)NR78R79; -(CX2)pNR80COR64; -<br>
-(CX2)pNR80COR77;<br>
-(CX2)pNR80CONR78R79; -(CX2)pC6H4NR80CONR78R79; or -(CX2)pNR20CO-[(CX2)u-<br>
XX]r-CH3 where XX is -O-; -NR20-, or -S-; u is 1-3, and t is 1-6;<br>
R75 is lower alkyl; lower alkenyl; or aryl-lower alkyl;<br>
R33 and R75 taken together can form: -(CX2)2-6-; -(CX2)2O(CX2)2-; -(CX2)2S(CX2)2-; or<br>
-(CX2)2NR57(CX2)2-;<br>
R75 and R82 taken together can form: -(CX2)2-6-; -(CX2)2O(CX2)2-; -(CX2)2S(CX2)2-; or<br>
-(CX2)2NR57(CX2)2-;<br>
R76 isH; lower alkyl; lower alkenyl; aryl-lower alkyl; -(CX2)oOR72; -(CX2)oSR72;<br>
-(CX2)oNR33R34; -(CX2)oOCONR33R75; -(CX2)oNR20CONR33R82;<br>
-(CX2)oCOOR75; -(CX2)oCONR58R59; -(CX2)oPO(OR60)2; -(CX2)pSO2R62;<br>
or<br>
-(CX2)oCOR64;<br><br><br><br><br>
R72 is	H; lower alkyl; aryl; or aryl-lower alkyl;<br>
R78 and R82 taken together can form: -(CX2)2-6-; -(CX2)2O(CX2)2-; -(CX2)2S(CX2)2-; or<br>
-(CX2)2NR57(CX2)2-;<br>
R79 is	H; lower alkyl; aryl; or aryl-lower alkyl; or<br>
R78 and R79, taken together, can be -(CX2)2-7-; -(CX2)2O(CX2)2-; or-(CX2)2NR57(CX2)2-;<br>
R80is	H; or lower alkyl;<br>
R81 is	H; iower alkyl; or aryl-lower alkyl;<br>
R82 is H; lower alkyl; aryl; heteroaryl; or aryl-lower alkyl;<br>
R81 aad R82 taken together can form: -(CX2)2-6-; -(CX2)2O(CX2)2-; -(CX2)2S(CX2)2-; or<br><br>
-(CX2)2NR57(CX2)2-;<br>
R83 is H; lower alkyl; aryl; or -NR78R79;<br>
R84 is -(CH2)m(CHR61)sOH; -(CX2)PCONR78R79; (CX2)PNR80CONR78R79;<br>
-(CH2)pC6H4CONR78R79; or -(CX2)PC6H4NR80CONR78R79;<br>
R85 is lower alkyl; or lower alkenyl;<br>
R86 is H, alkyl; alkenyl; (CX2)POR85;-(CX2)PSR85<br>
R87 is H; alkyl; alkenyl; heteroaryl, aryl-lower alkyl; -(CX2)pOR55; -(CX2)pOCONR75R82;<br>
-(CX2)pNR20CONR78R82; -(CX2)pCOOR57, or -(CX2)pPO(OR60)2;<br>
X is H; or optionally halogen;R71 is H; lower alkyl; lower alkenyl; -(CX2)p(CHR61)sOR75; -<br>
-(CX2)p(CHR61)sSR75;<br>
-(CX2)p(CHR61)sNR33R34;-(CH2)p(CHR61)sOCONR33R75;<br>
-(CX2)p(CHR61)sNR20CONR33R82;<br>
-(CX2)o(CHR61)sCOOR75; -(CH2)pCONR58R59; -(CH2)pPO(OR62)2; -(CH2)pSO2R62; or<br>
-(CX2)o-C6R67R68R69R70R76;<br>
R72 is H; lower alkyl; lower alkenyl; -(CX2)p(CHR86)sOR85; or<br>
-(CX2)p(CHR86)sSR85;<br>
R73 is -(CX2)oR77; -(CH2)rO(CH2)(CH2)oR77; -(CX2)rS(CH2)oR77; or<br>
-(CX2)rNR20(CH2)oR77;<br>
R74 is -(CX2)pNR78R79; -(CX2)pNR77R80; -(CX2)pC(=NR80)NR78R79; -<br>
(CX2)pC(=NOR50)NR78R79;<br>
(CX2)pC(=NNR78R79)NR78R79; -(CX2)pNR80C(=NR80)NR78R79;<br>
-(CX2)pN=C(NR78R80)NR79R80; -(CX2)pC6H4NR78R79; -(CH2)pC6H4NR77R80;<br>
-(CX2)pC6H4C(=NR80)NR78R79;-(CX2)pC6H4C(=NOR50)NR78R79;<br>
-(CX2)pC6H4C(=NNR78R79)NR79R79;--(CX2)pC6H4NR80C(=NR80)NR78R79;<br>
-(CX2)pC6H4C=C(NR78R80)NR79R80;-(CX2)rO(CX2)mNR78R79; -<br>
-(CX2)rO(CX2)mNR77R80;<br>
-(CX2)rO(CX2)pC(=NR80)NR78R79;-(CX2)rO(CX2)pC(=NOR50)NR78R79;<br>
-(CX2)rO(CX2)pC(=NNR78R79)NR78R79;-(CX2)rO(CH2)mNR80C(=NR80)NR78R79;<br>
-(CX2)rO(CX2)mN=C(NR78R80)NR79R80;-(CX2)rO(CX2)pC6H4CNR78R79;<br>
-(CX2)rO(CX2)pC6H4C(=NR80)NR78R79; -(CX2)rO(CX2)pC6H4C(=NOR50)NR78R79;<br>
-(CX2)rO(CX2)pC6H4C(=NNR78R79)NR78R79;<br>
-(CX2)rO(CX2)pC6H4NR80C(=NR80) NR78R79;-(CX2)rS(CX2)mNR78R79;<br>
-(CX2)rS(CX2)mNR77R80;-(CX2)rS(CX2)pC(=NR80)NR78R79;<br>
-(CX2)rS(CX2)pC(=NOR50)NR78R79;-(CX2)rS(CX2)pC(=NNR78R79)NR78R79;<br>
-(CX2)rS(CX2)mNR80C(=NR80)NR78R79;-(CX2)rS(CX2)mN=c(NR78R80)NR79R80;<br><br>
-(CX2)rS(CX2)pC6H4CNR78R79; -(CX2)rS(CX2)pC6H4C(=NR80)NR78R79;<br>
-(CX2)rS(CX2)pC6H4C(=NOR50)NR78R79;-<br>
-(CX2)rS(CX2)pC6H4C(=NNR78R79)NR78R79;<br>
-(CX2)rS(CX2)pC6H4NR80C(=NR80)NR78R79; -(CX2)pNR80COR64; -<br>
-(CX2)pNR80COR77;<br>
-(CX2)pNR80CONR78R79; -(CX2)pC6H4NR80CONR78R79; or -(CX2)pNR20CO-[(CX2)u-<br><br><br>
X]r-CH3 where X is -O-; -NR20-, or -S-; u is 1-3, and t is 1-6;<br>
R75 is lower alkyl; lower alkenyl; or aryl-lower alkyl;<br>
R33 and R75 taken together can form: -(CX2)2-6-; -(CX2)2O(CX2)2-; -(CX2)2S(CX2)2-; or<br>
-(CX2)2NR57(CX2)2-;<br>
R75 and R82 taken together can form: -(CX2)2-6-; -(CX2)2O(CX2)2-; -(CX2)2S(CX2)2-; or<br>
-(CX2)2NR57(CX2)2-;<br>
R76 isH; lower alkyl; lower alkenyl; aryl-lower alkyl; -(CX2)oOR72; -(CX2)oSR72;<br>
-(CX2)oNR33R34; -(CX2)oOCONR33R75; -(CX2)oNR20CONR33R82;<br>
-(CX2)oCOOR75; -(CX2)oCONR58R59; -(CX2)oPO(OR60)2; -(CX2)pSO2R62;<br>
or<br>
-(CX2)oCOR64;<br>
R77 is	-C6R67R68R69R70R76; or a heteroaryl group of one of the formulae<br><br><br><br><br><br>
R78 is	H; lower alkyl; aryl; or aryl-lower alkyl;<br>
R78 and R82 taken together can form: -(CX2)2-6-; -(CX2)2O(CX2)2-; -(CX2)2S(CX2)2-; or<br>
-(CX2)2NR57(CX2)2-;<br>
R79 is	H; lower alkyl; aryl; or aryl-lower alkyl; or<br>
R78 and R79, taken together, can be -(CX2)2-7-; -(CX2)2O(CX2)2-; -(CX2)2NR57(CX2)2-;<br>
R80 is	H; or lower alkyl;<br>
R81 is	H; lower alkyl; or aryl-lower alkyl;<br>
R82 is H; lower alkyl; aryl; heteroaryl; or aryl-lower alkyl;<br>
R33 and R82 taken together can form: -(CX2)2-6-; -(CX2)2O(CX2)2-; -(CX2)2S(CX2)2-; or<br>
-(CX2)2NR57(CX2)2-;<br>
R83 is H; lower alkyl; aryl; or -NR78R79;<br>
R84 is -(CX2)m(CHR61)sOH; -(CX2)pCONR78R79; -(CX2)pNR80CONR78R79;<br>
-(CX2)pC6H4CONR78R79; or -(CX2)pC6H4NR80CONR78R79;<br>
R85 is lower alkyl; or lower alkenyl;<br>
R86 is H, alkyl; alkenyl; -(CX2)pOR85; -(CX2)pSR85;<br>
R87 is H alkyl; alkenyl; heteroaryl, aryl-lower alkyl; -(CX2)POR55; -(CX2)POCONR75R82;<br>
-(CX2)PNR20CONR78R82; -(CX2)pCOONR57, or-(CX2)pPO(OR60);<br>
X is H, or optionally halogen;<br>
with the proviso that in said chain of 12 α-amino acid residues Z the amino acid residues in<br>
positions 1 to 12 are:<br>
P1:	of type C or of type D or of type E or of type F, or the residue<br>
is Pro;<br><br>
P2:	of type D or of typeE;<br>
P3:	of type C or of type D, or the residue is Gly or Pro;<br>
P4:	of type C or of type E or of type F; or the residue is Gly Gly or<br>
Pro;<br>
P5:	of type E or of type D or of type C, or the residue is Gly or Pro;<br>
P6:	of type E or of type F or of type C or of formula -A-CO-, or the<br>
residue is Gly or Pro;<br>
P7:	of type C or of type E or of type F or of formula -B-CO-;<br>
P8:	of type D or of type C, or type F, or the residue is Pro;<br>
P9:	of type Cor of type E or of type Dor of type F;<br>
P10: of type E;<br>
P11: of type C or of type F, or the residue is Pro or Gly; and<br>
P12: of type C or of type D or of type E or of type F, or the residue<br>
is Pro; or<br>
P4 and P9 and/or P2 and P11, taken together, can form a group of type H;<br>
and<br>
at P6, P10 and P11 also D-isomers being possible;<br>
or, alternatively,<br>
P1:	of type C or of type D or of type E or of type F, or the residue<br>
is Pro;<br>
P2:	of type C or of type F, or the residue is Pro or Gly;<br>
P3:	of type E;<br>
P4:	of type C or of type E or of type D or of type F;<br>
P5:	of type D or of type C, or of type F, or the residue is Pro;<br>
P6:	of type Cor of type E or of type For of formula -B-CO-;<br>
P7:	of type E or of type For of type C or of formula -A-CO-, or the<br>
residue is Gly or Pro;<br>
P8:	of type E or of type D or of type C, or the residue is Gly or Pro;<br>
P9:	of type Cor of type E or of type F;<br>
P10: of type C or of type D, or the residue is Gly or Pro;<br>
P11: of type D or of type E; and<br>
P12: of type Cor of type D or of type E or of type F, or the residue<br>
is Pro; or<br>
P4 and P9 and/or P2 and P11, taken together, can form a group of type H;<br>
and<br><br>
at P2, P3 and P7 also D-isomers being possible;<br>
and pharmaceutically acceptable salts thereof.<br>
2.	Compounds according to claim 1 wherein in the claim of 12 α-amino acids<br>
residues Z<br>
the amino acid residue in position P4 is of type C, or of type E or of type F; P8 is of type<br>
D or of type C, or the residue is Pro; and at P10 and P11 also D isomers are possible; or<br>
alternatively,<br>
the amino acid residue on position P5 is of type D or of type C or the residue is Pro; P9 is<br>
of type C or of type E or of type F and at none of the positions P1 to P12 D-isomers are<br>
possible.<br>
3.	Compounds according to claims 1 or 2 wherein<br><br>
is a group of formula (a1) or (a2).<br>
4.	Compounds according to claim 3 wherein A is a group of one of the formulae Al<br>
to A69;<br>
R1 is hydrogen or lower alkyl;<br>
R2 is H; lower alkyl; lower alkenyl; -(CH2)mOR55 (where R55 is lower alkyl; or lower<br>
alkenyl); -(CH2)mSR56 (where R56 is lower alkyl; or lower alkenyl);-(CH2)mNR33R34<br>
(where R33 is lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken<br>
together are -(CH2)2-6-; -(CH2)2O(CH2)2-;<br>
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -<br>
-(CH2)mOCONR33R75 (where R33 is H; lower alkyl; or lower alkenyl; R75 is lower alkyl; or<br>
R33 and R75 taken together are<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or<br>
lower alkyl);<br>
 -(CH2)mNR20CONR33R82 (where R20 is H; or lower alkyl; R33 is H; or lower alkyl; or<br>
lower alkenyl; R82 is H; or lower alkyl; or R33 and R82 taken together are -(CH2)2-6-;<br><br>
-(CH2)2O(CH2)2-;<br>
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -<br>
(CH2)oN(R20)COR64(where: R20 is H; or lower alkyl; R64 is lower alkyl; or lower alkenyl);<br>
-(CH2)oCOOR57; (where R57 is lower alkyl; or lower alkenyl); -(CH2)OCONR58R59 (where<br>
R58 is lower alkyl; or lower alkenyl; and R59 is H; or lower alkyl; or R58 and R59 taken<br>
together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60 is<br>
lower alkyl; or lower alkenyl); -(CH2)oSO2R62 (where R62 is lower alkyl; or lower<br>
alkenyl); or -(CH2)qC6H4R8 (where R8 is H; F; C1; CF3; lower alkyl; lower alkenyl; or<br>
lower alkoxy);<br>
R3 is H; lower alkyl; lower alkenyl; -(CH2)mOR55 (where R55 is lower alkyl; or lower<br>
alkenyl);<br>
-(CH2)mSR56 (where R56 is lower alkyl; or lower alkenyl); -(CH2)mNR33R34 (where R33 is<br>
lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are<br>
-(CH2)2-6-;<br>
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower<br>
alkyl);<br>
-(CH2)mOCONR33R75 (where R33 is H; or lower alkyl; or lower alkenyl; R75 is lower alkyl;<br>
or R33 and R75 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -<br>
(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)mNR20CONR33R82 (where R20<br>
is H; or lower alkyl; R33 is H; or lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or<br>
R33 and R82 taken together are -(CH2)2-6-;<br>
 -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower<br>
alkyl);<br>
 -(CH2)oN(R20)COR64 (where: R20 is H; or lower alkyl; R64 is lower alkyl; or lower<br>
alkenyl);<br>
-(CH2)oCOOR57 (where R57 is lower alkyl; or lower alkenyl); -(CH2)oCONR58R59 (where<br>
R58 is lower alkyl; or lower alkenyl; and R59 is H; lower alkyl; or R58 and R59 taken<br>
together are -(CH2)2-6-;<br>
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower<br>
alkyl);<br>
-(CH2)oPO(OR60)2 (where R60 is lower alkyl; or lower alkenyl); -(CH2)oSO2R62 (where R62<br>
is lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8 is H; F; Cl; CF3; lower<br>
alkyl; lower alkenyl; or lower alkoxy).<br><br>
R4 is H; lower alkyl; lower alkenyl; -(CH2)m0R55 (where R55 is lower alkyl; or lower<br>
alkenyl);<br>
-(CH2)mSR56 (where R56 is lower alkyl; or lower alkenyl); -(CH2)mNR33R64 (where R33 is<br>
lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are<br>
-(CH2)2-6-;<br>
 -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower<br>
alkyl);<br>
-(CH2)mOCONR33R75 (where R33 is H; or lower alkyl; or lower alkenyl; R75 is lower alkyl;<br>
or R33 and R75 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -<br>
(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)mNR20CONR33R82 (where R20<br>
is H; or lower alkyl; R33 is H; or lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or<br>
R33 and R82 taken together are -(CH2)2-6-;<br>
 -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower<br>
alkyl);<br>
 -(CH2)mN(R20)COR64 where: R20 is H; or lower alkyl; R64 is lower alkyl; or lower<br>
alkenyl);<br>
 -(CH2)oCOOR57 (where R57 is lower alkyl; or lower alkenyl); -(CH2)OCONR58R59 (where<br>
R58 is lower alkyl; or lower alkenyl; and R59 is H; or lower alkyl; or R58 and R59 taken<br>
together are -(CH2)2-6-;<br>
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or (CH2)2NR57(CH2)2-; where R57: isH; or lower<br>
alkyl);<br>
-(CH2)oPO(OR60)2 (where R60 is lower alkyl; or lower alkenyl); -(CH2)oSO2R62 (where R62<br>
is lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8 is H; F; C1; CF3; lower<br>
alkyl; lower alkenyl; or lower alkoxy).<br>
R5 is lower alkyl; lower alkenyl; -(CH2)oOR55 (where R55 is lower alkyl; or lower<br>
alkenyl);<br>
-(CH2)oSR56 (where R56 is lower alkyl; or lower alkenyl); -(CH2)oNR33R64 (where R33 is<br>
lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; <br>
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -<br>
(CH2)OOCONR33R75 (where R33 is H; or lower alkyl; or lower alkenyl; R75 is lower alkyl;<br>
or R33 and R75 taken together are<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or (CH2)2NR57(CH2)2-; where R57 is H; or<br>
lower alkyl); -(CH2)oNR20CONR33R82 (where R20 is H; or lower lower alkyl; R33 is H; or<br>
lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or R33 and R82 taken together are<br><br>
-(CH2)2-6-; -(CH2)2O(CH2)2-;<br>
-(CH2)2S(CH2)2-; or (CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);<br>
(CH2)oN(R20)COR64 (where: R20 is H; or lower alkyl; R64 is alkyl; alkenyl; aryl; aryl-<br>
lower alkyl; or heteroaryl-lower alkyl); -(CH2)oCOOR57 (where R57 is lower alkyl; or<br>
lower alkenyl); -(CH2)oCONR58R59 (where R58 is lower alkyl; or lower alkenyl; and R59 is<br>
H; or lower alkyl; or R58 and RS9 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-;<br>
-(CH2)2S(CH2)2-; or (CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);<br>
-(CH2)oPO(OR60)2 (where R60 is lower alkyl; or lower alkenyl); -(CH2)oSO2R62 (where R62<br>
is lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8 is H; F; C1; CF3; lower<br>
alkyl; lower alkenyl; or lower alkoxy):<br>
R6 is H; lower alkyl; lower alkenyl; -(CH2)oOR55 (where R55 is lower alkyl; or lower<br>
alkenyl);<br>
-(CH2)oSR56 (where R56 is lower alkyl; or lower alkenyl); -(CH2)oNR33R34 (where R33 is<br>
lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-;<br>
 -(CH2)2S(CH2)2-; or (CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -<br>
(CH2)oOCONR33R75 (where R33 is H; or tower alkyl; or lower alkenyl; R75 is lower alkyl;<br>
or R33 and R75 taken together are<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or (CH2)2NR57(CH2)2-; where R57 is H; or<br>
lower alkyl); -(CH2)oNR20CONR33R82 (where R20 is H; or lower lower alkyl; R33 is H; or<br>
lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or R33 and R82 taken together are -<br>
(-(CH2)2-6-; -(CH2)2O(CH2)2-;<br>
 -(CH2)2S(CH2)2-; or (CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -<br>
(CH2)oN(R20)COR64 (where R20 is H; or lower alkyl; R64 is lower alkyl; or lower alkenyl);<br>
-(CH2)oCOOR57 (where R57 is lower alkyl; or lower alkenyl); -(CH2)oCONR58R59 (where<br>
R58 is lower alkyl; or lower alkenyl; and R59 is H; or lower alkyl; or R58 and R59 taken<br>
together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60 is<br>
lower alkyl; or lower alkenyl); -(CH2)oSO2R62 (where R62 is lower alkyl; or lower<br>
alkenyl); or -(CH2)qC6H4R8 (where R8 is H; F; C1; CF3; lower alkyl; lower alkenyl; or<br>
lower alkoxy);<br>
R7 is lower alkyl; lower alkenyl; -(CH2)qOR55 (where R55 is lower alkyl; or lower<br>
alkenyl);<br>
-(CH2)qSR56 (where R56 is lower alkyl; or lower alkenyl); -(CH2)qNR33R64 (where R33 is<br>
lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are<br><br>
-(CH2)2-6-; -(CH2)2O(CH2)2-;<br>
 -(CH2)2S(CH2)2-; or (CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -<br>
(CH2)qOCONR33R75 (where R33 is H; or lower alkyl; or lower alkenyl; R75 is lower alkyl;<br>
or R33 and R75 taken together are<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or (CH2)2NR57(CH2)2-; where R57 is H; or<br>
lower alkyl); (CH2)qNR20CONR33R82 (where R20 is H; or lower alkyl; R33 is H; or lower<br>
alkyl; or lower alkenyl; R82 is H; or lower alkyl; or R33 and R82 taken together ate -(CH2)2-<br>
6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or (CH2)2NR57(CH2)2-; where R57 is H; or lower<br>
alkyl); -(CH2)qN(R20)COR64(where: R20 is H; or lower alkyl; R64 is lower alkyl; or lower<br>
alkenyl); -(CH2)rCOOR57 (where R57 is lower alkyl; or lower alkenyl);<br>
-(CH2)qCONR58R59 (where R58 is lower alkyl; or lower alkenyl; and R59 is H; or lower<br>
alkyl; or R58 and R59 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)rPO(OR60)2 (where R60 is<br>
lower alkyl; or lower alkenyl); -(CH2)rSO2R62 (where R62 is lower alkyl; or lower<br>
alkenyl); or -(CH2)qC6H4R8 (where R8 is H; F; C1; CF3; lower alkyl; lower alkenyl; or<br>
lower alkoxy);<br>
R8 is H; F; Cl; CF3; lower alkyl; lower alkenyl; -(CH2)oOR55 (where R55 is lower alkyl; or<br>
lower alkenyl); -(CH2)oSR56 (where R56 is lower alkyl; or lower alkenyl); -(CH2)oNR33R34<br>
(where R33 is lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken<br>
together are -(CH2)2-6-;<br>
 -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or (CH2)2NR57(CH2)2-; where R57 is H; or lower<br>
alkyl);<br>
(CH2)oOCONR33R75 (where R33 is H; or lower alkyl; or lower alkenyl; R75 is lower alkyl;<br>
or R33 and R75 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -<br>
(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)oNR20CONR33R82 (where R20<br>
is H; or lower alkyl; R33 is H; or lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or<br>
R33 and R82 taken together are -(CH2)2-6-;<br>
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or (CH2)2NR57(CH2)2-; where R57 is H; or lower<br>
alkyl);<br>
-(CH2)oN(R20)COR64 (where R20 is H; or lower alkyl; R64 is lower alkyl; or lower<br>
alkenyl);<br>
-(CH2)oCOOR57 (where R57 is lower alkyl; or lower alkenyl); -(CH2)oCONR58R59 (where<br>
R58 is lower alkyl; or lower alkenyl; and R59 is H; or lower alkyl; or R58 and R59 taken<br>
together are -(CH2)2-6-; <br>
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or (CH2)2NR57(CH2)2-; where R57 is H; or lower<br><br>
alkyl);<br>
-(CH2)oPO(OR60)2 (where R60 is lower alkyl; or lower alkenyl); -(CH2)oSO2R62 (where R62<br>
is lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8 is H; F; C1; CF3; lower<br>
alkyl; lower alkenyl; or lower alkoxy);<br>
R9 is lower alkyl; lower alkenyl; -(CH2)oOR55 (where R55 is lower alkyl; or lower<br>
alkenyl);<br>
-(CH2)oSR56 (where R56 is lower alkyl; or lower alkenyl); -(CH2)oNR33R34 (where R33 is<br>
lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are -<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-;<br>
-(CH2)2S(CH2)2-; or (CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);<br>
-(CH2)oOCONR33R75 (where R33 is H; or lower alkyl; or lower alkenyl; R75 is lower alkyl;<br>
or R33 and R75 taken together are<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or (CH2)2NR57(CH2)2-; where R57 is H; or<br>
lower alkyl); -(CH2)mNR20CONR33R82 (where R20 is H; or lower lower alkyl; R33 is H; or<br>
lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or R33 and R82 taken together are -<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-;<br>
-(CH2)2S(CH2)2-; or (CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -<br>
-(CH2)oN(R20)COR64(where R20 is H; or lower alkyl; R64 is lower alkyl; or lower alkenyl);<br>
-(CH2)oCOOR57 (where R57 is lower alkyl; or lower alkenyl); (CH2)oCONR58R59 (where<br>
R58 is lower alkyl; or lower alkenyl; and R59 is H; or lower alkyl; or R58 and R59 taken<br>
together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60 is<br>
lower alkyl; or lower alkenyl); -(CH2)oSO2R62 (where R62 is lower alkyl; or lower<br>
alkenyl); or -(CH2)qC6H4R8 (where R8 is H; F; C1; CF3; lower alkyl; lower alkenyl; or<br>
lower alkoxy);<br>
R10 is lower alkyl; lower alkenyl; -(CH2)oOR55 (where R55 is lower alkyl; or lower<br>
alkenyl);<br>
-(CH2)oSR56 (where R56 is lower alkyl; or lower alkenyl); -(CH2)oNR33R34 (where R33 is<br>
lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-;<br>
 -(CH2)2S(CH2)2-; or (CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -<br>
(CH2)oOCONR33R75 (where R33 is H; or lower alkyl; or lower alkenyl; R75 is lower alkyl;<br>
or R33 and R75 taken together are<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or (CH2)2NR57(CH2)2-; where R57: H is or<br>
lower alkyl); -(CH2)oNR20CONR33R82 (where R20 is H; or lower lower alkyl; R33 is H; or<br><br>
lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or R33 and R82 taken together are -<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-;<br>
 -(CH2)2S(CH2)2-; or (CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);<br>
-(CH2)oN(R20)COR64(where R20 is H; or lower alkyl; R64 is lower alkyl; or lower alkenyl);<br>
-(CH2)oCOOR57 (where R57 is lower alkyl; or lower alkenyl); -(CH2)oCONR58R59 (where<br>
R58 is lower alkyl; or lower alkenyl; and R59 is H; lower alkyl; or R58 and R59 taken<br>
together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60 is<br>
lower alkyl; or lower alkenyl); -(CH2)oSO2R62 (where R62 is lower alkyl; or lower<br>
alkenyl); or -(CH2)qC6H4R8 (where R8 is H; F; C1; CF3; lower alkyl; lower alkenyl; or<br>
lower alkoxy);<br>
R11 is H; lower alkyl; lower alkenyl; -(CH2)mOR55 (where R55 is lower alkyl; or lower<br>
alkenyl);<br>
-(CH2)mSR56 (where R56 is lower alkyl; or lower alkenyl); -(CH2)mNR33R34 (where R33 is<br>
lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are<br>
-(CH2)2-6-; <br>
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or-(CH2)2NR57(CH2)2-; where R57 is H; or lower<br>
alkyl);<br>
-(CH2)mOCONR33R75 (where R33 is H; or lower alkyl; or lower alkenyl; R75 is lower alkyl;<br>
or R33 and R75 taken together ar -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -<br>
(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)mNR20CONR33R82 (where R20<br>
is H; or lower alkyl; R33 is H; or lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or<br>
R33 and R82 taken together are -(CH2)2-6-;<br>
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower<br>
alkyl);<br>
-(CH2)mN(R20)COR64 (where R20 is H; or lower alkyl; R64 is lower alkyl; or lower<br>
alkenyl);<br>
-(CH2)oCOOR57 (where R57 is lower alkyl; or lower alkenyl); -(CH2)oCONR58R59 (where<br>
R58 is lower alkyl; or lower alkenyl; and R59 is H; lower alkyl; or R58 and R59 taken<br>
together are -(CH2)2-6-; <br>
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower<br>
alkyl);<br>
-(CH2)oPO(OR60)2 (where R60 is lower alkyl; or lower alkenyl); -(CH2)oSO2R62 (where R62<br>
is lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8 is H; F; Cl; CF3; lower<br>
alkyl; lower alkenyl; or lower alkoxy);<br><br>
R12 is H; lower alkyl; lower alkenyl; -(CH2)mOR55 (where R55 is lower alkyl; or lower<br>
alkenyl);<br>
-(CH2)mSR56 (where R56 is lower alkyl; or lower alkenyl); -(CH2)mNR33R64 (where R33 is<br>
lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are<br>
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower<br>
alkyl);<br>
-(CH2)mOCONR33R75 (where R33 is H; or lower alkyl; or lower alkenyl; R75 is lower alkyl;<br>
or R33 and R75 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -<br>
-(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)mNR20CONR33R82 (where R20<br>
is H; or lower lower alkyl; R33 is H; or lower alkyl; or lower alkenyl; R82 is H; or lower<br>
alkyl; or R33 and R82 taken together are -(CH2)2-6-;<br>
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower<br>
alkyl);<br>
-(CH2)mN(R20)COR64 (where: R20 is H; or lower alkyl; R64 is lower alkyl; or lower<br>
alkenyl);<br>
-(CH2)rCOOR57 (where R57 is lower alkyl; or lower alkenyl); -(CH2)rCONR58R59 (where<br>
R58 is lower alkyl; or lower alkenyl; and R59 is H; or lower alkyl; or R58 and R59 taken<br>
together are -(CH2)2-6-;<br>
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower<br>
alkyl);<br>
-(CH2)rPO(OR60)2 (where R60 is lower alkyl; or lower alkenyl); -(CH2)oSO2R62 (where R62<br>
is lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8 is H; F; Cl; CF3; lower<br>
alkyl; lower alkenyl; or lower alkoxy):<br>
R13 is lower alkyl; lower alkenyl; -(CH2)oOR55 (where R55 isis lower alkyl; or lower<br>
alkenyl);<br>
-(CH2)qSR56 (where R56 is lower alkyl; or lower alkenyl); -(CH2)qNR33R64 (where R33 is<br>
lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are -<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-;<br>
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -<br>
-(CH2)qOCONR33R75 (where R33 is H; or lower alkyl; or lower alkenyl; R75 is lower alkyl;<br>
or R33 and R73 taken together are<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or<br>
lower alkyl); -(CH2)qNR20CONR33R82 (where R20 is H; or lower lower alkyl; R33 is H; or<br>
lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or R33 and R82 taken together are -<br><br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; <br>
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -<br>
-(CH2)qN(R20)COR64 (where: R20 is H; or lower alkyl; R64 is lower alkyl; or lower<br>
alkenyl); -(CH2)rCOOR57 (where R57 is lower alkyl; or lower alkenyl); -<br>
(CH2)qCONR58R59 (where R58 is lower alkyl; or lower alkenyl; and R59 is H; or lower<br>
alkyl; or R58 and R59 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)rPO(OR60)2 (where R60 is<br>
lower alkyl; or lower alkenyl); -(CH2)rSO2R62 (where R62 is lower alkyl; or lower<br>
alkenyl); or -(CH2)qC6H4R8 (where R8 is H; F; Cl; CF3; lower alkyl; lower alkenyl; or<br>
lower alkoxy);<br>
R14 is H; lower alkyl; lower alkenyl; -(CH2)mOR55 (where R55 is lower alkyl; or lower<br>
alkenyl);<br>
-(CH2)mSR56 (where R56 is lower alkyl; or lower alkenyl); -(CH2)mNR33R64 (where R33 is<br>
lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are -<br>
-(CH2)2-6-; <br>
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower<br>
alkyl);<br>
-(CH2)mOCONR33R75 (where R33 is H; or lower alkyl; or lower alkenyl; R75 is lower alkyl;<br>
or R33 and R75 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -<br>
-(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)qNR20CONR33R82 (where R20<br>
is H; or lower lower alkyl; R33 is H; or lower alkyl; or lower alkenyl is R82: H; or lower<br>
alkyl; or R33 and R82 taken together are -(CH2)2-6-;<br>
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or - -(CH2)2NR57(CH2)2-; where R57 is H; or lower<br>
alkyl);<br>
-(CH2)oN(R20)COR64 (where: R20 is H; lower alkyl; R64 is lower alkyl; or lower alkenyl);<br>
-(CH2)oCOOR57 (where R57 is lower alkyl; or lower alkenyl); -(CH2)oCONR58R59 (where<br>
R58 is lower alkyl; or lower alkenyl; and R59 is H; or lower alkyl; or R58 and R59 taken<br>
together are -(CH2)2-6-; <br>
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or - -(CH2)2NR57(CH2)2-; where R57 is H; or lower<br>
alkyl);<br>
-(CH2)oPO(OR60)2 (where R60 is lower alkyl; or lower alkenyl); -(CH2)oSO2R62 (where R62<br>
is lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8 is H; F; Cl; CF3; lower<br>
alkyl; lower alkenyl; or lower alkoxy);<br>
R15 is lower alkyl; lower alkenyl; -(CH2)oOR55 (where R55 is lower alkyl; or lower<br>
alkenyl);<br><br>
-(CH2)oSR56 (where R56 is lower alkyl; or lower alkenyl); -(CH2)oNR33R64 (where R33 is<br>
lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; <br>
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);<br>
-(CH2)oOCONR33R75 (where R33 is H; or lower alkyl; or lower alkenyl; R75 is lower alkyl;<br>
or R33 and R75 taken together are<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or<br>
lower alkyl); -(CH2)oNR20CONR33R82 (where R20 is H; or lower lower alkyl; R33 is H; or<br>
lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or R33 and R82 taken together are<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; <br>
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);<br>
-(CH2)oN(R20)COR64 (where R20 is H; or lower alkyl; R64 is lower alkyl; or lower<br>
alkenyl); -NR20COlower alkyl (R20=H; or lower alkyl); being particularly favoured;<br>
-(CH2)oCOOR57 (where R57 is lower alkyl; or lower alkenyl); -(CH2)oCONR58R59 (where<br>
R58 is lower alkyl, or lower alkenyl; and R59 is H; lower alkyl; or R58 and R59 taken<br>
together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where<br>
R57 is H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60 is lower alkyl; or lower alkenyl);<br>
-(CH2)oSO2R62 (where R62 is lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8<br>
is H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy);<br>
R16 is lower alkyl; lower alkenyl; -(CH2)oOR55 (where R55 is lower alkyl; or lower<br>
alkenyl);<br>
-(CH2)oSR56 (where R56 is lower alkyl; or lower alkenyl); -(CH2)oNR33R34 (where R33 is<br>
lower alky; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are -<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; <br>
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);<br>
-(CH2)oOCONR33R75 (where R33 is H; or lower alkyl; or lower alkenyl; R75 is lower alkyl;<br>
or R33 aad R75 taken together are<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or<br>
lower alkyl); -(CH2)oNR20CONR33R82 (where R20 is H; or lower lower alkyl; R33 is H; or<br>
lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or R33 and R82 taken together are<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; <br>
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);<br>
-(CH2)oN(R20)COR64 (where R20 is H; or lower alkyl; R64 is lower alkyl; or lower<br>
alkenyl); -(CH2)oCOOR57 (where R57 is lower alkyl; or lower alkenyl);<br>
-(CH2)oCONR58R59 (where R58 is lower alkyl; or lower alkenyl; and R59 is H; or lower<br><br>
alkyl; or R58 and R59 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60 is<br>
lower alkyl; or lower alkenyl); -(CH2)oS02R62 (where R62 is lower alkyl; or lower<br>
alkenyl); or -(CH2)qC6H4R8 (where R8 is H; F; C1; CF3; lower alkyl; lower alkenyl; or<br>
lower alkoxy); and<br>
R17 is lower alkyl; lower alkenyl; -(CH2)qOR55 (where R55 is lower alkyl; or lower<br>
alkenyl);<br>
-(CH2)qSR56 (where R56 is lower alkyl; or lower alkenyl); -(CH2)qNR33R34 (where R33 is<br>
lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; <br>
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);<br>
-(CH2)qOCONR33R75 (where R33 is H; or lower alkyl; or lower alkenyl; R75 is lower alkyl;<br>
or R33 and R75 taken together are<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or<br>
lower alkyl); -(CH2)qNR20CONR33R82 (where R20 is H; or lower alkyl; R33 is H; or lower<br>
alkyl; or lower alkenyl; R82 is H; or lower alkyl; or R33 and R82 taken together are -(CH2)2-<br>
6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower<br>
alkyl); -(CH2)qN(R20)COR64 (where: R20 is H; or lower alkyl; R64 is lower alkyl; or lower<br>
alkenyl); -(CH2)rCOOR57 (where R57 is lower alkyl; or lower alkenyl); -<br>
-(CH2)qCONR58R59 (where R58 is lower alkyl; or lower alkenyl; and R59 is H; lower alkyl;<br>
or R58 and R59 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -<br>
(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)rPO(OR60)2 (where R60 is<br>
lower alkyl; or lower alkenyl);<br>
-(CH2)rSO2R62 (where R62 is lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8<br>
is H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy).<br>
5.	Compounds according to claim 3 or 4 wherein A is a group of one of the formulae<br>
A5 (with R2 being H); A8; A22; A25; A38 (with R2 being H); A42; and A50.<br>
6.	Compounds according to claim 5 wherein A is a group of formula<br><br><br>
wherein R20 is H or lower alkyl; and R64 is alkyl; alkenyl; aryl; aryl-lower alkyl; or<br>
heteroaryl-lower alkyl.<br>
7.	Compounds according to claim 6 wherein R64 is n-hexyl; n-heptyl; 4-<br>
(phenyl)benzyl; diphenylmethyl, 3-atnino-propyl; 5-amino-pentyl; methyl; ethyl;<br>
isopropyl; isobutyl; n-propyl; cyclohexyl; cyclohexylmethyl; n-butyl; phenyl; benzyl; (3-<br>
indolyl)methyl; 2-(3-indolyl)ethyl; (4-phenyl)phenyl; or n-nonyl.<br>
8.	Compounds according to claim 3 wherein A is a group of one of the formulae A70<br>
to A104;<br>
R20 is H; or lower alkyl;<br>
R18 is lower alkyl;<br>
R19 is lower alkyl; lower alkenyl; -(CH2)p0R55 (where R55 is lower alkyl; or lower<br>
alkenyl);<br>
-(CH2)pSR56 (where R56 is lower alkyl; or lower alkenyl); -(CH2)pNR33R34 (where R33 is<br>
lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-;<br>
 -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);<br>
-(CH2)pOCONR33R75 (where R33 is H; or lower alkyl; or lower alkenyl; R75 is lower alkyl;<br>
or R33 and R75 taken together are<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or<br>
lower alkyl); -(CH2)pNR20CONR33R82 (where R20 is H; or lower lower alkyl; R33 is H; or<br>
lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or R33 and R82 taken together are -<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-;<br>
 -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);<br>
-(CH2)pN(R20)COR64 (where: R20 is H; or lower alkyl; R64 is lower alkyl; or lower<br>
alkenyl); (CH2)PCOOR57 (where R57: lower alkyl; or lower alkenyl); (CH2)pCONR58R59<br>
(where R58 is lower alkyl; or lower alkenyl; and R59 is H; or lower alkyl; or R58 and R59<br>
taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-;<br>
where R57 is H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60 is lower alkyl; or lower<br>
alkenyl); -(CH2)pSO2R62 (where R62 is lower alkyl; or lower alkenyl); or (CH2)oC6H4R8<br>
(where R8 is H; F; C1; CF3; lower alkyl; lower alkenyl; or lower alkoxy);<br>
R21 is H; lower alkyl; lower alkenyl; -(CH2)oOR55 (where R55 is lower alkyl; or lower<br>
alkenyl);<br>
(CH2)oSR56 (where R56 is lower alkyl; or lower alkenyl); -(CH2)oNR33R34 (where R33 is<br><br>
lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are -<br>
(-(CH2)2-6-; -(CH2)2O(CH2)2-; <br>
 -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);<br>
-(CH2)oOCONR33R75 (where R33 is H; or lower alkyl; or lower alkenyl; R75 is lower alkyl;<br>
or R33 and R75 taken together are<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or<br>
lower alkyl);<br>
-(CH2)oNR20CONR33R82 (where R20 is H; or lower lower alkyl; R33 is H; or lower alkyl; or<br>
lower alkenyl; R42 is H; or lower alkyl; or R33 and R82 taken together are -(CH2)2-6-;<br>
 -(CH2)2O(CH2)2-; <br>
 -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);<br>
-(CH2)oN(R20)COR64 (where: R20 is H; or lower alkyl; R64 is lower alkyl; or lower<br>
alkenyl); -(CH2)oCOOR57 (where R57 is lower alkyl; or lower alkenyl); -<br>
(CH2)oCONR58R59 (where R58 is lower alkyl, or lower alkenyl; and R59 is H; lower alkyl;<br>
or R58 and R59 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
-(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60 is<br>
lower alkyl; or lower alkenyl); -(CH2)oSO2R62 (where R62 is lower alkyl; or lower<br>
alkenyl); or -(CH2)qC6H4R8 (where R8 is H; F; Cl; CF3; lower alkyl; lower alkenyl; or<br>
lower alkoxy);<br>
R22 is lower alkyl; lower alkenyl; -(CH2)oOR55 (wheare R55 is lower alkyl; or lower<br>
alkenyl);<br>
-(CH2)oSR56 (where R56 is lower alkyl; or lower alkenyl); -(CH2)oNR33R34 (where R33 is<br>
lower alkyl; or lower alkenyl, R34 is H; or lower alkyl; or R33 and R34 taken together are<br><br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; <br>
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);<br>
-(CH2)oOCONR33R75 (where R33 is H; or lower alkyl; or lower alkenyl; R75 is lower alkyl;<br>
or R33 and R73 taken together are<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or<br>
lower alkyl); (CH2)oNR20CONR33R82 (where R20 is H; or lower alkyl; R33 is H; or lower<br>
alkyl; or lower alkenyl; R82 is H; or lower alkyl; or R33 and R82 taken together are -(CH2)2-<br>
6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower<br>
alkyl); -(CH2)oN(R20)COR64 where R20 is H; or lower alkyl; R64 is lower alkyl; or lower<br>
alkenyl); -(CH2)oCOOR57 (where R57 is lower alkyl; or lower alkenyl);<br>
-(CH2)oCONR58R59 (whre R58 is lower alkyl, or lower alkenyl; and R59 is H; lower alkyl;<br>
or R58 and R59 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br><br>
-(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60 is<br>
lower alkyl; or lower alkenyl);<br>
-(CH2)oS02R62 (where R62 is lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8<br>
is H; F; Cl; CF; lower alkyl; lower alkenyl; or lower alkoxy);<br>
R23 is H; lower alkyl; lower alkenyl; -(CH2)oOR55 (where R55 is lower alkyl; or lower<br>
alkenyl);<br>
-(CH2)oSR56 (where R56 is lower alkyl; or lower alkenyl); -(CH2)oNR33R34 (where R33 is<br>
lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are -<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; <br>
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);<br>
-(CH2)oOCONR33R75 (where R33 is H; or lower alkyl; or lower alkenyl; R75 is lower alkyl;<br>
or R33 and R75 taken together are<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or<br>
lower alkyl); -(CH2)oNR20CONR33R82 (where R20 is H; or lower alkyl; R33 is H; or lower<br>
alkyl; or lower alkenyl; R82 is H; or lower alkyl; or R33 and R82 taken together are -(CH2)2-<br>
6-; -(CH2)2O(CH2)2-; <br>
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);<br>
-(CH2)oN(R20)COR64 (where: R20 is H; or lower alkyl; R64 is lower alkyl; or lower<br>
alkenyl); -NR20COlower alkyl (R20=H; or lower alkyl) being particularly favoured;<br>
-(CH2)oCOOR57 (where R57 is lower alkyl; or lower alkenyl); -(CH2)oCONR58R59 (where<br>
R58 is lower alkyl, or lower alkenyl; and R59 is H; lower alkyl; or R58 and R59 taken<br>
together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where<br>
R57 is H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60 is lower alkyl; or lower alkenyl);<br>
-(CH2)oSO2R62 (where R62 is lower alkyl; or lower alkenyl); or -(CH2)oC6H4R8 (where R8<br>
is H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy);<br>
R24 is lower alkyl; lower alkenyl; -(CH2)oOR55 (where R55 is lower alkyl; or lower<br>
alkenyl);<br>
-(CH2)oSR56 (where R56 is lower alkyl; or lower alkenyl); -(CH2)oNR33R34 (where R33 is<br>
lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; <br>
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -<br>
(CH2)oOCONR33R75 (where R33 is H; or lower alkyl; or lower alkenyl; R75 is lower alkyl;<br>
or R33 and R75 taken together are<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or<br>
lower alkyl); -(CH2)oNR20CONR33R82 (where R20 is H; or lower lower alkyl; R33 is H; or<br><br>
lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or R33 and R82 taken together are<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; <br>
 -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);<br>
-(CH2)oN(R20)COR64 (where: R20 is H; or lower alkyl; R64 is lower alkyl; or lower<br>
alkenyl); -NR20COlower alkyl (R20=H; or lower alkyl) being particularly favoured;<br>
-(CH2)oCOOR57 (where R57 is lower alkyl; or lower alkenyl); (CH2)oCONR58R59 (where<br>
R58 is lower alkyl, or lower alkenyl; and R59 is H; lower alkyl; or R58 and R59 taken<br>
together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where<br>
R57 is H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60 is lower alkyl; or lower alkenyl);<br>
-(CH2)oSO2R62 (where R62 is lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8<br>
is H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy);<br>
R25 is H; lower alkyl; lower alkenyl; -(CH2)mOR55 (where R55 is lower alkyl; or lower<br>
alkenyl);<br>
-(CH2)mNR33R34 (where R33 is lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or<br>
R33 and R34 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or<br>
 -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)mOCONR33R75 (where R33 is<br>
H; or lower alkyl; or lower alkenyl; R75 is lower alkyl; or R33 and R75 taken together are<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or <br>
-(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)mNR20CONR33R82 (where R20<br>
is H; or lower alkyl; R33 is H; or lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or<br>
R33 and R82 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or <br>
-(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)mN(R20)COR64 (where: R20 is<br>
H; or lower alkyl; R64 is lower alkyl; or lower alkenyl); -(CH2)oCOOR57 (where R57 is<br>
lower alkyl; or lower alkenyl); -(CH2)oC0NR58R59 (where R58 is lower alkyl; or lower<br>
alkenyl; and R59 is H; lower alkyl; or R58 and R59 taken together are -(CH2)2-6-; <br>
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower<br>
alkyl);<br>
-(CH2)oPO(OR60)2 (where R60 is lower alkyl; or lower alkenyl); -(CH2)oSO2R62 (where R62<br>
is lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8 is H; F; Cl; CF3; lower<br>
alkyl; lower alkenyl; or lower alkoxy);<br>
R26 is H; lower alkyl; lower alkenyl; -(CH2)mOR55 (where R55 is lower alkyl; or lower<br>
alkenyl);<br>
-(CH2)mNR33R34 (where R33 is lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or<br>
R33 and R34 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or <br>
-(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)mOCONR33R75 (where R33 is<br><br>
H; or lower alkyl; or lower alkenyl; R75 is lower alkyl; or R33 and R75 taken together are<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or <br>
-(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)mNR20CONR33R82 (where R20<br>
is H; or lower alkyl; R33 is H; or lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or<br>
R33 and R82 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or <br>
 -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)mN(R20)COR64 (where: R20 is<br>
H; or lower alkyl; R64 is lower alkyl; or lower alkenyl); -(CH2)oCOOR57 (where R57 is<br>
lower alkyl; or lower alkenyl); -(CH2)oCONR58R59 (where R58 is lower alkyl; or lower<br>
alkenyl; and R59 is H; lower alkyl; or R58 and R59 taken together are -(CH2)2-6-; <br>
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower<br>
alkyl);<br>
-(CH2)oPO(OR60)2 (where R60 is lower alkyl; or lower alkenyl); -(CH2)oSO2R62 (where R62<br>
is lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8 is H; F; Cl; CF3; lower<br>
alkyl; lower alkenyl; or lower alkoxy); or, alternatively, R25 and R26 taken together are<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; <br>
-(CH2)2S(CH2)2-; or -(CH2)2NR34(CH2)2-;<br>
R27 is H; lower alkyl; lower alkenyl; -(CH2)oOR55 (where R55 is lower alkyl; or lower<br>
alkenyl);<br>
-(CH2)oSR56 (where R56 is lower alkyl; or lower alkenyl); -(CH2)oNR33R34 (where R33 is<br>
lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-;<br>
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);<br>
-(CH2)oOCONR33R75 (where R33 is H; or lower alkyl; or lower alkenyl; R75 is lower alkyl;<br>
or R33 and R75 taken together are<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or<br>
lower alkyl); -(CH2)oNR20CONR33R82 (where R20 is H; or lower lower alkyl; R33 is H; or<br>
lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or R33 and R82 taken together are -<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; <br>
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);<br>
-(CH2)oN(R20)COR64 (where R20 is H; or lower alkyl; R64 is lower alkyl; or lower<br>
alkenyl); -(CH2)oCOOR57 (where R57 is lower alkyl; or lower alkenyl);<br>
-(CH2)oCONR58R59 (where R58 is lower alkyl, or lower alkenyl; and R59 is H; lower alkyl;<br>
or R58 and R59 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60 is<br>
lower alkyl; or lower alkenyl); -(CH2)oSO2R62 (where R62 is lower alkyl; or lower<br><br>
alkenyl); or -(CH2)qC6H4R8 (where R8 is H; F; Cl; CF3; lower alkyl; lower alkenyl; or<br>
lower alkoxy);<br>
R28 is lower alkyl; tower alkenyl; -(CH2)oOR55 (where R55 is lower alkyl; or lower<br>
alkenyl);<br>
-(CH2)oSR56 (where R56 is lower alkyl; or lower alkenyl); -(CH2)oNR33R34 (where R33 is<br>
lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are -<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; <br>
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);<br>
-(CH2)oOCONR33R75 (where R33 is H; or lower alkyl; or lower alkenyl; R75 is lower alkyl;<br>
or R33 and R75 taken together are<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or<br>
lower alkyl); -(CH2)oNR20CONR33R82 (where R20 is H; or lower alkyl; R33 is H; or lower<br>
alkyl; or lower alkenyl; R82 is H; or lower alkyl; or R33 and R82 taken together are -(CH2)2-<br>
6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower<br>
alkyl); -(CH2)oN(R20)COR64(where: R20 is H; or lower alkyl; R64 is lower alkyl; or lower<br>
alkenyl); (CH2)oCOOR57 (where R57 is lower alkyl; or lower alkenyl);<br>
-(CH2)oCONR58R59 (where R58 is lower alkyl, or lower alkenyl; and R59 is H; lower alkyl;<br>
or R58 and R39 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60 is<br>
lower alkyl; or lower alkenyl);	<br>
-(CH2)oSO2R62 (where R62 is lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8<br>
is H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy); and<br>
R29 is lower alkyl; lower alkenyl; -(CH2)oOR55 (where R55 is lower alkyl; or lower<br>
alkenyl);<br>
-(CH2)oSR56 (where R56 is lower alkyl; or lower alkenyl); -(CH2)oNR33R34 (where R33 is<br>
lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or R33 and R34 taken together are -<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; <br>
-(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);<br>
-(CH2)oOCONR33R75 (where R33 is H; or lower alkyl; or lower alkenyl; R75 is lower alkyl;<br>
or R33 and R75 taken together are<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or<br>
lower alkyl); -(CH2)oNR20CONR33R82 (where R20 is H; or lower alkyl; R33 is H; or lower<br>
alkyl; or lower alkenyl; R82 is H; or lower alkyl; or R33 and R82 taken together ane -(CH2)2-<br>
6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower<br>
alkyl); -(CH2)oN(R20)COR64 R20 is H; or lower alkyl; R64 is lower alkyl; or lower<br><br>
alkenyl); -NR20COlower-alkyl (R20=H; or lower alkyl) being particularly favoured;<br>
-(CH2)oCOOR57 (where R57 is lower alkyl; or lower alkenyl);<br>
-(CH2)oCONR58R59 (where R58 is lower alkyl, or lower alkenyl; and R59 is H; lower alkyl;<br>
or R58 and R59 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or <br>
 -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)oPO(OR60)2 (where R60 is<br>
lower alky]; or lower alkenyl);<br>
-(CH2)oSO2R62(where R62 is lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8<br>
is H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy).<br>
9.	Compounds according to claim 8 wherein R23, R24 and R29 are -NR20-CO-lower<br>
alkyl where R20 is H; or lower alkyl.<br>
10.	Compounds according to claim 8 or 9 wherein A is a group of one of the formulae<br>
A74 (with R22 being H); A75; A76; A77 (wife R22 being H); A78; and A79.<br>
11.	Compounds according to any one of claims 3 to 10 wherein B is a group of<br>
formula<br>
-NR20CH(R71)- or an enantiomer of one of the groups A5 (with R2 being H); A8; A22;<br>
A25; A38 (with R2 being H); A42; A47; and A50.<br>
12.	Compounds according to claim 11 wherein B-CO is Ala; Arg; Asn; Cys; Gln; Gly;<br>
His; He; Leu; Lys; Met; Phe; Pro; Ser, Thr; Trp; Tyr; Val; Cit; Orn; tBuA; Sar; t-BuG;<br>
4AmPhe; 3AmPhe; 2AmPhe; Phe(mC(NH2)=NH; Phe(pC(NH2)=NH; Phe(mNHC<br>
(NH2)=NH; Phe(pNHC (NH2)=NH; Phg; Cha; C4al; C5al; Nle; 2-Nal; 1-Nal; 4Cl-Phe;<br>
3C1-Phe; 2C1-Phe; 3,4Cl2Phe; 4F-Phe; 3F-Phe; 2F-Phe; Tic; Thi; Tza; Mso; AcLys; Dpr;<br>
A2Bu; Dbu; Abu; Aha; Aib; Y(Bzl); Bip; S(Bzl); T(Bzl); hCha; hCys; hSer, hArg; hPhe;<br>
Bpa; Pip; OctG; MePhe; MeNle; MeAla; Melle; MeVal; or MeLeu.<br>
13.	Compounds according to claim 11 or 12 wherein B is a group, having (L)-<br>
configuration, of formula<br><br><br>
wherein R20 is H; or lower alkyl; and R64 is alkyl; alkenyl; aryl; aryl-lower alkyl; or<br>
heteroaryl-lower alkyl.<br>
14.	Compounds according to claim 13 wherein R64 is n-hexyl; n-heptyl; 4-<br>
(phenyl)benzyl; diphenylmethyl, 3-amino-propyl; 5-amino-pentyl; methyl; ethyl;<br>
isopropyl; isobutyl; n-propyl; cyclohexyl; cyclohexylmethyl; n-butyl; phenyl; benzyl; (3-<br>
indolyl)methyl; 2-(3-indolyl)ethyl; (4-phenyl)phenyl; or n-nonyl.<br>
15.	Compounds according to claim 1 wherein<br><br>
is a group of formula (bl) or (cl);<br>
R1 is H; or lower alkyl;<br>
R20 is H; or lower alkyl;<br>
R30 is H; or methyl;<br>
R31 is H; lower alkyl; lower alkenyl; -(CH2)pOR55 (where R55 is lower alkyl; or lower<br>
alkenyl);<br>
-(CH2)pNR33R34 (where R33 is lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or<br>
R33 and R34 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -<br>
(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)pOCONR33R75 (where R33 is<br>
H; or lower alkyl; or lower alkenyl; R75 is lower alkyl; or R33 and R75 taken together are -<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or <br>
 -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)pNR20CONR33R82 (where R20<br>
is H; or lower alkyl; R33 is H; or lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or<br>
R33 and R82 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or <br>
-(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)oN(R20)COR64 (where: R20 is<br>
H; or lower alkyl; R64 is lower alkyl; or lower alkenyl); -(CH2)oCOOR57 (where R57 is<br>
lower alkyl; or lower alkenyl); -(CH2)oCONR58R59 (where R58 is lower alkyl, or lower<br>
alkenyl; and R59 is H; lower alkyl; or R58 and R59 taken together are -(CH2)2-6-; <br>
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower<br>
alkyl);<br>
-(CH2)oPO(OR60)2 (where R60 is lower alkyl; or lower alkenyl); -(CH2)oSO2R62 (where R62<br><br>
is lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8 is H; F; Cl; CF3; lower<br>
alkyl; lower alkenyl; or lower alkoxy); most preferably -CH2CONR58R59 (where R58 is H;<br>
or lower alkyl; and R59 is lower alkyl; or lower alkenyl);<br>
R32 is H; or methyl;<br>
R33 is lower alkyl; lower alkenyl; -(CH2)mOR55 (where R55 is lower alkyl; or lower<br>
alkenyl);<br>
-(CH2)mNR34R63 (where R34 is lower alkyl; or lower alkenyl; R63 is H; or lower alkyl; or<br>
R34 and R63 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or <br>
-(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)mOCONR75R82 (where R75 is<br>
lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or R75 and R82 taken together are<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or <br>
-(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)mNR20CONR78R82 (where R20<br>
is H; or lower alkyl; R78 is H; or lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or<br>
R78 and R82 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or <br>
-(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)mN(R20)COR64 (where: R20<br>
is H; or lower alkyl; R64 is lower alkyl; or lower alkenyl); -(CH2)oCOOR57 (where R57 is<br>
lower alkyl; or lower alkenyl); (CH2)oCONR58R59 (where R58 is lower alkyl; or lower<br>
alkenyl; and R59 is H; lower alkyl; or R58 and R59 taken together are -(CH2)2-6-; <br>
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57: H; or lower<br>
alkyl);<br>
R34 is H; or lower alkyl;<br>
R35: isH; lower alkyl; lower alkenyl; -(CH2)mOR55 (where R55: lower alkyl; or lower<br>
alkenyl);<br>
-(CH2)mNR33R34 (where R33 is lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or<br>
R33 and R34 taken together are-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)mOCONR33R75 (where R33 is<br>
H; or lower alkyl; or lower alkenyl; R75 is lower alkyl; or R33 and R75 taken together are<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or <br>
-(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)mNR20CONR33R82 (where R20<br>
is H; or lower alkyl; R33 is H; or lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or<br>
R33 and R82 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)mN(R20)COR64 (where: R20 is<br>
H; or lower alkyl; R64 is lower alkyl; or lower alkenyl); -(CH2)oCOOR57 (where R57 is<br>
lower alkyl; or lower alkenyl); -(CH2)oCONR58R59 (where R58 is lower alkyl; or lower<br>
alkenyl; and R59 is H; lower alkyl; or R58 and R59 taken together are -(CH2)2-6-; <br><br>
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower<br>
alkyl);<br>
R36: lower alkyl; lower alkenyl; or aryl-lower alkyl;<br>
R37 is H; lower alkyl; lower alkenyl; -(CH2)p0R55 (where R55 is lower alkyl; or lower<br>
alkenyl);<br>
-(CH2)pNR33R34 (where R33 is lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or<br>
R33 and R34 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or <br>
-(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);- (CH2)pOCONR33R75 (where R33 is<br>
H; or lower alkyl; or lower alkenyl; R75 is lower alkyl; or R33 and R75 taken together are<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or <br>
-(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)pNR20CONR33R82 (where R20<br>
is H; or lower alkyl; R33 is H; or lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or<br>
R33 and R82 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or <br>
-(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)pN(R20)COR64 (where: R20 is<br>
H; or lower alkyl; R64 is lower alkyl; or lower alkenyl); -(CH2)oCOOR57 (where R57 is<br>
lower alkyl; or lower alkenyl); -(CH2)oCONR58R59 (where R58 is lower alkyl, or lower<br>
alkenyl; and R59 is H; lower alkyl; or R58 and R59 taken together are -(CH2)2-6-; <br>
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower<br>
alkyl);<br>
-(CH2)oPO(OR60)2 (where R60 is lower alkyl; or lower alkenyl); -(CH2)oSO2R62 (where R62<br>
is lower alky; or lower alkenyl); or -(CH2)qC6H4R8 (where R8 is H; F; Cl; CF3; lower<br>
alkyl; lower alkenyl; or lower alkoxy); and<br>
R38 is H; lower alkyl; lower alkenyl; -(CH2)pOR55 (where R55 is lower alkyl; or lower<br>
alkenyl);<br>
-(CH2)pNR33R34 (where R33 is lower alkyl; or lower alkenyl; R34 is H; or lower alkyl; or<br>
R33 and R34 taken together sre -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or <br>
-(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)pOCONR33R75 (where R33 is<br>
H; or lower alkyl; or lower alkenyl; R75 is lower alkyl; or R33 and R75 taken together are -<br>
-(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or <br>
-(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl); -(CH2)pNR20CONR33R82 (where R20<br>
is H; or lower alkyl; R33 is H; or lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or<br>
R33 and R82 taken together are -(CH2)2-6-; -(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or <br>
-(CH2)2NR57(CH2)2-; where R57 is H; or lower alkyl);-(CH2)pN(R20)COR64 (where: R20 is<br>
H; or lower alkyl; R64 is lower alkyl; or lower alkenyl); -(CH2)oCOOR57 (where R57 is<br>
lower alkyl; or lower alkenyl); -(CH2)oCONR58R59 (where R58 is lower alkyl, or lower<br><br>
alkenyl; and R59 is H; lower alkyl; or R58 and R59 taken together are -(CH2)2-6-; <br>
-(CH2)2O(CH2)2-; -(CH2)2S(CH2)2-; or -(CH2)2NR57(CH2)2-; where R57 is H; or lower<br>
alkyl);<br>
-(CH2)oPO(OR60)2 (where R60 is lower alkyl; or lower alkenyl); -(CH2)oSO2R62 (where R62<br>
is lower alkyl; or lower alkenyl); or -(CH2)qC6H4R8 (where R8 is H; F; C1; CF3; lower<br>
alkyl; lower alkenyl; or lower alkoxy).<br>
16.	Compounds according to claim 15 wherein R1 is H; R20 is H; R30 is H; R31 is<br>
carboxymethyl; or lower alkoxycarbonylmethyl; R32 is H; R35 is methyl; R36 is methoxy;<br>
R37 is H and R38 is H.<br>
17.	Compounds according to any one of claims 1 to 16 wherein the α -amino acid<br>
residues in positions 1 to 12 of the chain Z are:<br>
P1:	of type C or of type D or of type E or of type F;<br>
P2:	of type D;<br>
P3:	of type C, or the residue is Gly or Pro;<br>
P4:	of type C or of type E or of type F, or the residue is Gly or Pro;<br>
P5:	of type E, or the residue is Gly or Pro;<br>
P6:	of type E or of type F or of formula -A-CO-, or the residue is<br>
Gly or Pro;<br>
P7:	of type C or of type E or of type F or of formula -B-CO-;<br>
P8:	of type D, or of type F;<br>
P9:	of type E or of type For of type C;<br>
P10:	of type E;<br>
PI 1:	of type F or of type C, or the residue is Gly or Pro; and<br>
P12:	of type C or of type D or of type E, or of type F; or<br>
P4 and P9 and/or P2 and P11, taken together, can form a group of type<br>
H;and<br>
at P6, P10 and P1 1 also D-isomers being possible;<br>
or, alternatively,<br>
P1:	of type C or of type D or of type E, or of type F;<br>
P2:	of type F or of type C, or the residue is Gly or Pro;<br>
P3:	of type E;<br>
P4:	of type E or of type F or of type C;<br>
P5:	of type D, or of Type F;<br><br>
P6: of type C or of type E or of type F orof formula-B-CO-;<br>
P7: of type C or of type F or of formula-A-CO-, or the residue is<br>
Gly or Pro;<br>
P8: of type E, or the residue is Gly or Pro;<br>
P9: of type Cor of type E or of type F, or the residue is Gly or Pro;<br>
P10: of type C, or the residue is Gly or Pro;<br>
P11: of type D;and<br>
P12: of type C or of type D or of type E or of type F; or<br>
P4 and P9 and/or P2 and P11, taken together, can form a group of type<br>
H;and<br>
at P2, P3, and P7 also D-isomers being possible.<br>
18. Compounds according to claim 16 wherein the α -amino acid residues in positions<br>
1 to 12 of the chain Z are:<br>
P1: Ala, Cit, Thr, Thr, Asp, Glu;<br>
P2: Trp,Tyr,<br>
P3: Ile,Val, Nle,Chg,Cha;<br>
P4: Dab, Lys, Gln;<br>
P5: Lys, Dab, Orn;<br>
P6: Dab,DDab;Lys;<br>
P7: His, Lys, Gln, Dab;<br>
P8: Tyr, Trp, Ser,<br>
P9	Dab, Lys;<br>
P10: Dab, Lys;<br>
P11: Ala, Abu, Thr, Gly, Pro, Hse, Ile, Nva, DAla, DVal, Aib, Nle,<br>
Chg, Cha, Gln, Asp, Glu, Cpa, t-BuG, Leu, Val, Asn;<br>
P12: Dab, Lys, Gln, Ser;<br>
19. A compound of formula I according to claim 1 wherein the template is DPro-LPro<br>
and the amino acid residues in position 1-12 are:<br>
P1: Thr,<br>
P2: Trp;<br>
P3: He;<br>
P4: Dab;<br>
P5: Lys;<br><br>
P6:	Dab;<br>
P7:	Dab;<br>
P8:	Trp;<br>
P9:	Dab;<br>
P10:	Dab;<br>
Pll:	Ala; and<br>
P12:	Dab<br>
20. A compound of formula I according to claim 1 wherein the template is DPro-LPro<br>
and the ammo acid residues in position 1-12 are:<br>
P1:	Thr,<br>
P2:	Trp;<br>
P3:	Ile;<br>
P4:	Dab;<br>
P5:	Lys;<br>
P6:	Dab;<br>
P7:	Dab;<br>
P8:	Trp;<br>
P9:	Dab;<br>
P10:	Dab;<br>
Pll:	Gly;and<br>
P12:	Dab<br>
,21. A compound of formula I according to claim 1 wherein me template is DPro-LPro<br>
and the amino acid residues in position 1-12 are:<br>
P1:	Thr,<br>
P2:	Trp;<br>
P3:	Ile;<br>
P4:	Dab;<br>
P5:	Lys;<br>
P6:	Dab;<br>
P7:	Dab;<br>
P8:	Trp;<br>
P9:	Dab;<br><br>
P10:	Dab;<br>
Pll:	Abu; and<br>
P12:	Dab<br>
22. A compound of formula I according to claim 1 wherein the template is DPro-LPro<br>
and the amino acid residues in position 1-12 are:<br>
P1:	Thr,<br>
P2:	Trp;<br>
P3:	Ile;<br>
P4:	Dab;<br>
P5:	Lys;<br>
P6:	Dab;<br>
P7:	Dab;<br>
P8:	Trp;<br>
P9:	Dab;<br>
P10:	Dab;<br>
Pll:	Thr; and<br>
P12:	Dab<br>
23. A compound of formula I according to claim 1 wherein the template is DPro-LPro<br>
and the amino acid residues in position 1-12 are:<br>
P1:	Thr;<br>
P2:	Tyr,<br>
P3:	Ile;<br>
P4:	Dab;<br>
P5:	Lys;<br>
P6:	Dab;<br>
P7:	Dab;<br>
P8:	Trp;<br>
P9:	Dab;<br>
P10: Dab;<br>
Pll: Ala; and<br>
P12: Dab<br><br>
24. A compound of formula I according to claim 1 wherein the template is DPro-LPro<br>
and the atnino acid residues in position 1-12 are:<br>
P1:	Ala;<br>
P2:	Trp;<br>
P3:I	le;<br>
P4:	Dab<br>
P5:	Lys;<br>
P6:	Dab;<br>
P7:	Dab;<br>
P8:	Trp;<br>
P9:	Dab;<br>
P10:	Dab;<br>
Pll:	Ala; and<br>
P12:	Dab<br>
25.	A compound of formula I according to claim 1 wherein the template is DPro-LPro<br>
and the amino acid residues in position 1-12 are:<br>
P1:	Thr,<br>
P2:	Trp;<br>
P3:	He;<br>
P4:	Lys;<br>
P5:	Lys;<br>
P6-.	Dab,<br>
P7:	Dab;<br>
P8:	Trp;<br>
P9:	Dab;<br>
P10-.	Dab;<br>
Pll:	Ala; and<br>
P12:	Dab<br>
26.	A compound of formula I according to claim 1 wherein the template is DPro-LPro<br>
and the amino acid residues in position 1-12 are:<br>
P1: Thr;<br>
P2:	Trp;<br><br>
P3:	He;<br>
P4:	Dab;<br>
P5:	Lys;<br>
P6:	Lys;<br>
P7:	Dab;<br>
P8:	Trp;<br>
P9:	Dab;<br>
P10:	Dab;<br>
PU:	Ala; and<br>
P12:	Dab<br>
27. A compound of formula I according to claim 1 wherein the template is DPro-LPro<br>
and the ammo acid residues in position 1-12 are:<br>
P1:	Thr,<br>
P2:	Trp;<br>
P3:	He;<br>
P4:	Dab;<br>
P5:	Lys;<br>
P6:	Dab;<br>
P7:	Dab;<br>
P8:	Trp;<br>
P9:	Dab;<br>
P10:	Dab;<br>
P11:	Ala; and<br>
P12:	Lys<br>
28. A compound of formula I according to claim 1 wherein the template is DPro-LPro<br>
and the amino acid residues in position 1-12 are:<br>
P1:	Thr;<br>
P2:	Trp;<br>
P3:	Ile;<br>
P4:	Gln;<br>
P5:	Lys;<br>
P6:	Dab;<br>
P7:	Dab;<br><br>
P8:	Trp;<br>
P9:	Dab;<br>
P10:	Dab;<br>
Pll:	Ala; and<br>
P12:	Dab<br>
29.	A compound of formula I according to claim 1 wherein the template is DPro-LPro<br>
and the ammo acid residues in position 1-12 are:<br>
P1:	Thr,<br>
P2:	Trp;<br>
P3:	Val;<br>
 P4:	Dab;<br>
P5:	Lys;<br>
P6:	Dab;<br>
P7:	Dab;<br>
P8:	Trp;<br>
P9:	Dab;<br>
P10:	Dab;<br>
Pll:	Ala; and<br>
P12:	Dab<br>
30.	A compound of formula I according to claim 1 wherein the template is DPro-LPro<br>
and the amino acid residues in position 1-12 are:<br>
P1:	Thr;<br>
P2:	Trp;<br>
P3:	Ile;<br>
P4:	Dab;<br>
P5:	Lys;<br>
P6:	Dab;<br>
P7:	Dab;<br>
P8:	Trp;<br>
P9:	Dab;<br>
P10:	Dab;<br>
Pll:	Hse;and<br><br>
P12:	Dab<br>
31. A compound of formula I according to claim 1 wherein the template is DPro-LPro<br>
and the amino acid residues in position 1-12 are:<br>
P1:	Thr,<br>
P2:	Trp;<br>
P3:	Ile;<br>
P4:	Gln;<br>
P5:	Lys;<br>
P6:	Dab;<br>
P7:	Dab;<br>
P8:	Trp;<br>
P9:	Dab;<br>
P10:	Dab;<br>
Pll:	Ala; and<br>
P12:	Gln<br>
32.	A compound of formula I according to claim 1 wherein the template is DPro-DPro<br>
and the amino acid residues in position 1-12 are:<br>
P1: Glu;<br>
P2:	Trp;<br>
P3: Ile;<br>
P4: Dab;<br>
P5:	Lys;<br>
P6:. DDab;<br>
P7: Dab;<br>
P8:	Trp;<br>
P9: Dab;<br>
P10: Dab;<br>
Pll: Ala; and<br>
P12: Gln<br>
33.	A compound of formula I according to claim 1 wherein the template is DPro-LPro<br>
and the amino acid residues in position 1-12 are:<br>
P1:	Thr,<br>
P2: Trp;<br>
P3:	Ile;<br><br>
P4:	Dab;<br>
P5:	Orn;<br>
P6:	DDab;<br>
P7:	Dab;<br>
P8:	Trp;<br>
P9:	Dab;<br>
P10:	Dab;<br>
Pll:	Ala; and<br>
P12:	Ser<br>
34.	A compound of formula I according to claim 1 wherein the template is DPro-LPro<br>
and the amino acid residues in position 1-12 are:<br>
P1:	Glu;<br>
P2:	Trp;<br>
P3:	Ile;<br>
P4:	Gln;<br>
P5:	Lys;<br>
P6:	Dab;<br>
P7:	Dab;<br>
P8:	Ser;<br>
P9:	Dab;<br>
P10:	Dab;<br>
Pll:	Ala; and<br>
P12:	Ser<br>
35.	Enantiomers of the compounds of formula I as defined in claim 1.<br>
36.	Compounds according to any one of claims 1 to 35 for use as therapeutically active<br>
substances.<br>
37.	Compounds according the claims 36 having selective antimicrobial activity being<br>
in particular against Pseudomonas aeruginosa.<br>
38.	A pharmaceutical composition containing a compound according to any one of<br>
claims 1 to 35 and a pharmaceutically inert carrier.<br><br>
39.	Compositions according to claim 3 8 in a form suitable for oral, topical,<br>
transdermal, injection, buccal, transmucosal, pulmonary or inhalation administration.<br>
40.	Compositions according to claim 38 or 39 in form of tablets, dragees, capsules,<br>
solutions, liquids, gels, plaster, creams, ointments, syrup, slurries, suspensions, spray,<br>
nebuliser or suppositories.<br>
41.	The use of compounds according to any one of claims 1 to 35 for the manufacture<br>
of a medicament for treating or preventing infections or diseases related to such<br>
infections.<br>
42.	The use according to claim 41 wherein said infections are related to respiratory<br>
diseases such as cystic fibrosis, emphysema and asthma; related to skin or soft tissue<br>
diseases such as surgical wounds, traumatic wounds or burn wounds; related to<br>
gastrointestinal diseases such as epidemic diarrhea, necrotizing enterocolitis or typhlitis;<br>
related to eye diseases such as keratitis or endophthalmitis; related to ear diseases such as<br>
otitis; related to CNS diseases such as brain abscess or meningitis; related to bone<br>
diseases such as osteochondritis or osteomyelitis; related to cardiovascular diseases such<br>
as endocartitis or pericarditis; related to gastrourinal diseases such as epididymitis,<br>
prostatitis or uremritis; related to cancer, or related to HIV.<br><br>
43.	The use of compounds according to any one of claims 1 to 35 as disinfectants or<br>
preservatives for foodstuffs, cosmetics, medicaments and other nutrient-containing<br>
materials.<br>
44.	A process for the manufacture of compounds according to any one of claims 1-34<br>
which process comprises<br><br>
(a)	coupling an appropriately functionalized solid support with an appropriately N-<br>
protected derivative of that amino acid which in the desired end-product is in position 5,6<br>
or 7, any functional group which may be present in said N-protected amino acid<br>
derivative being likewise appropriately protected;<br>
(b)	removing the N-protecting group from the product thus obtained;<br>
(c)	coupling the product thus obtained with an appropriately N-protected derivative of<br>
that amino acid which in the desired end-product is one position nearer the N-termraal<br><br>
amino acid residue, any functional group which may be present in said N-protected amino<br>
acid derivative being likewise appropriately protected;<br>
(d)	removing the N-protecting group from the product thus obtained;<br>
(e)	repeating steps (c) and (d) until the N-terminal amino acid residue has been<br>
introduced;<br>
(f)	coupling the product thus obtained with a compound of the general formula<br><br>
is as defined in claim 1 and X is an N-protecting group or, if<br><br>
is to be group (al) or (a2), as defined in claim 1, alternatively<br>
(fa)	coupling the product obtained in step (e) with an appropriately N-protected<br>
derivative of an amino acid of the general formula<br>
HOOC-B-H	III	or HOOC-A-H	IV<br>
wherein B and A are as defined in claim 1, any functional group which may be<br>
present in said N-protected amino acid derivative being likewise appropriately<br>
protected;<br>
(jjj)	removing the N-protecting group from the product thus obtained; and<br>
(kkk)	coupling the product thus obtained with an appropriately N-protected<br>
derivative of an amino acid of the above general formula IV and, respectively, HI,<br>
any functional group which may be present in said N-protected amino acid<br>
derivative being likewise appropriately protected;<br>
(g)	removing the N-protecting group from the product obtained in step (f) or (fc);<br>
(h) coupling the product thus obtained with an appropriately N-protected derivative of<br>
that amino acid which in the desired end-product is in position 12, any functional group<br><br>
which may be present in said N-protected amino acid derivative being likewise<br>
appropriately protected;<br>
(i) removing the N-protecting group from the product thus obtained;<br>
(j) coupling the product thus obtained with an appropriately N-protected derivative of<br>
that amino acid which in the desired end-product is one position farther away from<br>
position 12, any functional group which may be present in said N-protected amino acid<br>
derivative being likewise appropriately protected;<br>
(k) removing the N-protecting group from the product thus obtained;<br>
(1) repeating steps (j) and (k) until all amino acid residues have been introduced;<br>
(m) if desired, selectively deprotecting one or several protected functional group(s)<br>
present in the molecule and appropriately substituting the reactive group(s) thus liberated;<br>
(o) detaching the product thus obtained from the solid support;<br>
(p) cyclizing the product cleaved from the solid support;<br>
(q) if desired, forming one or two interstrand linkage(s) between side-chains of<br>
appropriate amino acid residues at opposite positions of the (3-strand region;<br>
(r) removing any protecting groups present on functional groups of any members of<br>
the chain of amino acid residues and, if desired, any protecting group(s) which may in<br>
addition be present in the molecule; and<br>
(s) if desired, converting the product thus obtained into a pharmaceutically acceptable<br>
salt or converting a pharmaceutically acceptable, or unacceptable, salt thus obtained into<br>
the corresponding free compound of formula I or into a different, pharmaceutically<br>
acceptable, salt.<br>
45. A process for the manufacture of compounds according to any one of claims 1-34<br>
which process comprises<br>
(a') coupling an appropriately functionalized solid support with a compound of the<br>
general formula<br><br><br>
is as defined in claim 1 and X is an N-protecting group or, if<br><br>
is to be group (a1) or (a2), as defined in claim 1, alternatively<br>
(a'a) coupling said appropriately functionaliZed solid support with an<br>
appropriately N-protected derivative of an amino acid of the general formula<br>
HOOC-B-H	III	or HOOC-A-H	IV<br>
wherein B and A are as defined in claim 1, any functional group which may be<br>
present in said N-protected amino acid derivative being likewise appropriately<br>
protected;<br>
(a'b) removing the N-protecting group from the product thus obtained; and<br>
(a'c) coupling the product thus obtained with an appropriately N-protected<br>
derivative of an amino acid of the above general formula IV and, respectively, III,<br>
any functional group which may be present in said N-protected amino acid<br>
derivative being likewise appropriately protected;<br>
(b') removing the N-protecting group from the product obtained in step (a') or (a'c);<br>
(c') coupling the product thus obtained with an appropriately N-protected derivative of<br>
that amino acid which in the desired end-product is in position 12, any functional group<br>
which may be present in said N-protected amino acid derivative being likewise<br>
appropriately protected;<br>
(d') removing the N-protecting group from the product thus obtained;<br>
(e') coupling the product thus obtained with an appropriately N-protected derivative of<br>
that amino acid which in the desired end-product is one position farther away from<br>
position 12, any functional group which may be present in said N-protected amino acid<br>
derivative being likewise appropriately protected;<br>
(f) removing the N-protecting group from the product thus obtained;<br>
(g1) repeating steps (e') and (f) until all amino acid residues have been introduced;<br>
(h') if desired, selectively deprotecting one or several protected functional group(s)<br>
present in the molecule and appropriately substituting the reactive group(s) thus liberated;<br>
(i') detaching the product thus obtained from the solid support;<br>
(j') cyclizing the product cleaved from the solid support;<br><br>
(k') if desired forming one or two interstrand linkages) between side-chains of<br>
appropriate ammo acid residues at opposite positions of the P-strand region;<br>
(I') removing any protecting groups present on functional groups of any members of<br>
the chain of amino acid residues and, if desired, any protecting group(s) which may in<br>
addition be present in the molecule; and<br>
(m') if desired, converting the product thus obtained into a pharmaceutically acceptable<br>
salt or converting a pharmaceutically acceptable, or unacceptable, salt thus obtained into<br>
the corresponding free compound of formula I or into a different, pharmaceutically<br>
acceptable, salt<br>
46. A modification of the process of claim 44 or 45 for the manufacture of compounds<br>
according to claim 35 in which enantiomers of all chiral starting materials are used.<br><br>
Template-fixed β-hairpin peptidomimetics of the general formula (I) wherein Z is a template-fixed chain of 12 α-amino acid residues which, depending on their positions in the chain <br>
(counted starting from the N-terminal amino acid) are Gly, or Pro, or of certain types which, as the remaining Symbols in the above formula, are defined in the description and the claims, and salts thereof, have the property to selectively inhibit the growth of or to kill microorganisms such as Pseudomonas aeruginosa. They can be used as disinfectants for foodstuffs, cosmetics, medicaments or<br>
other nutrient-containing materials, or as medicaments to treat or prevent infections. These β-hair-pin peptidomimetics can be manufactured by processes which are based on a mixed solid- and Solution phase synthetic strategy.</td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzM1Mi1LT0xOUC0yMDA4LSgwOS0wNi0yMDE0KS1DT1JSRVNQT05ERU5DRS5wZGY=" target="_blank" style="word-wrap:break-word;">3352-KOLNP-2008-(09-06-2014)-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzM1Mi1LT0xOUC0yMDA4LSgwOS0wNi0yMDE0KS1GT1JNLTEzLnBkZg==" target="_blank" style="word-wrap:break-word;">3352-KOLNP-2008-(09-06-2014)-FORM-13.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzM1Mi1LT0xOUC0yMDA4LSgwOS0wNi0yMDE0KS1QRVRJVElPTiBVTkRFUiBSVUxFIDEzNy5wZGY=" target="_blank" style="word-wrap:break-word;">3352-KOLNP-2008-(09-06-2014)-PETITION UNDER RULE 137.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzM1Mi1LT0xOUC0yMDA4LSgxOS0wOC0yMDEzKS1BQlNUUkFDVC5wZGY=" target="_blank" style="word-wrap:break-word;">3352-KOLNP-2008-(19-08-2013)-ABSTRACT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzM1Mi1LT0xOUC0yMDA4LSgxOS0wOC0yMDEzKS1DTEFJTVMucGRm" target="_blank" style="word-wrap:break-word;">3352-KOLNP-2008-(19-08-2013)-CLAIMS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzM1Mi1LT0xOUC0yMDA4LSgxOS0wOC0yMDEzKS1DT1JSRVNQT05ERU5DRS5wZGY=" target="_blank" style="word-wrap:break-word;">3352-KOLNP-2008-(19-08-2013)-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzM1Mi1LT0xOUC0yMDA4LSgxOS0wOC0yMDEzKS1GT1JNLTEzLnBkZg==" target="_blank" style="word-wrap:break-word;">3352-KOLNP-2008-(19-08-2013)-FORM-13.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzM1Mi1LT0xOUC0yMDA4LSgxOS0wOC0yMDEzKS1GT1JNLTIucGRm" target="_blank" style="word-wrap:break-word;">3352-KOLNP-2008-(19-08-2013)-FORM-2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzM1Mi1LT0xOUC0yMDA4LSgxOS0wOC0yMDEzKS1PVEhFUlMucGRm" target="_blank" style="word-wrap:break-word;">3352-KOLNP-2008-(19-08-2013)-OTHERS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzM1Mi1LT0xOUC0yMDA4LSgyMy0wOS0yMDEzKS1BTk5FWFVSRSBUTyBGT1JNIDMucGRm" target="_blank" style="word-wrap:break-word;">3352-KOLNP-2008-(23-09-2013)-ANNEXURE TO FORM 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzM1Mi1LT0xOUC0yMDA4LSgyMy0wOS0yMDEzKS1DT1JSRVNQT05ERU5DRS5wZGY=" target="_blank" style="word-wrap:break-word;">3352-KOLNP-2008-(23-09-2013)-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzM1Mi1LT0xOUC0yMDA4LSgyMy0wOS0yMDEzKS1QRVRJVElPTiBVTkRFUiBSVUxFIDEzNy5wZGY=" target="_blank" style="word-wrap:break-word;">3352-KOLNP-2008-(23-09-2013)-PETITION UNDER RULE 137.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzM1Mi1rb2xucC0yMDA4LWFic3RyYWN0LnBkZg==" target="_blank" style="word-wrap:break-word;">3352-kolnp-2008-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzM1Mi1LT0xOUC0yMDA4LUFTU0lHTk1FTlQucGRm" target="_blank" style="word-wrap:break-word;">3352-KOLNP-2008-ASSIGNMENT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzM1Mi1rb2xucC0yMDA4LWNsYWltcy5wZGY=" target="_blank" style="word-wrap:break-word;">3352-kolnp-2008-claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzM1Mi1LT0xOUC0yMDA4LUNPUlJFU1BPTkRFTkNFLTEuMS5wZGY=" target="_blank" style="word-wrap:break-word;">3352-KOLNP-2008-CORRESPONDENCE-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzM1Mi1rb2xucC0yMDA4LWNvcnJlc3BvbmRlbmNlLnBkZg==" target="_blank" style="word-wrap:break-word;">3352-kolnp-2008-correspondence.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzM1Mi1rb2xucC0yMDA4LWRlc2NyaXB0aW9uIChjb21wbGV0ZSkucGRm" target="_blank" style="word-wrap:break-word;">3352-kolnp-2008-description (complete).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzM1Mi1rb2xucC0yMDA4LWZvcm0gMS5wZGY=" target="_blank" style="word-wrap:break-word;">3352-kolnp-2008-form 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzM1Mi1rb2xucC0yMDA4LWZvcm0gMTMucGRm" target="_blank" style="word-wrap:break-word;">3352-kolnp-2008-form 13.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzM1Mi1LT0xOUC0yMDA4LUZPUk0gMy0xLjEucGRm" target="_blank" style="word-wrap:break-word;">3352-KOLNP-2008-FORM 3-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzM1Mi1rb2xucC0yMDA4LWZvcm0gMy5wZGY=" target="_blank" style="word-wrap:break-word;">3352-kolnp-2008-form 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzM1Mi1rb2xucC0yMDA4LWZvcm0gNS5wZGY=" target="_blank" style="word-wrap:break-word;">3352-kolnp-2008-form 5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzM1Mi1LT0xOUC0yMDA4LUdQQS5wZGY=" target="_blank" style="word-wrap:break-word;">3352-KOLNP-2008-GPA.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzM1Mi1rb2xucC0yMDA4LWludGVybmF0aW9uYWwgcHVibGljYXRpb24ucGRm" target="_blank" style="word-wrap:break-word;">3352-kolnp-2008-international publication.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzM1Mi1rb2xucC0yMDA4LWludGVybmF0aW9uYWwgc2VhcmNoIHJlcG9ydC5wZGY=" target="_blank" style="word-wrap:break-word;">3352-kolnp-2008-international search report.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzM1Mi1rb2xucC0yMDA4LW90aGVycy5wZGY=" target="_blank" style="word-wrap:break-word;">3352-kolnp-2008-others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzM1Mi1rb2xucC0yMDA4LXBjdCBwcmlvcml0eSBkb2N1bWVudCBub3RpZmljYXRpb24ucGRm" target="_blank" style="word-wrap:break-word;">3352-kolnp-2008-pct priority document notification.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzM1Mi1rb2xucC0yMDA4LXBjdCByZXF1ZXN0IGZvcm0ucGRm" target="_blank" style="word-wrap:break-word;">3352-kolnp-2008-pct request form.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzM1Mi1rb2xucC0yMDA4LXNwZWNpZmljYXRpb24ucGRm" target="_blank" style="word-wrap:break-word;">3352-kolnp-2008-specification.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=YWJzdHJhY3QtMDMzNTIta29sbnAtMjAwOC5qcGc=" target="_blank" style="word-wrap:break-word;">abstract-03352-kolnp-2008.jpg</a></p>
		<br>
		<div class="pull-left">
			<a href="264290-factor-xa-compounds.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="264292-an-apparatus-and-a-method-for-assigning-uplink-resources.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>264291</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>3352/KOLNP/2008</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>52/2014</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>26-Dec-2014</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>19-Dec-2014</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>14-Aug-2008</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>UNIVERSITAT ZURICH</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>RAMISTRASSE 71, CH-8006 ZURICH</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>GOMBERT, FRANK</td>
											<td>AM REBHANG 20, 79588 HUTTINGEN</td>
										</tr>
										<tr>
											<td>2</td>
											<td>VRIJBLOED, WIM</td>
											<td>UNTERE FUCHSRAINSTRASSE 16, CH-4313 MOHLIN</td>
										</tr>
										<tr>
											<td>3</td>
											<td>DIAS, RICARDO</td>
											<td>GORENMATTSTRASSE 25, CH-4102 BINNINGEN</td>
										</tr>
										<tr>
											<td>4</td>
											<td>DEMARCO, STEVE, J.</td>
											<td>ROTACHERSTRASSE 13, CH-4457 DIEGTEN</td>
										</tr>
										<tr>
											<td>5</td>
											<td>ROBINSON, JOHN, ANTHONY</td>
											<td>TOBELSTRASSE 24, CH-8615 WERMATSWIL</td>
										</tr>
										<tr>
											<td>6</td>
											<td>SRINIVAS, NITYAKALYANA</td>
											<td>KLINGENTALSTRASSE 83, CH-4057 BASEL</td>
										</tr>
										<tr>
											<td>7</td>
											<td>OBRECHT, DANIEL</td>
											<td>IM EICHACKER 21, CH-4112 BATTWIL</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>C07K 7/06,C07K 14/00</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/CH2007/000017</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2007-01-15</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>PCT/CH2006/000036</td>
									<td>2006-01-16</td>
								    <td>Switzerland</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/264291-template-fixed-peptidomimetics-with-antimicrobial-activity by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 00:39:39 GMT -->
</html>
